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1.1 Introduction  
1.1.1 General introduction “vaccination” 
The human race has always been threatened by diseases. In order to protect humans 
against infections and epidemics vaccination as deliberate attempt has become more 
and more the focus of scientific development. Since the time of Edward Jenner (1749-
1823), the “father of modern vaccination”, several major diseases could be controlled 
using vaccination such as diphtheria, tetanus, rubella or smallpox [1-3]. Moreover, in 
the case of smallpox, vaccination was carried out until the late 1970s with the success 
of eradication. During the last two centuries, vaccination has demonstrated a huge 
impact on human and animal health and has significantly reduced morbidity and 
mortality. Nonetheless, it was a long way from Jenner´s development of large scale 
vaccination using the direct arm-to-arm-transmission of the “lymph” from people who 
are afflicted to modern vaccines (e.g.: DNA or sub-unit vaccines) [4]. The risks of 
transmissions of other diseases along the direct inoculation process did not end until 
the 1890s when glycerin preservation of the vaccine solution (lymph from infected 
animals) was introduced by Robert Koch. Around the same time Louis Pasteur 
perceived that an attenuated (weakened) form of the microbe (virus) could provide 
immunity with minimized risk of infection. The Pasteur concept of attenuation offered 
the possibility to make vaccines cultivatable and standardly reproducible [5]. The next 
major step was the introduction of “killed vaccines”, which used e.g. heat or chemical 
treatment to destroy the microorganism, at the end of the 19th century. This concept 
was also applied for bacterial toxins to produce the so called “toxoids” which were 
used to induce immunity against diseases such as diphtheria and tetanus. Despite the 
developments of the vaccine modifications, the vaccine production was still 
rudimentary and focused on immunization and collection of “lymph” from animals for 
human immunization. The vaccine production substantially improved after the 
introduction of the chorioallantoic membrane of fertile hen´s egg as a growing 
medium for vaccine strains [6]. The next significant development of vaccine 
production exceeded after the usage of cell cultures in the second half of the 20th 
century while the last important introduction process of improving vaccine efficacy 
and safety was established using the technology of recombinant vaccine production [7, 
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8]. During the last two decades several recombinant vaccines were licensed such as 
high-potency zoster vaccine, quadrivalent human papilloma virus and cold-adapted 
influenza vaccine (CAIV) [9].  
Vaccine-mediated protection is a complex reaction. The efficacy of vaccines is 
primarily demonstrated via evidence of antigen-specific antibody titer [10]. It should 
be kept in mind that the immunity is not only a result of the peak of vaccine-mediated 
antibodies, it is also important that a long-term protection is induced [11-13]. This 
persisting protection can be generated by circulating specific antibodies and/or 
memory cells which are capable of a rapid immune response after a subsequent 
exposure to the same or comparable antigen. The efficacy of the immunity depends on 
a precise interaction between different immune cells such as B cells and T cells. The 
antibodies with high binding affinities to specific pathogens are produced in B-
lymphocytes while T-lymphocytes (CTL) (CD8+) limit the spreading of the infection 
within the host by killing infected cells or secreting antimicrobial cytokines [14, 15].  
The balance and the moderation of the immune cells is provided by T-helper-
lymphocytes (Th) (CD4+). This group of immune cells is further divided into two 
subpopulations Th1 and Th2 which are regulated by regulatory T cells (Treg) [16]. 
Moreover, the activation of specific vaccine-mediated (antigen-mediated) B and/or T 
lymphocyte response is mainly induced by antigen presenting cells (APC) such as 
monocytes, macrophages, dendritic cells (DCs) or Langerhans cells (LCs). They can 
start maturation after being activated by antigen exposition while they migrate to the 
draining lymph nodes to induce a cascade of immune cells (e.g. B and T cells) [17]. 
Generally, T and B-cells are activated after direct pathogen exposure (vaccination) or 
contact with antigen presenting APCs while Th1 and Th2 moderate the immune 
response and support the differentiation of the immature T and B cells to effector cells 
(CTL or B plasma cells) [12]. 
In order to demonstrate the efficacy of a vaccine and/or vaccination route it is not 
enough to detect involved immune cells and secreted mediators (cytokines) but a 
formal demonstration of vaccine-mediated protection is mandatory [18, 19]. 
Therefore, studies of titer changes, appearance of clinical symptoms, and 
hospitalization have been documented to show a successful vaccination technology.  
The goal of vaccination is to induce a sufficient number of memory cells after priming 
(first contact with antigen) which reactivate, proliferate and differentiate rapidly after 
being exposed to the same antigen again. Furthermore, these maturated cells display 
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and secrete e.g. antibodies with significantly higher affinity to the antigen compared to 
avidity after priming. The vaccination should make the immune system capable to 
reactivate memory cells and to induce rapid antibody secretion over a threshold faster 
than the incubation time of the pathogen to protect the host sufficiently.  
 
1.1.2 Influenza and the development of influenza 
vaccine 
The influenza virus belongs to the family of orthomyxoviridae. Influenza is classified 
in three genera; A, B and C, depending on the type specific nucleoprotein (NP). 
Usually, influenza A and B cause the human influenza disease which is characterized 
by fever, cough, body aches etc. The characteristic of the virus is a single stranded 
RNA (ssRNA) with a helical symmetry, divided in eight RNA fragments (seven for 
influenza C) with a negative polarity (Figure 1.1.1). Each RNA fragment encodes at 
least one of the virus proteins. The genomic fragments are closely associated with the 
nucleoprotein to form a helical structure. Moreover, every genomic fragment 
possesses its own duplicating proteins (PB1, PB2 and PA) which amplify the viral 
RNA within the host cell. The RNA replicas are also utilized as mRNA to modify the 
host protein production into viral related protein production. An envelope, which 
originates from the host`s cytoplasmic membrane, surrounds the RNA fragments while 
viral proteins and new viruses are assembled. The viral envelope is associated with 
membrane proteins, such as hemagglutinin (HA), neuraminidase (NA), matrix protein 
(M1) and an ionic channel protein (M2). Due to their importance for viral life history 
strategy HA and NA are examined in detail. The ratio of HA to NA on the envelope is 
8:1 to 10:1 [13, 15]. The trimeric hemagglutinin can mediate the attachment to a host 
cell sialic acid residue and initiate the virus fusion with the host cell. At present, 17 
subtypes of hemagglutinin are known for the influenza A virus. On the contrary, the 
tetrameric neuraminidase promotes the release of the virus from the host cell-
membrane and the distribution of self-assembled virus duplicates (virions) by cleavage 
between sialic acid residue and glycosaccharide. Moreover, NA is able to cleave the 
mucus proteins secreted inside the host´s respiratory tract, which leads to a formation 
of small droplets [16, 17]. The droplets form a delivery system to transport influenza 
viruses to the airways of the next host when the influenza disease carrying individual 
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sneezes or coughs. Currently, nine subtypes of neuraminidase are known for the 
influenza A virus. Both membrane proteins (HA and NA) can constantly change due 
to the viral structure and RNA organization. This continuous antigenic evolution of the 
influenza virus is based on two mechanisms: the antigenic drift and antigenic shift [12, 
15]. 
High mutation rates and accumulations of point mutations in the eight RNA fragments 
(seven for influenza C) caused by the virus’ own multiplying proteins (PB1, PB2 and 
PA) during the amplification create an astonishing high genomic alteration of the 
surface antigens HA and NA. Small genomic differences, called as antigenic drift, can 
lead to slightly changed viral proteins. These randomly occurring mutations in proteins 
(e.g.: HA and NA) can cause a circumvention of the host`s immune response. 
Moreover, sufficient alteration of the antigenic proteins can initiate a reinfection and 
can lead to a coexistence of subpopulations of several influenza viruses in the host at 
the same time. In response to the selection pressure to evade human (host) immunity, 
obvious changes in the genetic composition of the influenza virus occur every two to 
eight years. Alterations (point mutation) can lead to reduced antibody binding affinity 
to a known influenza strain. Influenza B is showing relatively little antigenic drift, 
whereas influenza A strains are demonstrating a high flexibility in genomic 
composition [15, 18, 19]. The impact of the antigenic drift to human health varies 
from season to season. Typically, 5-15% of the worldwide population is infected by 
seasonal influenza epidemics either asymptomatically or with clinical illness [4-6, 20]. 
Moreover, influenza A virus is capable of infecting mammalian as well as avian hosts 
depending on the subtype of hemagglutinin. This broad range of hosts enables the 
virus to mix up homologous RNA fragments if two or more influenza viruses of 
different strains infect the same host cell. This exchange of RNA fragments, the basis 
for genetic re-assortments and antigenic shift, can result in new viruses that have never 
been present in circulation, yet [4, 15]. The antigenic shift, resulting from double 
(triple etc.) infections, is capable to emerge a deadly influenza disease such as the 
1918 Spain flu which caused over 50 million deaths worldwide, the Hong Kong Flu 
1968 with over 34000 deaths in USA or the most recent one, the swine flu in 2009 
with over 18500 deaths [21-24]. However, the antigenic shift has happened rarely up 
to the present, and approximately three times in a century [25, 26].  
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Figure 1.1.1: Structure of influenza A particle. Types of membrane protein: hemagglutinin 
(HA), neuraminidase (NA) and ionic channel (M2-protein). Within the virus envelope are 
located eight single stranded (-)-RNA segments, whereas every segment contains an individual 
protein complex. 
 
In the early 1930s the influenza virus was firstly isolated  in pigs and few years later it 
was shown in humans that the swine influenza virus had caused the influenza 
pandemic in 1918 [20-22]. Shortly after the discovery of the virus, two vaccines were 
introduced from embryonated eggs, one live attenuated and the other with killed whole 
viruses [23-25]. Today, influenza vaccines are mainly composed of the subunit 
hemagglutinin (HA). The production of live attenuated influenza viruses in 
embryonated eggs could result in rapid virus mutations and a revirulence of the strain 
within the host [26, 27]. This drawback was overcome after the development of new 
technologies such as reverse genetics and cold-adaption which demonstrated improved 
safety and long-term immunity. The cold adaption allows the virus to grow in cooler 
body parts (e.g.: nasal passage with approximately 32°C) but limited the amplification 
in warmer internal organs (37°C) [28, 29]. The cold adaption is a concept of co-
infection of cell cultures with wild and attenuated strains which results in reassortants 
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(“mixing of gens”) due to the segmental genomes of the virus. Reassortants have also 
been used for vaccines with killed (inactivated) viruses (sub-unit vaccines, purified 
protein or polysaccharide) [9]. This concept may be improved by new technologies 
(e.g.: phage display, reverse genetics, and recombinant vaccines) to simplify the 
annual influenza sub-unit vaccine development and production [30].   
Inactivated (seasonal) influenza vaccine induces rapid local and systemic immune 
response in up to 90% of the tested patients (developing a hemagglutination inhibition 
titer (HAI) above 40) within two weeks after immunization [31]. Nonetheless, several 
studies have demonstrated the necessity of a second (boost) injection of inactivated 
unadjuvanted influenza vaccine to provoke a sufficient immunogenicity in unprimed 
patients, particularly in children. 
The inactivated influenza vaccines which are inoculated and amplified in embryonated 
eggs are primarily purified using centrifugation and chromatographic steps to reduce 
residual egg material [6]. Subsequently, the virus envelopes which are important for 
the virus reactogenicity and infectivity, are disrupted to assure viral inactivation using 
detergents such as tri-N-butyl phosphate, Triton X-100 or Triton N101 [32]. The 
envelope disruptions lead to a mixture of antigenic proteins in the inactivated 
influenza vaccine. Beside hemagglutinin the main immunogenic protein, 
neuraminidase, nucleoprotein or matrix proteins are included in varying amounts in 
the vaccine. A further purification step can be implemented to provide an influenza 
vaccine consisting of only HA. Over the last decades, inactivated influenza virus 
vaccine has been administered by intramuscular, oral, intranasal, subcutaneous or 
intradermal routes. The most reproducible immune responses and lowest occurrence of 
adverse reactions have been associated with intramuscular application route [33].  
However, recent studies demonstrated that intradermal routes using a prefilled liquid-
jet based device require fewer antigens (of the inactivated influenza vaccine) than 
intramuscular injection to induce a comparable immunogenicity but resulted in more 
but mild irritations at the application side [17, 34].  
An alternative approach to inactivated influenza virus vaccine is an administration of 
live attenuated influenza vaccine (LAIV). While the reassortant virus strain for 
vaccine production should contain the genes for the surface antigens (HA and NA), it 
must also demonstrate a minor virus reactogenicity and infectivity to prevent 
significant illnesses [35]. Several methods have been used to prepare attenuated 
influenza strains such as host-range, temperatures-sensitive, and cold-adaption. 
8 
 
However, host-range strains could not be reliably attenuated and demonstrated a 
reversion of virulence and were not further investigated. Cold-adaption of virus strains 
at successively lower temperature (25°C) led to reduced virus replication capabilities 
and additional virus attenuation at higher temperatures (39°C) [36]. 
Growing at successively lower temperature (25°C) of cold-adapted virus strains led to 
reduced virus replication. Reassortant influenza virus strains are generated by 
coinfection of the wild-type virus and the cold-adapted virus in a host cell (e.g. 
mammalian cell lineage). In contrast to the inactivated influenza vaccine LAIVs are 
sprayed directly into the nose using a syringe to provide an environment of 
approximately 30-33°C for attenuated virus amplification. The capability of virus 
amplification and the resulting point mutations can provide a higher cross- protection 
against drifted influenza strains and a long-term persistence of immunity also may 
occur compared to inactivated influenza vaccines [37, 38]. Analysis of the genetic 
sequences revealed that none of the changes occurred at positions that refer to virus 
attenuation or antigenicity which promises a high vaccine safety [39]. Furthermore, 
the nasal immunization strategy can provoke an additional mucosal IgA protection 
beside the serum IgG protection. This supplementary protection can also be induced 
using the intradermal vaccination route.  
An emerging influenza pandemic will create a surge of a rapid and global vaccination, 
and new immunization strategies will be needed to optimize the protection of 
unprimed persons, particularly when a certain vaccine may be limited.  
 
1.1.3 Intradermal route versus intramuscularly 
injection  
The way of vaccine administration can have considerable impact on efficacy of the 
procedure, compliance, and safety. Currently licensed vaccines are administered via 
one of five main routes: the majority of the vaccines is applied intramuscularly 
(hepatitis A and B, diphtheria, or tetanus); subcutaneously applied vaccines are 
measles, mumps, or rubella; intradermal route is used for BCG and rabies; intranasal 
administration site is utilized for live attenuated influenza vaccine (LAIV), and 
poliomyelitis and cholera are applied orally [40].  
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It should be kept in mind that the route of vaccine administration can also control the 
efficacy and class of immune response (moderation of cellular and/or humoral 
immunity).  
While administering vaccines intramuscularly several aspects should be considered 
such as injection site (e.g. gluteal, quadriceps or deltaoid muscle), needle size based on 
volume, muscle size, overlying subcutaneous tissue and desired deposition depths 
[41]. However, to avoid any nerve injuries (e.g. sciatic nerve at the gluteal region) and 
severe pain, health-care worker should pay strict attention to the administration 
instructions. In order to reduce the pain and discomfort, several methods were 
described associated with intramuscular injections such as pre-treatment with topical 
local anaesthetics (e.g. lidocaine) or topical refrigerant spray [42].  
In contrast, the intradermal vaccine administration would circumvent some of the 
intramuscular drawbacks (detailed description in Chapters 1.1.4 and 1.1.5) such as 
improving patient compliance, easy handling and elicited immune response. 
Moreover, intensive training of health-care personnel is redundant due to easy 
accessibility of the administration site and a lack of free nerve ending and blood 
vessels in the targeted area (epidermis) of the immunocompetent cells.  
Despite all the indisputable benefits for patients, the intradermal vaccination offers 
further significant advantages such as dose sparing.  
Conventionally, the inactivated influenza vaccine (subunit-vaccine) is administered 
intramuscularly (i.m.) to protect the host against influenza and its severe 
complications. Influenza vaccines are currently supplied in multi-dose vials which are 
typically overfilled to accommodate the dead space in needle and syringe. A 
conversion to prefilled single-dose syringe can reduce the waste of vaccine 
significantly [43-45]. As the next step of dose sparing would be a direct targeting of 
immunocompetent cells to minimize a vaccine waste in the tissue. Intradermal 
influenza vaccination demonstrated equivalent or even superior immune response after 
vaccination using needle and syringe and also promises a substantial dose reduction 
which is useful when vaccines are scarce [46]. 
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1.1.4 Skin as vaccine administration site 
The intradermal injection of tuberculin by Charles Mantoux in 1910 formed the basis 
for intradermal vaccination which is still used today for rabies and Bacillus Calmette-
Guérin (BCG) [47]. The most impressive achievement of intradermal vaccination is 
the program launched from the World Health Organization (WHO) which eradicated 
the smallpox in the 1980 by applying a small amount of the potent vaccine with a 
bifurcated needle into skin [48, 49].  
The skin excels as a target tissue due to easy accessibility and high immunogenicity. It 
is the least invasive route and demonstrated less unanticipated serious adverse effects 
than other administration routes (e.g. paralysis after nasal administration, abscesses 
after intramuscular injections). Additionally, a high number of dendritic cells and 
Langerhans cells, which form a synergistic network throughout the different skin 
layers, lead to an improved immune response. These cells can activate antigen-specific 
B and T-cells in the draining lymph nodes after antigen exposure [50, 51]. 
The skin comprises of three major layers such as epidermis, dermis and hypodermis 
(subcutis).  
The epidermis is approximately 150-200 µm thick and consists of 90% of 
keratinocytes and some Langerhans cells (LCs) and melanocytes are also located in 
this tissue [52]. The outermost layer of the epidermis is the stratum corneum (SC) 
which is only 10-20 µm thick in humans and consists of 10-20 layers of corneocytes. 
These cells are terminally differentiated keratinocytes which derived from the basal 
lamina and differentiate during the 30 day lasting migration towards the skin surface 
(stratum corneum). Despite the low layer thickness, SC serves as an effective physical 
and chemical barrier.  
While the Langerhans cells populate the epidermal layer of the skin, they form a tight 
network as a first line of immunological defence to rapidly detect intruding pathogens 
which breach through the stratum corneum (SC). After a pathogen exposure LCs 
scavenge the antigen and start maturating and migrating to the lymph nodes. While 
cells leave the network, continuous proliferations of LCs replenish the ranks to ensure 
a tight functioning network [53].  
The dermis is located below the basal lamina which is comprised of collagen, elastin, 
and reticular fibres. This 1.5–3 mm thick flexible and elastic layer consists of a dense 
network of capillary blood and lymphatic vessels. While fibroblast are the dominant 
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cells type, the endothelial cells play a significant role in the inflammatory process by 
secreting different kinds of cytokines e.g. to induce vasodilation and vasomotion 
and/or converting leukocytes and trafficking of APCs. Furthermore, heterogenic 
populations of dendritic cells (DCs) are located in this layer. The composition of the 
cutaneous DC population changes depending on the type and degree of inflammation. 
New blood-derived DCs can migrate into the tissue while others leave towards the 
draining lymph nodes to present the pathogens. Performing this continuous turnover, a 
rapid immunogenic response and permanent adaption to the inflammation can be 
ensured [53]. The subcutaneous tissue is a loose connective tissue where the larger 
blood vessels are located to supply the capillaries in the dermis. In order to address the 
APCs located in the lower layers (epidermis and dermis) the vaccine administration 
has to disrupt or bypass the SC [54, 55].  
 
 
Figure 1.1.2: Microscopical image of hematoxylin and eosin stained pig skin  
 
1.1.5 Intradermal vaccination with focus on 
epidermal powder immunization 
New concepts of intradermal vaccine administration are currently under investigation 
to improve the patient compliance and reduce vaccine dosage at the same time, 
compared to intramuscular injections [56]. 
12 
 
Several methods are currently in the scientific focus such as microneedles, tattoo 
vaccination, or epidermal powder immunization. Generally, needles are used not only 
to deposit vaccines intradermally, it is also the main route to deliver vaccine 
intramuscularly, subcutaneously except few jet-based injectors [57]. However, the 
administration of liquid vaccines using conventional needles and syringes holds the 
risk of pain, discomfort, needle-stick injuries and thereby the transmission of blood-
borne diseases. 
In contrast, penetration of the skin using microneedles is a huge scientific area which 
resulted in manifold designs and conception of microneedles [58]. While solid 
microneedles often form a basis for simple skin piercing or coating, hollow or 
biodegradable microneedles are more complex in preparation. Dissolving 
(biodegradable) microneedles prepared from e.g. carboxymethylcellulose, polyvinyl 
alcohol are pressed into the skin (manually or using a device) and subsequently 
dissolve within few minutes to administer the incorporated vaccine. The amount of 
delivered vaccine can differ while a certain vaccine volume can be directly injected 
using the hollow microneedles. Another approach is using a high-frequency oscillating 
needle for tattoo vaccination to deliver (DNA-) vaccines instead of tattoo ink into the 
skin. The promising methods highly depend on the deposited DNA concentration to 
elicit a sufficient immune response [59, 60]. 
Epidermal powder immunization excels as a needle-free application. In contrast to the 
liquid-based vaccine delivery, the EPI deposits dried particles into the skin at 
supersonic speed. Using this concept, the administered volume can be drastically 
reduced (100 to 500-fold) while the vaccine stability can also be improved [61, 62].  
The dry state may offer a superior long-term stability of the vaccine in comparison to 
liquid formulations. 
In contrast to PowderJect® which used helium gas to blow the spray-dried vaccine 
particles into the skin, the concept of ballistic intradermal vaccination uses a 
pyrotechnical activator as energy source to administer collapse freeze-dried particles 
to the APCs in the epidermis [62-64]. Using such a powerful energy source to 
accelerate the vaccine particles, the device should be designed to canalize the 
generated pressure towards the vaccine particles and contain the blast within the 
combustor due to safety reasons. Energy transfer and safety could be improved using a 
suitable filling material in the combustor surrounding the pyrotechnical activator 
compared to air-filling. Furthermore, the device should resist the mechanical stress 
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and the supersonic acceleration, which could be provided by an optimal choice of 
materials. Beside the properties of the device, the design of the particles could also 
have an impact to skin penetration. Particle characteristics such as size, density, shape 
and morphology have a great influence on the penetration depth of the particles. The 
new concept of collapse freeze-drying can provide lyophilized particles with an 
increased (high) rigidity of the particles [65, 66]. 
Furthermore, particle surface structure and particle porosity can also prevent 
fragmentation of the particles during acceleration and penetration through the 
mechanical barrier (stratum corneum). 
The usage of sugars (carbohydrates) as excipients to stabilize the vaccine during the 
preparation process implicates a rather low density of the particles (700–1200 kg/m³) 
but also promises a fast dissolving and a broad distribution of the vaccine within the 
tissue. However, to achieve appropriate momentum to deposit the low density vaccine 
particles into the skin and prevent inducing pain sizes of 20–70 mm were needed [66]. 
14 
 
1.2 Objectives of this thesis 
This work will outline the manufacturing of a collapse freeze-dried vaccine used as a 
vehicle for a new pyrotechnical device for epidermal powder immunization.  
As a proof of concept, a liquid model vaccine (influenza vaccine) should be stabilized 
using collapse freeze-drying process. In order to provide particles for epidermal 
powder immunization, particles in a range of 20 µm to 80 µm should be prepared to 
avoid pain and bleeding during the application. A characterization and monitoring 
should be conducted to determine any part of the manufacturing process and storage 
conditions of the lyophilizates and the particles (2-8°C, 25°C and 40°C) over a time 
period of 12 months (Chapter 2 and 3). 
 
In preliminary tests (not published work of Elsa Etzl) particles with velocities below 
400 m/s could not breach the mechanical barrier of the skin. In order to determine the 
velocity requirements to penetrate the skin visualization methods of particle velocity 
and skin penetration should be established. A pyrotechnical energy source was 
anticipated to generate sufficient particle velocity for epidermal powder 
administration. Investigations of safety and particle acceleration were to be performed 
to develop a new pyrotechnical device (Chapter 4 and 5).   
 
As proof of concept, a successful immunization using the collapse freeze-dried 
vaccine and the new pyrotechnical device should demonstrated in an animal model. 
The vaccine particles should breach the mechanical barrier of the skin (stratum 
corneum) to deliver the vaccine to the immunocompetent cells located in the 
epidermis. Pigs as laboratory animals should be assessed to provide a proper skin 
model for epidermal powder immunization of humans in the future. The 
administration side, histological changes of the tissue after vaccination and induction 
of immune response should be monitored to demonstrate the successful realization of 
the concept (Chapter 6).  
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2. Chapter - Stability of collapse 
lyophilized influenza vaccine 
formulations 
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2.1 Abstract 
A clear limitation of many liquid vaccines is the obligatory cold-chain distribution 
system. Therefore, distribution of a dried vaccine formulation may be beneficial in 
terms of vaccine stability, handling and transport. Collapse freeze-drying is a process 
which utilizes fairly aggressive but at the same time economic lyophilization cycles 
where the formulation is dried above its glass transition temperature.  
In this study, we used collapse freeze-drying for a thermosensitive model influenza 
vaccine (Pandemrix
®
). The dried lyophilizates were further cryo-milled to engineer 
powder particles in the size range of approximately 20 µm to 80 µm which is 
applicable for epidermal powder immunization. 
Vaccine potency and stability were neither affected by high temperature input during 
collapse lyophilization nor over a storage period of six months. Furthermore, cryo-
milled vaccine lyophilizates showed good storage stability of up to three months at 
high storage temperature (40°C). 
Stabilized collapse lyophilized vaccines do not need a cold-chain-distribution system. 
This technique can provide a powerful tool for the worldwide distribution of vaccine 
and for new application technologies such as engineered powder immunization. 
 
Keywords:  
Powder immunization; vaccination; influenza vaccine; collapse lyophilization; cryo-
milling 
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2.2 Introduction  
Vaccination is one of the most effective medical interventions to prevent viral 
infections [1]. The World Health Organization (WHO) recommends coverage of at 
least 70% - 80% of the population for effective immunization [2-4]. In addition, 
proper storage and handling of vaccines is very important since many vaccines feature 
low stability in liquid formulations, and often storage at 2-8°C is recommended [5]. 
Exposure to temperatures outside the recommended range can compromise vaccine 
stability and result in reduced vaccine potency, making cost-intensive cold-chain 
storage and distribution mandatory.  
New strategies for vaccine stabilization as well as new and simple administration 
technologies are needed to improve accessibility to vaccination. A well-known process 
for pharmaceutical protein stabilization is lyophilization, which is a time and energy 
consuming process. Therefore, a more economical collapse lyophilization process was 
established. Collapse lyophilization is characterized by freeze-drying above the glass 
transition temperature (Tg`). Higher temperatures are exerted on the product while the 
time period which is necessary to dry the vaccine is shortened distinctively compared 
to conventional lyophilization [6]. Not only can the primary drying time be drastically 
shortened but also can a relaxation of the amorphous sugar matrix be achieved by 
exposure to the higher temperature in the end phase of the drying cycle. This leads to 
visually inhomogeneous but stable products [7, 8]. In addition to a faster and more 
economic process, collapse freeze-drying leads to more dense lyophilizates with a low 
specific surface area (SSA) [7, 9]. Smaller SSA of collapse lyophilizates presents 
lower interfaces for proteins to accumulate and subsequently interact with their 
surroundings. Due to the dry state of proteins in lyophilizates, degradation at higher 
temperature can often be avoided. 
In terms of vaccine application, intradermal administration of vaccines using devices 
such as microneedles or epidermal powder immunization (EPI) could simplify the 
accessibility to vaccination [10-12]. The skin, not only organized as a mechanical 
barrier to pathogens, is also an active immune organ [13]. Highly specialized 
intradermal immune cells (Langerhans cells and dendritic cells) located in the 
epidermis can trigger immune response after an intradermal administration of vaccines 
22 
 
[13-15]. In addition, vaccine administration into the skin using EPIs is a minimally 
invasive type of application, which increases patient compliance and eliminates 
needle-stick injuries. The lack of tissue lesions, bleedings, and needle-stick injuries 
after EPI administration can help to minimize the risk of disease transmission [16, 17].  
In our study, we used an influenza vaccine as a model because the antigen 
hemagglutinin (HA) is (very) thermo-sensitive and thus a suitable indicator for 
temperature related product changes. Furthermore, influenza vaccinations are in focus 
due to their socioeconomic importance [18-20]. Influenza infections circulate 
worldwide, can occur among people of all ages regardless of socioeconomic 
background, and are associated with high morbidity and mortality. In particular, 
people aged 65 or older and younger children are at risk [1,21-24]. Annual influenza 
epidemics in developing countries are a public health and economic concern when 
health care and surveillance systems are less developed, and thus an influenza 
infection can spread faster and more distinctive.  
A commercially available H1N1 vaccine (Pandemrix
®
, GlaxoSmithKline, Rixensart, 
Belgium) was chosen. The process of preparation and stabilization by collapse 
lyophilization was controlled by monitoring stability and biological activity of 
hemagglutinin. Changes were detected using analytical methods such as a 
hemagglutination inhibition assay (HAI), westernblot analysis, and subvisible particle 
measurements. Quantification of hemagglutinin in the H1N1 vaccine was performed 
using reversed-phase liquid chromatography (RP-HPLC). In order to determine the 
quality of the lyophilizates, residual moisture and SSA of lyophilizates were 
measured. Collapse-freeze drying results in more compact collapse lyophilizates 
which will then form the basis for highly dense powder particles for epidermal powder 
administration [7]. The freeze-dried H1N1 model vaccine lyo cakes were subsequently 
ground by cryo-milling to achieve particles in the range of 20 µm – 80 µm.d. In this 
study, we demonstrate a successful stabilization and characterization of a thermo-
sensitive model influenza vaccine for epidermal powder immunization.  
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2.3 Material and Methods  
2.3.1 Materials 
A H1N1 influenza vaccine (Pandemrix
®
, GlaxoSmithKline, Rixensart, Belgium) was 
used as a model vaccine and was kindly provided by the Bavarian State Ministry of 
Environment and Public Health. The commercial product contains 15 µg/ml 
hemagglutinin formulated in phosphate buffer with polysorbate 80, octoxynol 10 and 
thiomersal. Prior to administration, the vaccine is normally mixed with the adjuvant 
AS03 containing squalene, DL-α- tocopherol, and polysorbate 80. The adjuvant part 
was not used in our experiments. Sodium hydrogen phosphate monohydrate was 
purchased from Gruessing (Gruessing, Filsum, Germany), and sodium dihdydrogen 
phosphate dehydrate, sodium phosphate monobasic and dibasic, sodium hydroxide, 
and sodium chloride were obtained from Applichem (Applichem, Darmstadt, 
Germany). Trehalose was used as lyoprotectant and purchased from BDH Prolabo 
(VWR, Ismaning, Germany). Mannitol was used as bulking agent and obtained from 
Boehringer Ingelheim (Ingelheim, Germany). All other chemical were of at least 
analytical grade. 
 
2.3.2 Methods 
2.3.2.1 Tangential flow filtration (TFF) for vaccine 
concentration enrichment 
The influenza vaccine was concentrated using a tangential flow filtration method as 
described by Kommareddy et al. [25]. A filtration cassette Minimate™ (PALL, 
Dreieich, Germany) with a cut-off pore size of 5 kDa was used. Prior to usage, the 
TFF cassette was sanitized with 0.5 M NaOH at 45°C for 45 min as recommended by 
the manufacturer (PALL, Dreieich, Germany). Subsequently, the TFF cassette was 
rinsed with highly purified water (Sartorius Arium Pro, Sartorius, Goettingen, 
Germany) until a neutral pH was measured using a seveneasy® pH-meter (Mettler 
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Toledo, Giessen, Germany). After saturation of the TFF-cassette membrane with 
200 ml of circulating vaccine solution over a time period of 60 min, concentration of 
the vaccine was carried out at a temperature of 2-8°C. Concentration of H1N1 
influenza vaccine (Pandemrix
®
) was performed at a flow rate of 100 ml/min as 
recommended by the manufacturer (PALL, Dreieich, Germany). A peristaltic pump 
(Masterflex, Ponndorf, Germany) was used to pressurize the membrane chamber while 
the vaccine solution was in contact with the membrane. The initial vaccine volume 
was reduced to 4%, which results in a hemagglutinin concentration which is 10 -
13 times higher than the initial concentration (final concentration 150 µg/ml). The 
final hemagglutinin concentration was determined by fluorescence detection following 
reversed phase high performance liquid chromatography (RP-HPLC) as described 
later. Subsequently, the concentrated vaccine was dialyzed against 10 mM phosphate 
buffer (0.22 µm filtered) (PALL life Sciences, Ann Arbor, USA) to reduce salts in 
order to avoid a phase separation during freeze-drying.  
 
2.3.2.2 Adjustment of vaccine concentration  
The amount of hemagglutinin in the concentrated vaccine solution was determined by 
RP-HPLC and calculated as follows: the area under the curve (AUC) of HA of the 
commercial product was compared to the AUC of modified vaccine solution. The 
hemagglutinin peak was recorded using a fluorescence detector (λex 280 nm and 
λem 335 nm) and the AUC of the commercial product (15 µg/ml hemagglutinin) was 
determined. The AUC of the commercial product was then compared to the 
concentrated vaccine solution by TFF. Prior to lyophilization, the concentration of 
hemagglutinin was adjusted to 150 µg/ml with 10 mM phosphate buffer. 
 
2.3.2.3 Preparation of a heat-stressed vaccine sample as 
control 
Pandemrix
®
 was heated to 70°C for 100 minutes in a Binder FED 53 heating chamber 
(Binder GmbH, Tuttlingen, Germany) to obtain a control vaccine for the analytics 
containing heat-stressed hemagglutinin.  
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2.3.2.4 Addition of lyoprotectants and bulking agents 
The concentrated vaccine solution was mixed with trehalose and mannitol (1:1) (w/w) 
to obtain a final concentration of 15% solid content and a hemagglutinin concentration 
of 3.75 µg/mg in the lyophilizate. The mixture was gently stirred at approximately 
50 rpm using a magnetic stirrer (IGAMAG RCT, IKA®-Werke GmbH & Co. KG, 
Staufen, Germany) to dissolve the excipients. The final concentration of 150 µg/ml in 
the final lyophilization mixture (H1N1 influenza vaccine-carbohydrate solution) was 
determined using fluorescence detection following RP-HPLC.  
 
2.3.2.5 Lyophilization process 
The final vaccine-carbohydrate solution (2.625 ml) was pipetted into DIN 10R vials 
(MGlas AG, Muennerstadt, Germany) with a resulting filling level of approximately 
1 cm, semi-stoppered using Westar®RS.stoppers (Westpharma, Exton, USA) and 
transferred to the freeze-dryer. Lyophilization was performed using a Martin Christ 
Epsilon 2-6D freeze-dryer (Martin Christ, Osterode, Germany) equipped with a pirani 
pressure sensor. The middle shelf was loaded with 126 vials. Vials containing the final 
vaccine-carbohydrate solution were bordered by two rows of edge vials containing a 
15% trehalose-mannitol (1:1) (w/w) solution in 10 mM phosphate buffer to obtain a 
homogenous temperature impact to the vaccine-carbohydrate formulation in the 
center. At the start of the lyophilization cycle, samples were equilibrated at 4°C for 
one hour and subsequently frozen to -50°C using a ramp within 1.5 hours. The 
freezing temperature was isothermally held for one hour. Afterwards, the temperature 
was increased to -40°C using a ramp of 0.33°C/min. When the process reached -40°C 
the chamber pressure was reduced to 1.98 mbar. After a short equilibration time the 
shelf temperature was increased to 45°C within 2 hours. Primary drying was carried 
out for 24 hours at 45°C. After the primary drying, the chamber pressure was further 
decreased to 0.3 mbar. These conditions (0.3 mbar / 45°C) were maintained for further 
20 hours. At the end of the secondary drying, the temperature was reduced to the 
storage temperature of 4°C. Finally, the samples were stoppered at approximately 
800 mbar with dry nitrogen gas atmosphere and crimped after unloading as described 
by Kis et al. [72]. 
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The final protein (HA) concentration content of the HA in collapse lyophilizates were 
determined using RP-HPLC with fluorescence detection. 
 
2.3.2.6 Cryo-milling of lyophilizates and sieving  
Cryo-milling was performed using a Retsch CryoMill (Retsch Technology GmbH, 
Haan, Germany). Samples were cooled to -196°C using liquid nitrogen in stainless 
steel milling jars (Retsch Technology GmbH, Haan, Germany). An amount of 
approximately 1.5 g of the lyophilizates was filled into a stainless steel jar and two 
steel balls were added. A pre-cooling for 10 min with a milling frequency of 5 Hz was 
carried out before grinding was performed at 25 Hz for 15 sec. To avoid water 
condensation after the milling process, the chilled jar was placed into a custom made 
glovebox (workshop at the Ludwig-Maximilians-University Munich, Germany) which 
was flushed with nitrogen gas of low humidity (< 3%). Jars were left to equilibrate to 
room-temperature for two hours. Afterwards sieving through sieves (Retsch 
Technology GmbH, Haan, Germany) with mesh sizes of 20 µm, 40 µm, 80 µm and 
125 µm was performed. Classifying by sieving was carried out for 10 minutes and the 
powder was weighed afterwards. These steps were repeated until the mass of the 
powder on each sieve did not differ more than 1% from the previous weighing. 
Aliquots of the ground and classified samples were filled in DIN 10R vials under dry 
nitrogen atmosphere and stoppered with Westar
®
RS.stoppers (Westpharma, Exton, 
USA). 
 
2.3.2.7 Residual moisture content determination by Karl-
Fischer titration 
Residual moisture contents of all lyophilizates and the cryo-milled lyophilizates were 
analyzed to determine successfully stabilized collapse freeze-dried products. Residual 
moisture determination was performed using a Karl-Fischer direct injection method 
(737 KF Coulometer, Metrohm, Filderstadt, Germany). Sample aliquots between 
10 mg to 50 mg were filled in DIN 2R vials (Mglas AG, Muennerstadt, Germany) in a 
Glovebox under dry nitrogen gas atmosphere (< 10%) measured with a thermo-
hygrometer (TFA Dostmann, Wertheim, Germany). Each vial was filled with 
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approximately 2.5 ml methanol (Hydranal
®
-Methanol dry, Sigma-Aldrich, 
Taufkirchen, Germany) with very low water content and were placed into an 
ultrasonic bath for 15 minutes (Sonorex TK52, Bandelin electronics, Berlin, 
Germany). Finally, 1 ml of the solution was injected into the coulometric titrator. 
Results were calculated and are given as relative water content in percentage (m/m). 
Three independent measurements of samples of each storage temperature and time 
point were collected.  
 
2.3.2.8 Specific surface area (SSA) determination 
The Brunauer-Emmet-Teller (BET) krypton gas adsorption method was used to 
determine the SSA of lyophilizates and cryo-milled lyophilizates. The krypton 
adsorption on the surface of the specimen carried out in a liquid nitrogen bath (77.3 K) 
using an Autosorb 1 (Quantachrome, Odelzhausen, Germany). Weighed samples were 
outgassed for 2 hours at room temperature using the Autosorb 1 outgassing connection 
(Quantachrome, Odelzhausen, Germany). Sample measurement was performed 
applying an eleven point measurement curve. Data were collected using the Autosorb 
1 software (Quantachrome, Odelzhausen, Germany), and the SSA was calculated 
using a multipoint BET method fit. Three independent measurements were performed. 
To identify the impact of HA to SSA, 10 mM phosphate buffer was also mixed with 
trehalose and mannitol (1:1) (w/w) to a 15% solid content (w/w). 
 
2.3.2.9 Scanning electron microscopy (SEM) 
Samples were attached onto an adhesive carbon tape (Bal-tec GmbH, Germany) and 
subsequently sputtered with carbon under high vacuum (MED 020, Bal-tec GmbH, 
Germany). Samples were viewed using a scanning-electron microscope (Supra 55VP, 
Zeiss SMT, Germany) under high vacuum. Scanning electron micrographs were 
recorded at 100 fold and 300 fold magnifications. 
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2.3.2.10 Storage conditions for lyophilizates and cryo-
milled lyophilizates 
Samples (lyophilizates and cryo-milled lyophilizates) were stored at temperatures of 2-
8°C, 25°C, and 40°C in order to determine the stability of hemagglutinin over a period 
of up to six months at room humidity (65-80%). Data were collected after 2, 4, 12 
weeks, and 6 months. Collapse freeze-dried samples (0.395 mg) were reconstituted 
with 2.23 ml highly purified water for further examination to obtain a final 
concentration of 15 µg/ml of the samples for each storage time point. 
 
2.3.2.11 Reversed-phase liquid chromatography  
(RP-HPLC) 
For the determination of the hemagglutinin content in the samples an RP-HPLC 
method was established using a Dionex HPLC system equipped with a Dionex P680 
HPLC Pump, ASI-100 automated sample injector, Dionex Column oven, Dionex RF-
2000 Fluorescence Detector and a Dionex UVD170u UV/VIS-detector (Dionex, 
Idstein, Germany). A Phenomenex Jupiter 5 µ, C18, 300 A column (250 x 4.6 mm) 
(Phenomenex, Aschaffenburg, Germany) was used for separation. Chromatographic 
separation was carried out at 60°C with a gradient elution over 30 min at a flow rate of 
1.0 ml/min. Eluent A consisted of highly purified water with 0.1% trifluoric acid and 
eluent B comprised 75% 2-propanol, 25% acetonitrile and 0.1% trifluoric acid. At the 
start the eluent mixture consisted of 20% eluent B, which was increased to 36% within 
10 min. During the next 4 min eluent B was increased to 95% and this concentration 
was held for further 4 min. Eluent B was abruptly reduced again to 20% after the 
plateau phase. The column was flushed for 12 min with eluent B at 20% to achieve re-
equilibration. 25 µl of each sample was injected and hemagglutinin content was 
determined using the intrinsic fluorescence of hemagglutinin at λex 280 nm and 
λem 335 nm. For each storage temperature and time point, three independent 
measurements of the specimens were analyzed. The lyophilized and cryo-milled 
samples were collected at each time point (2 weeks, 4 weeks 12 weeks and 6 months) 
and were compared against the heat stressed control vaccine (70°C/100 min), and the 
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liquid vaccine-carbohydrate solution stored at 2-8°C. Data acquisition and analysis 
was performed using Chromeleon 6.80 software (Dionex, Idstein, Germany).  
 
2.3.2.12 Light obscuration measurements 
Light obscuration was measured using a PAMAS SVSS-35 particle counter (PAMAS 
- Partikelmess- und Analysensysteme GmbH, Rutesheim, Germany) equipped with an 
HCB-LD-25/25 sensor. Particle diameters in the range of 1 to 200 µm were 
determined in reconstituted lyophilizates, H1N1 commercial product, heat stressed 
vaccine, and buffer medium. Prior to each measurement, the system was rinsed with 
3.0 ml highly purified water. The measurement was started when the particle counts 
> 1 µm in highly purified water was below 10 particles/ml and no particles > 10 µm 
were detected. Subvisible particles were counted in a sample volume of 0.3 ml. The 
measurement was repeated three times for each storage temperature (2-8°C, 25°C, and 
40°C) at every time point (2/4/12 weeks and 6 month). Data was collected using the 
PAMAS PMA software (PAMAS - Partikelmess- und Analysensysteme GmbH, 
Rutesheim, Germany). Results were given in cumulative particle per ml.  
 
2.3.2.13 Turbidity measurements 
Turbidity of reconstituted samples was determined using a Hach Lange Nephla 
nephelometer (Hach Lange GmbH, Düsseldorf, Germany). Samples (2.0 ml) were 
analyzed in pre-rinsed turbidity glass cuvettes with a flat bottom (Hach Lange GmbH, 
Düsseldorf, Germany). Turbidity was measured at a wavelength of λ = 860 nm and 
detected at an angle of 90°. Turbidity is reported in formazine nephelometric units 
(FNU). Each sample was measured twice. After the first measurement the cuvette was 
turned 90° and was measured again. For each time point and storage temperature, 
three specimens were analysed. Pandemrix
®
 commercial product and Pandemrix
®
 heat 
stressed vaccine as well as the buffer mediums were investigated and compared to the 
reconstituted lyophilizates for control purposes. 
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2.3.2.14 Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-Page) 
SDS-Page analysis was performed to determine proteins, protein fractions, 
degradation of antigen and the protein content of the vaccine. The different forms of a 
hemagglutinin (e.g. subunit, monomer, dimer, trimer of HA) were separated by their 
electrophoretic mobility. Reconstituted samples (15 µg/ml) were mixed with Laemmli 
buffer at a ratio of 1:1 (250 mM Tris(hydroxymethyl)-aminomethane, 1% of a 0.1% 
Bromphenol blue solution (Merck Darmstadt, Germany), 4% SDS (Sigma-Aldrich 
Taufkirchen, Germany), 23% of glycerol (AppliChem, Darmstadt, Germany). The 
mixtures were boiled at 95°C for 20 min in a block-thermostat Grant QBT (Grant 
Instruments, Cambridgeshire, Great Britain). 10 µl of each cooled sample was pipetted 
into a well of a Novex NuPAGE 10% Bis-Tris gel (life technologies, Carlsbad, USA). 
Mark12 protein standard ladder (life technologies, Carlsbad, USA) was used for 
comparison. Separation was performed with an electrophoresis module (Bio-Rad, 
Munich, Germany). The module was filled with a diluted Novex NuPAGE MES SDS-
Runnung buffer 20x (life technologies, Carlsbad, USA) as recommended. 
Electrophoresis was carried out at 100 V for 15 min and 160 V for a further 45 min. 
The SDS-Page gel was then transferred for 60 minutes into a bath of Imperial Protein 
stain (Thermo Fischer scientific, Rockford, USA) to develop a Coomassie brilliant 
blue staining. Finally the SDS-Page gel was scanned (Epson Perfection V370, Epson, 
Japan), and the protein fractions were compared to the protein standard ladder.  
 
2.3.2.15 Westernblot analysis 
The structural integrity of hemagglutinin was tested by Westernblot analytics. A SDS-
Page gel (10% Bis-Tris gel) was prepared according to the SDS-Page assay described 
above up to the staining step. Instead of a Mark12 Protein standard ladder, a 
MagicMark western protein standard (life technologies, Carlsbad, USA) was used. 
After protein separation, proteins were transferred to a nitrocellulose membrane 
(Hybond-ECL™, Amersham Bioscience, Freiburg, Germany) via tank electro-blotting 
for 90 min at 100 V. A blotting sandwich was prepared containing 10% Bis-Tris gel 
and nitrocellulose membrane, which were embedded in a layer of Rotilabo blotting 
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paper (Roth, Karlsruhe, Germany) and pads. The blotting sandwich was transferred 
into a box filled with cold Tank buffer cooled using a thermal pack (cooled to -80°C) 
within the blotting tank and storage in a chilled room at 2°-8°C to avoid excessive heat 
during electro-blotting. A 5x Tank buffer containing 240 mM Tris (hydroxymethyl)-
aminomethane (Sigma-Aldrich, Taufkirchen, Germany), 195 mM Glycine 
(Applichem, Darmstadt, Germany) and highly purified water to 1000 ml was used. 
20% of 5x Tank buffer was mixed with 20% methanol and highly purified water to the 
final volume. After blotting, the nitrocellulose membrane was shortly washed with 
10% of a 10x Tris-buffered saline and Tween 20 solution (TBS-T). The 10x TBS-T 
contains 500 mM Tris(hydroxymethyl)-aminomethane (Merck, Darmstadt, Germany), 
3.8 M NaCl (BDH Prolabo, VWR, Ismaning, Germany), 1% Tween 20 (Fluka, Sigma-
Aldrich, Taufkirchen, Germany), diluted with highly purified water to the required 
quantity. Afterwards, the nitrocellulose membrane was incubated in a 5% milk powder 
blocking solution for 2 hours on a horizontal shaker (100 rpm per minute) (VWR 
Ismaning, Germany) and subsequently washed with TBS-T. Thereafter, incubation in 
20 ml of 1% milk powder TBS-T solution with a murine monoclonal anti-
hemagglutinin antibody (Sino biological Inc., Beijing, China) at a concentration of 
1.5 µg/ml was carried out for 12 hours at 2-8°C. After a further washing step the 
nitrocellulose membrane was incubated with a secondary antibody, polyclonal anti-
mouse-antibody with a fluorophor (λex 778 nm and λem 795 nm) (LI-COR, Lincoln, 
USA) in a 20 ml of 1% milk powder-TBS-T solution for 2 hours in a horizontal shaker 
(100 rpm per minute) (VWR Ismaning, Germany). After the final washing step with 
TBS-T, the membrane was analyzed using a LI-COR Odyssey infrared imaging 
system (LI-COR, Lincoln, USA).  
 
2.3.2.16 Hemagglutination inhibition assay (HAI) 
Biological activity of hemagglutinin was tested by an adapted hemagglutination 
inhibition assay [26, 27]. A 25% chick whole-blood solution (Labor Dr. Merk & 
Kollegen GmbH, Ochsenhausen, Germany) was diluted with Dextrose-Gelatine-
Veronal buffer (DGV-buffer) (Labor Dr. Merk & Kollegen GmbH, Ochsenhausen, 
Germany) to a final concentration of 0.5% (v/v). Each well of a 96 microtiter V-
shaped well-plate (Nunc V96, Thermo Fischer scientific, Rockford, USA) was filled 
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with 50 µl of Agglutest buffer (Labor Dr. Merk & Kollegen GmbH, Ochsenhausen, 
Germany) excluding the first column. The first column of the microtiter plate was 
filled with 100 µl of each sample. Subsequently, two-fold dilution steps were 
performed each with a transfer of 50 µl. Finally, 50 µl of 0.5% chick whole-blood 
solution were added to each well. After agitating the microtiter plate at 350 rpm for 
30 sec, the well-plate was incubated at 37°C for 45 min. The endpoint was determined 
by the characteristic red dot formation of sedimented erythrocytes in the center of the 
well. The amount of hemagglutinin at the end point can be calculated of the serial 2-
fold dilution. Three independent samples of each storage temperature and time point 
were measured. 
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2.4 Results 
2.4.1 Hemagglutinin quantification using  
RP-HPLC 
Quantification of HA in all liquid vaccine samples as well as the reconstituted 
lyophilizates and cryo-milled lyophilizates was carried out using RP-HPLC. The 
retention time of hemagglutinin in all samples including the retention time of the 
commercially available product was approximately 17.40 min ± 0.15 min (Figure 
2.4.1). The results indicated that neither the storage period up to six months nor the 
process of cryo-milling altered the hemagglutinin concentration detected by the 
fluorescence detector. The deviation of the fluorescence units [mV*min] of cryo-
milled lyophilizates was slightly higher compared to non-cryo-milled lyophilizates. 
The stressed vaccine samples (70°C/100 min) unexpectedly exhibited a similar protein 
peak and fluorescence value as unstressed samples (Figure 2.4.1), no major changes to 
the hemagglutinin structure were observed.  
 
Figure 2.4.1: Fluorescence units of the commercially available product (15 µg/ml), stressed 
vaccine (15 µg/ml), and collapse lyophilized vaccine (15 µg/ml) after 6 months of storage 
Three independent measurements were performed (n=3) 
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2.4.2 Light obscuration measurements 
All freeze-dried samples (lyophilizates and cryo-milled lyophilizates) were 
reconstituted with highly purified water to a final concentration of 15 µg/ml. The 
samples were analyzed by light obscuration to determine any formation of aggregates 
induced by the preparation process (concentration by TFF, collapse lyophilization, 
cryo-milling) or storage conditions. The reconstituted samples (lyophilizate and cryo-
milled lyophilizate) were compared to the final vaccine-carbohydrate solution 
(15 µg/ml) stored at 2-8°C, the stressed vaccine (70°C/100 min, 15 µg/ml) stored at 2-
8°C and 0.22 µm filtered trehalose-mannitol solution. The results of the subvisible 
particle measurements > 1 µm > 10 µm are shown in Figure 2.4.2. 
Particle counts of particles > 1 µm were observed for the commercial product 
2754 counts/ml ± 40 counts/ml, the heat stressed vaccine (70°C/100 min) 
5005 counts/ml ± 73 counts/ml, collapse lyophilizates 4729 counts/ml± 879 counts/ml, 
and the cryo-milled lyophilized 5566 counts/ml ± 463 counts/ml. In all samples 
particle counts > 10 µm were below 600 counts/containment (10R vial), which is in 
line with the requirements by the European Pharmacopoeia (Ph. Eur.) for particle 
counts within a container (vial). Concentration by TFF and collapse lyophilization 
increased particles counts (>1 µm) to a level comparable to the stressed vaccine 
(Figure 2.4.2), stressed vaccine compared to t0 of reconstituted lyophilizates). The 
additional cryo-milling step increased the particle count approximately two to 
threefold in comparison to the final vaccine-carbohydrate solutions at the start of the 
study (time point t0). Measurements of reconstituted lyophilizates showed a 
homogenous particle distribution with low particle counts > 10 µm. On the contrary, 
subvisible particle distribution of cryo-milled lyophilizates depended on storage 
temperature and time period. Light obscuration measurements of cryo-milled samples 
stored at 2-8°C indicated higher counts of particles > 1 µm but lower counts for 
particles > 10 µm compared to the other storage temperatures. Lyophilizates stored at 
25°C and 40°C had comparable counts of particles > 1 µm. Particle counts for cryo-
milled lyophilizates stored at 25°C > 10 µm decreased over storage time whereas the 
reverse was seen for samples stored at 40°C. 
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Figure 2.4.2: A) Subvisible particles > 1 µm of vaccine lyophilizates B) subvisible 
particles  > 10 µm of lyophilizates C) subvisible particles > 1 µm of cryo-milled lyophilizates 
D) subvisible particles > 10 µm of cryo-milled lyophilizates stored at different storage 
temperatures and over a time period of six months. Three independent measurements were 
performed (n=3) for comparison of the buffer solution, commercial product, stressed vaccine 
(70°C/100min), lyophilizate, and cryo-milled lyophilizate. 
 
2.4.3 Turbidity measurements 
Generally, reconstituted lyophilizates showed a constant turbidity value over six 
months apart from reconstituted cryo-milled lyophilizates stored at 40°C The heat 
stressed vaccine as well as the cryo-milled lyophilizates showed an increased turbidity 
indicating an increased formation of agglomerations and therefore higher amounts of 
larger particles (Table 2.4.1). A rise in turbidity over time was detected in cryo-milled 
samples stored at 25°C and 40°C. The turbidity in cryo-milled lyophilizates stored at 
40°C increased distinctly after three and six months of storage. 
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Table 2.4.1: Turbidity of vaccine lyophilizates and cryo-milled lyophilizates stored at different 
storage temperatures and over a time period of six months. Three independent measurements 
were performed (n=3) for comparison of the buffer solution, commercial product, stressed 
vaccine (70°C/100min), lyophilizate, and cryo-milled lyophilizate. 
Sample Storage  
temperature [°C] 
Turbidity  
[FNU] 
Deviation  
[FNU] 
Time point 
Trehalose-mannitol buffer 2-8 0.50 ±0.01 All time points 
Commercial product 2-8 3.11 ±0.02 All time points 
Vaccine stressed (70°C/100min) 2-8 5.27 ±0.08  
Lyophilizate  11.56 ±0.14 t0  
Lyophilizate  2-8 11.43 ±0.33 2 weeks 
Lyophilizate  2-8 12.07 ±0.04 4 weeks 
Lyophilizate  2-8 14.01 ±0.16 12 weeks 
Lyophilizate  2-8 11.84 ±0.15 6 months 
Lyophilizate  25 11.27 ±0.15 2 weeks 
Lyophilizate  25 11.66 ±0.18 4 weeks 
Lyophilizate  25 11.85 ±0.45 12 weeks 
Lyophilizate  25 11.66 ±0.10 6 months 
Lyophilizate  40 11.64 ±0.56 2 weeks 
Lyophilizate  40 12.32 ±0.06 4 weeks 
Lyophilizate  40 11.63 ±1.04 12 weeks 
Lyophilizate  40 12.92 ±0.06 6 months 
Cryo-milled  2-8 11.89 ±0.45 2 weeks 
Cryo-milled  2-8 11.67 ±0.02 4 weeks 
Cryo-milled  2-8 12.07 ±0.42 12 weeks 
Cryo-milled  2-8 12.21 ±0.55 6 months 
Cryo-milled  25 11.01 ±0.74 2 weeks 
Cryo-milled  25 11.99 ±0.17 4 weeks 
Cryo-milled  25 13.18 ±0.06 12 weeks 
Cryo-milled  25 12.78 ±0.67 6 months 
Cryo-milled  40 11.54 ±0.47 2 weeks 
Cryo-milled  40 12.53 ±0.14 4 weeks 
Cryo-milled  40 16.24 ±0.23 12 weeks 
Cryo-milled  40 17.32 ±0.35 6 months 
 
2.4.4 Sodium dodecyl sulfate-Polyacrylamide gel 
electrophoresis (SDS-Page) 
SDS-Page was performed to confirm hemagglutinin integrity. Hemagglutinin could 
potentially aggregate or fragment during processing and storage. The antigen consists 
of two subunits, HA1 (Mw of approximately 55 kDa) and HA2 (Mw of approximately 
25 kDa). The monomer HA (Mw of 75 - 80 kDa) can form dimers (Mw of 150 - 160 
kDa) and trimers (Mw of approximately 210 kDa). Bands in the SDS-Page gel were 
observed at the predicted Mw of HA1, monomer, dimer and trimer in all samples at 
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different storage temperatures (Figure 2.4.3) Cryo-milled lyophilizates demonstrated 
similar migration patterns compared to non-ground lyophilizates. Bands were also 
detected at the predicted molecular weight (Mw) (Figure 2.4.3B). However, 6 month 
storage at 40°C of cryo-milled lyophilizates induced immobile formation of aggregates 
in the well (Figure 2.4.3B). Generally, higher storage temperature of the cryo-milled 
samples resulted in higher visible amounts of agglomerations (Figure 2.4.3A vs. B).  
  
Figure 2.4.3: SDS-Page results after 6 months of storage A) lyophilizate and B) cryo-milled 
samples at different storage temperatures. Column A1 and B1) commercial product; column 
A2 and B2) liquid pre-lyophilizate-carbohydrate formulation; A3) lyophilizate stored at 2-8°C; 
A4) lyophilizate stored at 25°C; A5) lyophilizate stored at 40°C; B3) cryo-milled lyophilizate 
stored at 2-8°C; B4) cryo-milled lyophilizate stored at 25°C; B5) cryo-milled lyophilizate 
stored at 40°C; C2) lyophilizate; C3) cryo-milled lyophilizate; and C4) liquid pre-lyophilizate 
formulation. 
 
2.4.5 Westernblot analysis 
Westernblot was performed to test structural integrity and antigenicity of 
hemagglutinin in the H1N1 vaccine. The various states of hemagglutinin (HA1, 
monomer, dimer, and trimer) were not observed in every sample in the assays. The 
three states of hemagglutinin (monomer, dimer, and trimer) were only detected at time 
point t0 in all samples (Figure 2.4.4C). Westernblot results of lyophilizates were 
consistent at all storage temperatures and over the time period of six months. Usually, 
monomer and dimer were observed at the predicted Mw (Figure 2.4.4) on the scans. 
Results of cryo-milled samples showed an alteration over the time period of six 
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months, especially for samples stored at 40°C. Nonetheless, the cryo-milled samples 
stored at 25°C demonstrated still a structural integrity of HA (six months of storage) 
(Figure 2.4.4B).  
  
 
Figure 2.4.4: A) Westernblot results after 6 months of storage A) lyophilizate, B) cryo-milled 
samples and C) samples at t0 at different storage temperatures. Column A1, B1 and C1) 
commercial product; column A2 and B2) liquid pre-lyophilizate-carbohydrate formulation; 
A3) lyophilizate stored at 2-8°C; A4) lyophilizate stored at 25°C; A5) lyophilizate stored at 
40°C;; B3) cryo-milled lyophilizate stored at 2-8°C; B4) cryo-milled lyophilizate stored at 
25°C; B5) cryo-milled lyophilizate stored at 40°C;.C2) lyophilizate; C3) cryo-milled 
lyophilizate; and C4) liquid pre-lyophilizate formulation. 
 
2.4.6 Hemagglutination inhibition assay (HAI) 
Similar erythrocyte sedimentation was observed for all reconstituted lyophilizates and 
cryo-milled lyophilizates at a defined dilution (64 fold) independent of storage 
temperatures or time period (Figure 2.4.5). Hemagglutinin in heat stressed vaccine 
(70°C / 100 min) as a negative control was not able to cross-link the erythrocytes. 
Erythrocyte sedimentations were observed in each well in the 2–fold dilution row from 
the start. HAI of lyophilizates demonstrated a consistent dilution of hemagglutinin (at 
64 fold dilution), where the sedimentation of erythrocytes occurred as red dots at the 
bottom of the wells (Figure 2.4.5). Hemagglutination of erythrocytes took also place at 
a dilution of 64 fold in samples of cryo-milled lyophilizates. However, a slightly 
increased deviation was observed in cryo-milled lyophilizates (Figure 2.4.5A). 
Hemagglutinin showed consistently good biological activity over the time period of 
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six months and at different storage temperatures. Therefore, the stage of dilution 
where the hemagglutination could not be established, was similar as in the first sample 
at t0 (64 fold dilution, equal to 0.23 µg/ml of hemagglutinin). The end point 
determined as red dots with sedimented erythrocytes were clearly distinguishable to 
the diffuse patch of erythrocyte in non-hemagglutinated wells.  
 
 
Figure 2.4.5: Results of hemagglutination inhibition assay of A) lyophilizates and B) cryo-
milled lyophilizates at different storage temperatures and different time points. Three 
independent measurements were performed (n=3). 
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2.4.7 Determination of the residual moisture 
content 
Generally, lyophilizates exhibited low residual moisture contents over time, reaching 
only 1.5% after 6 month at 40°C and approximately 1% for all other storage 
temperatures. Cryo-milled samples had 2-2.5% residual moisture after the milling. The 
residual moisture was below 3%, only at 40°C the residual moisture increased to 3.5% 
after storage (Figure 2.4.6). 
 
 
Figure 2.4.6: Residual moisture content of A) vaccine lyophilizates and B) cryo-milled 
vaccine lyophilizates stored at different storage temperatures and over a time period of six 
months. Three independent measurements were performed (n=3)  
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2.4.8 Scanning electron microscopy (SEM) 
Electron microscopy was performed to confirm the structure of the collapse 
lyophilizate. Characteristic large pores for collapse lyophilizates were clearly 
detectable (Figure 2.4.7A and B) in the electron micrographs of lyophilizates. The 
surface was rough with sharp edges (Figure 2.4.7A and B). After cryo-milling, 
particles in the SEM micrographs of lyophilizates displayed the expected powder size 
between 20 µm and 80 µm but with a different surface morphology (Figure 2.4.7C 
and D). Distinguishing a single particle from formation of particle agglomerates was, 
however, not possible using SEM analysis. 
  
  
Figure 2.4.7: Scanning electron micrographs A and B) lyophilizates (A: magnification: 100 
fold; B: magnification: 300 fold); C and D) cryo-milled lyophilizates (C: magnification: 100 
fold; D: magnification: 300 fold). 
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2.4.9 Determination of the specific surface area 
(SSA) 
Placebo collapse lyophilizates (carbohydrate solution) with trehalose-mannitol 
formulations (1:1) (w/w) and a 15% solid content (w/w) in a 10 mM phosphate buffer 
had a SSA of 0.5901 m²/g ± 0.0211 m²/g. Vaccine samples containing hemagglutinin 
demonstrated a lower SSA value compared to placebo samples (Table 2.4.2). The 
cryo-milling process increased the SSA almost to the value of non-ground placebo 
formulation.  
 
Table 2.4.2: Specific surface area (SSA) results measured using a BET-method. Three 
independent measurements were performed (n=3). 
Sample SSA 
[m
2
/g] 
Standard 
deviation 
[m
2
/g] 
Trehalose:mannitol (1:1) 15% solid content (w/w)  0.5990 0.0211 
Vaccine (trehalose:mannitol) 15% solid content [3.75 µg/mg] 0.2794 0.0482 
Cryo-milled vaccine (trehalose:mannitol) 15% solid content 
[3.75 µg/mg] 
0.5055 0.0627 
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2.5 Discussion 
In this work, we aimed to stabilize influenza vaccine as a model for temperature 
sensitive vaccines using collapse lyophilization. We were able to demonstrate that 
influenza vaccine in lyophilizates, prepared by collapse lyophilization, showed a 
sufficient stability at different storage temperatures over a time period of six months.  
The commercial vaccine and lyophilizates were characterized using RP-HPLC. 
Unexpectedly, RP-HPLC results did not reveal any alterations of the hemagglutinin 
structure (and/or function) induced by e.g. heat stress. All samples investigated 
showed comparable retention times and intrinsic fluorescence values. In contrast to 
this finding, the heat stressed samples lost their ability to cross-link erythrocytes which 
was supported by the HAI results.  
Further results from the HAI assay demonstrated that preparation and storage of 
collapse lyophilized at different temperatures vaccine had no detectable impact on 
biological activity. Consistently, inhibition of hemagglutination was observed in 
samples over the time period of six months at any storage temperatures (2°C-8°C, 
25°C and 40°C) up to dilutions of 1: 64. In addition, larger particles measured by light 
obscuration corresponding with less free and active hemagglutinin did not affect HAI 
results. Therefore, no reduction in biological activity of lyophilizates caused by 
formation of agglomerates was observed. Generally, counts of less than 6000 particle 
counts/ml > 1 µm can be considered as a low value for lyophilizates [86]. Moreover, 
counts of subvisible particles matched perfectly the requirements of Ph. Eur. In 
addition, constant turbidity results of reconstituted lyophilizates supported the findings 
of subvisible particle measurement (Table 2.4.1).  
Electrophoretic assays were performed to gain more insight into the structure of the 
agglomerates. SDS-Page is a suitable method to determine alterations of 
hemagglutinin induced by e.g. preparation stress, storage time and/or temperature. 
Unchanged migration distance and estimated Mw of hemagglutinin subunits and/or 
oligomers (HA1, monomer, dimer and trimer) support our assumption that collapse 
lyophilisation did not introduce detrimental modifications to hemagglutinin structure. 
Slightly different intensities of the bands might be attributed to surface irregularities of 
SDS-Page gel and/or the imaging technique using a scanner. Fluctuations in band 
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intensities were also observed in Westernblot analysis. A shift from smaller (HA1 and 
monomer) to larger hemagglutinin oligomers (dimer and trimer) could be deducted 
from the increasing intensities of the dimer and trimer bands (Figure 2.4.3 and Figure 
2.4.4) over the observed time period of six months. This also is in line with the results 
of light obscuration measurement. 
Physico-chemical stability of the freeze-dried samples was investigated by assessing 
moisture content, SSA and microscopic characteristics of the final lyophilizates. 
Moisture in lyophilizates can support chemical and microbiological degradation and 
therefore reduce vaccine stability. The determined values of residual moisture of up to 
1.5% for lyophilizates and 3% for cryo-milled lyophilizates are too low to affect 
lyophilizates integrity [29]. Collapse freeze-drying was performed to additionally 
reduce the SSA and to obtain more dense lyophilizates. SSA of the lyophilizates was 
measured directly after the collapse freeze-drying. The storage temperatures (2-8°C, 
25°C, and 40°C) of lyophilizates were below Tg of the sugar matrix (trehalose:107°C ; 
mannitol 92°C) [30, 31]. While the storage temperature is below Tg, SSA of 
lyophilizate would not show a temperature induced alteration of the sugar matrix [32, 
33]. However, the combination of storage temperature and residual moisture did not 
compromise the lyophilizate stability over a time period of six months.  
Additionally, we prepared powder particles by cryo-milling for EPI. The range of 20-
80 µm of powder particles was described and determined as sufficient to penetrate the 
skin without causing harm and pain [17, 34, 35]. Like the lyophilizates, cryo-milled 
samples were analyzed to determine the stability of the vaccine (hemagglutinin) and 
the stability of the powder particles. Stability can be compromised due to the 
additional cryo-milling step which leads to an increase of SSA. Nonetheless, 
comparable AUCs of the cryo-milled samples to lyophilizates were measured using 
RP-HPLC. However, the higher deviation of cryo-milled samples in fluorescence 
values indicated a thermodynamic process (data not shown). As described above, RP-
HPLC was not suitable to determine any stress impact. Therefore, biological activity 
was assessed using HAI, which revealed a slower sedimentation of erythrocytes in 
samples of cryo-milled lyophilizates and a less clear distinction between diffuse 
erythrocyte patch and red hemagglutinated erythrocyte dot after the incubation time. 
The altered hemagglutination might have been induced by additional stress factors 
during the cryo-milling process as e.g. mechanical and freeze-thaw stress. 
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Agglomeration processes were observed in light obscuration measurements. Stress 
during cryo-milling led to larger particle formation and formations of agglomerates. 
Hemagglutinin-oligomers of the monomers/subunits (SDS-Page and Westernblot) 
were detected in the electrophoretic assays which could be a result of a combination of 
cryo-milling process and storage at high temperatures. The alteration of hemagglutinin 
could reduce the affinity of the specific anti-hemagglutinin antibody to the antigen or 
even prevent binding completely. Both causes can result in a diminishing or a lack of 
bands in Westernblot results. 
Generally, we showed a successful stabilization of influenza vaccine using a fast and 
economic collapse lyophilization. Our technique appears to be capable of generating 
adequately stable hemagglutinin lyophilizates which can be stored at different 
temperatures (2 -8°C, 25°C and 40°C) and over a time period of up to six months. 
Collapse freeze-dried vaccine powder particles showed a high stability in the 
refrigerator (2 -8°C) or at ambient temperatures (25°C). Storage at 40°C resulted in a 
poorer stability of the antigen due to an increased alteration of hemagglutinin. 
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2.6 Conclusion 
We have demonstrated that stabilization of influenza vaccine is possible using collapse 
lyophilization. In the future, this technique could enable a more economical 
distribution of stabilized vaccine to regions in which a cold chain system for liquid 
vaccines is hard to maintain. The stabilization of highly temperature sensitive 
hemagglutinin by an aggressive collapse lyophilization seems promising. Furthermore, 
the lyophilized vaccine demonstrated a high resistance against elevated storage 
temperatures compared to the commercial liquid vaccine formulation. The different 
storage temperatures (2-8°C, 25°C and 40°C) did not affect the stability of the 
lyophilized vaccine.  
Although the stability of the powder particles was decreased compared to non-
processed lyophilizates when stored at 40 °C, vaccine powder particles for EPI seemed 
to be stable at 2-8°C or ambient room temperature (25°C) storage. 
High stability in combination with new developments in administration (EPI) could 
make vaccination more accessible and would close the gap between required and 
available vaccination. 
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3. Chapter - Stability of lyophilized 
influenza vaccine under long-
term storage conditions and in 
presence of oily components 
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3.1 Introduction  
Storage stability emerges as a major issue during the development of vaccine 
formulations. In order to achieve long term stability during storage, liquid vaccines are 
normally stored at 2-8°C due to an accelerated degradation or protein inactivation at 
temperatures outside this range. These temperature-dependent limitations make cost-
intensive cold-chain storage and distribution mostly mandatory, which is why new 
strategies for vaccine stabilization are becoming increasingly important to stabilize the 
product such as transferring the liquid vaccine into a dry state [1-4]. This principle can 
avoid or at least reduce water and temperature triggered protein degradation [5]. 
This work focused on the stabilization of a model vaccine using freeze-drying. In 
general, proteins can be stabilized and freeze-dried using lyoprotectants and 
cryoprotectants during the cycle [6]. In order to optimize the process, a more 
aggressive collapse lyophilization cycle was implemented to stabilize a thermo-
sensitive model vaccine and to reduce the specific surface area (SSA) simultaneously 
[7-10]. A lower SSA was targeted to obtain more dense lyophilizates which could be 
ground into dense and hard lyophilizate particles. These stable vaccine particles could 
provide a vehicle for new and easy to handle vaccine administrations technologies. 
The skin could be targeted as an easily accessible tissue to administer the vaccine 
particles using the concept of epidermal powder immunization (EPI). New studies 
have shown a high potential of improved immune response after skin vaccination [11-
18]. Using EPI, stable particles could be administered through the mechanical barrier 
(stratum corneum) into the epidermis to address the vaccine to the located antigen 
presenting cells (APCs) and induce a sufficient immune response. The stabilized 
vaccine using collapse freeze-drying and new minimal-invasive and easy handled 
administration strategies (e.g.: EPI) could prevent a fast spreading of the influenza 
disease [19]. Furthermore, the minimally invasive skin vaccination induce less pain 
and bleedings compared to the conventional intramuscular (i.m.) injection and could 
improve patient compliance and could eliminates the risk of disease transmission [20, 
21].  
Influenza vaccine was chosen as the model vaccine because of its high thermo-
sensitivity to monitor the impact of heat induced degradation [22-25]. Monitoring the 
sensitive influenza model vaccine, incorporated into a carbohydrate matrix, could 
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reveal induced degradations during the preparation, stabilization and storage at 
different storage temperatures (2-8°C, 25°C and 40°C) over a time period of 
12 months. As previously described (Chapter 2), a set of analytics was established to 
characterize the stability and activity of the vaccine, such as the hemagglutination 
inhibition assay (HAI), SDS-Page and westernblot analysis, subvisible particle 
measurements, reversed-phase liquid chromatography (RP-HPLC), and the residual 
moisture assay.  
The effects of adjuvants in vaccines should also be considered. Generally, adjuvants 
are mixed with the vaccines prior to application to induce an improved and/or 
moderated immune response, to reduce the needed antigen amount, and/or a 
superfluous booster application [26, 27]. The stabilized model vaccine (Pandemrix
®
, 
GlaxoSmithKline, Rixensart, Belgium) is administered with the adjuvant AS03. In 
order to provide the adjuvant advantages to the new administration technology (EPI), 
the vaccine was characterized in presence of the adjuvant and its oily components 
(DL-α-tocopherol, polysorbat 80, squalene, and paraffin). 
In this study, we demonstrate a successful stabilization and characterization of a 
thermo-sensitive model influenza vaccine for epidermal powder immunization over a 
time period of 12 months and a characterization of the vaccine in presence of oily 
components.  
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3.2 Material and Methods  
3.2.1 Materials 
In addition to the materials described in Chapter 2, H1N1 influenza vaccine 
(Pandemrix
®
, GlaxoSmithKline, Rixensart, Belgium), sodium hydrogen phosphate 
monohydrate (Gruessing, Filsum, Germany), sodium dihdydrogen phosphate 
dehydrate, sodium phosphate monobasic and dibasic, sodium hydroxide, and sodium 
chloride (Applichem, Darmstadt, Germany), trehalose (VWR, Ismaning, Germany), 
mannitol (Boehringer Ingelheim, Ingelheim, Germany), the following materials were 
used: the  adjuvant AS03 of the H1N1 influenza vaccine (Pandemrix
®
, 
GlaxoSmithKline, Rixensart, Belgium) containing squalene, DL-α- tocopherol, and 
polysorbate 80 is normally mixed with the vaccine prior to administration. In order to 
determine the vaccine stability in presence of oily components, the vaccine was mixed 
with the adjuvant (AS03) or with the oily ingredients of AS03 DL-α-tocopherol, 
polysorbat 80, and squalene, which were purchased from Sigma-Aldrich (Taufkirchen, 
Germany) and paraffin (100 cSt) was obtained from Merck KGaA (Darmstadt, 
Germany).  
 
3.2.2 Methods 
The preparation of lyophilizates and lyophilizate particles using the tangential flow 
filtration (TFF), the determination of concentration and adjustment of the vaccine 
concentration using RP-HPLC, the collapse freeze-dry cycle, and cryo-milling were 
previously described in detail in Chapter 2.  
Furthermore, the characterization of the vaccine and the lyophilizate stability 
(reconstituted with 2.23 ml highly purified water to obtain 7.5 µg HA/0.5 ml) under 
storage conditions of 2-8°C, 25°C, and 40°C at ambient humidity (65-80%) over a 
time period of 12 month was performed using the same assays as described in 
Chapter 2.  
The following analytics were used in particular: residual moisture content 
determination by Karl-Fischer titration, reversed-phase liquid chromatography (RP-
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HPLC), light obscuration measurements, turbidity measurements, sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-Page), westernblot analysis, and the 
hemagglutination inhibition assay (HAI).  
 
3.2.2.1 Determination of vaccine stability in presence of 
oily components (AS03, oily components of AS03, 
and paraffin) using HAI 
In order to determine the stability of the vaccine in presence of oily components, the 
commercial product (H1N1 vaccine) and/or the reconstituted lyophilizate was mixed 
with the adjuvant (AS03), oily components of AS03, or paraffin. The oily part of the 
adjuvant (AS03) consisted of 27.41 mg/dose (0.5 ml) and was comprised of 10.69 mg 
squalene, 11.86 mg DL-α- tocopherol, and 4.86 mg polysorbate 80. In order to 
determine the impact of the oily substances to the vaccine stability during the fixation 
with the oily components on the intradermal powder applicator, each solution, 
commercial product (CP) (7.5 µg/0.5 ml) or reconstituted lyophilizate (7.5 µg/0.5 ml), 
was mixed with 27.41 mg of the adjuvant (paraffin) or proportionally to the oily 
components (squalene, DL-α-tocopherol or polysorbate 80).  
In contrast to the final application using the vaccine applicator, where lyophilized 
vaccine particles were fixed with oily components, vaccine stability characterization in 
the presence of oily components was performed with vaccine solutions to maximize 
the contact and interaction between vaccine and adjuvant. The experiments to 
determine the stability were based on separation (RP-HPLC) or agglutination 
(hemagglutination inhibition assay) in a liquid environment.   
The impact of AS03 (or the oily components) on the assay was determined by the 
addition of AS03 to 10 mM PBS buffer instead of the vaccine solution while the 
robustness of the assay in presence of the oily components was characterized by 
mixing paraffin into the vaccine solution.  
Due to the high portion of oily components (up to 27.41 mg/0.5 ml) compared to the 
low vaccine dose (7.5 µg/0.5 ml) and the impact on the assay, the separation of the 
oily components was performed using a centrifuge at 10000 rpm (Sigma 4K15, Sigma 
Zentrifugen, Osterode am Harz, Germany) for 15 minutes. The liquid parts were 
extracted using a pipette after the phase separation had taken place. These steps were 
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repeated 10 times in order to separate as many oily components as possible from the 
mixture to minimize the impact of the oily components to the assay. 
 
3.2.2.2 Determination of vaccine stability in presence of 
oily components (AS03, oily components of AS03, 
and paraffin) using RP-HPLC 
In order to characterize the vaccine stability, the oily components and the vaccine in 
presence of the oily components were determined using RP-HPLC as previously 
described in Chapter 2. Samples (commercial product, reconstituted lyophilizate, and 
PBS buffer) were mixed with the oily components as described above 
(Chapter 3.2.2.1) and 25 µl of each sample was injected, separated using a reversed 
phase Phenomenex Jupiter 5 µ, C18, 300 A column (250 x 4.6 mm) (Phenomenex, 
Aschaffenburg, Germany), and detected using the intrinsic fluorescence of 
hemagglutinin at λex 280 nm and λem 335 nm.  
The samples mixed with the oily components were collected and were compared with 
the heat stressed control vaccine (70°C/100 min) and the commercial product solution 
stored at 2-8°C. Data acquisition and analysis were performed using the Chromeleon 
6.80 software (Dionex, Idstein, Germany).  
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3.3 Results 
3.3.1 Hemagglutinin (HA) quantification using 
RP-HPLC 
The determination of the HA content within the samples using the intrinsic 
fluorescence was performed using RP-HPLC. The retention time of HA at 
approximately 17.40 min ± 0.15 min was still unchanged for the storage samples at 
time point T5 (12 months) compared to the prior time points (t0, 2, 4, 12 weeks, and 6 
months) and the commercial product described in Chapter 2 (Figure 3.3.1A and B). 
Nonetheless, a second peak for the cryo-milled lyophilizates stored at 40°C was 
observed at 19.42 min ± 0.09 min with an area under the curve (AUC) of 
18.25 mV*min ± 9.1 min (Figure 3.3.1C). The results of the lyophilizates indicated 
uninfluenced storage stability while the cryo-milled samples demonstrated an 
alteration at high storage temperature (40°C) over 12 months. Similar protein peaks 
and fluorescence values were also observed for the stressed vaccine which 
demonstrated degraded vaccine as previously described in Chapter 2.  
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Figure 3.3.1: A) Fluorescence units of the commercially available product (15 µg/ml), stressed 
vaccine (15 µg/ml), and collapse lyophilized vaccine (15 µg/ml) after 12 months of storage at 
2-8°C, 25°C, and 40°C. B) Fluorescence units of the commercially available product (15 
µg/ml), stressed vaccine (15 µg/ml), and cryo-milled lyophilizates (15 µg/ml) after 12 months 
of storage at 2-8°C, 25°C, and 40°C). C) Chromatograms of cryo-milled lyophilized vaccine 
(t12months/40°C) and comparison to commercial product, lyophilized vaccine (t0) and cryo-
milled lyophilizate (t0) (second peak: RT: 19.42 min; AUC 18.25 mV*min ± 9.1 min). Three 
independent measurements were performed (n=3) 
 
3.3.2 Light obscuration measurements 
The freeze-dried samples were reconstituted and adjusted with highly purified water 
(2.625 ml) to a final concentration of 15 µg/ml. Vaccine alterations could induce 
formations of larger, particle forming aggregates, which could be determined using 
light obscuration measurements. In order to compare the degree of alteration, induced 
by the storage conditions over the observed storage time period, samples were 
compared to the results of the vaccine-carbohydrate solution (prior to lyophilization) 
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(15 µg/ml) stored at 2-8°C, the stressed vaccine (70°C/100 min, 15 µg/ml) stored at 2-
8°C and the 0.22 µm filtered trehalose-mannitol solution. The results of the subvisible 
particle measurements > 1 µm, > 10 µm, and > 25 µm are shown in Figure 3.3.2 
 
 
Figure 3.3.2 A) Subvisible particles > 1 µm of vaccine lyophilizates B) subvisible 
particles  > 10 µm of lyophilizates C) subvisible particles > 25 µm of vaccine lyophilizates 
stored at different storage temperatures and over a time period of 12 months. Three 
independent measurements were performed (n=3) for comparison of the buffer solution, the 
stressed vaccine (70°C/100min) and the lyophilizate  
 
The particle count > 1 µm of the lyophilizates increased slightly up to 
3058 counts/ml ± 132 counts/ml while the cryo-milled samples resulted in a 5-8 fold 
higher count of approximately 24636 counts/ml ± 350 counts/ml compared to the 
commercial product with only 2754 counts/ml ± 40 counts/ml. Nevertheless, in all 
samples particle counts > 10 µm were below 600 counts/container (DIN 10R vial), 
which is in line with the requirements by the European Pharmacopoeia 
(Ph. Eur. 2.9.19). The threshold of 600 counts/containment (DIN 10R vial) was only 
exceeded by the cryo-milled samples stored at 40°C/6 months at 
779 counts/ml ± 21 counts/ml which stabilized below 600 counts/ml at time point T5. 
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Moreover, the results of the cryo-milled samples demonstrated an opposed trend for 
particle counts > 1µm compared to particles > 10µm, particularly samples stored 
under 40°C conditions. Noteworthy was an increase of particle counts > 10 µm up to a 
storage period of 6 months (779 counts/ml ± 21 counts/ml ) followed by a drop after 
12 months (400 counts/ml ± 10 counts/ml). At the same time a leap of particle counts 
> 1 µm was observed from 7301 counts/ml ± 424 counts/ml to 
24636 counts/ml ± 350 counts/ml for the (same) samples stored at 40°C (Figure 
3.3.3:A and B). 
Thus, comparable to the particle counts > 1 µm, a low count of particles > 25 µm was 
observed for the lyophilizates, while cryo-milled samples resulted in 5-7 fold higher 
particle counts (Figure 3.3.2C and Figure 3.3.3C).  
  
 
 
Figure 3.3.3: A) Subvisible particles > 1 µm of cryo-milled lyophilizates B) subvisible 
particles  > 10 µm of cryo-milled lyophilizates C) subvisible particles > 25 µm of cryo-milled 
lyophilizates stored at different storage temperatures and over a time period of 12 months. 
Three independent measurements were performed (n=3) for comparison of the buffer solution, 
the commercial product, the stressed vaccine (70°C/100min) and the lyophilizate  
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3.3.3 Turbidity measurements 
As demonstrated in Chapter 2 for the turbidity results after 6 month of storage, the 
lyophilizates showed still a constant turbidity (Figure 3.3.4 and Table 3.3.1) while an 
increased turbidity over the time was observed for the cryo-milled samples. The 
lyophilization process induced an increase of turbidity compared to the commercial 
product or only heat stressed vaccine solution. While the turbidity of cryo-milled 
samples started at the same turbidity level as the lyophilized samples, the increase over 
the time might be a result of formations of small particle agglomerates. These trends 
continued for the samples stored for 12 months. The leap of particle counts for the 
cryo-milled lyophilizates stored at 40°C/12 months was reflected in the turbidity 
results for these samples. It should be kept in mind that the turbidity results of cryo-
milled samples stored at 2-8°C and 25°C were only 1-2 FNU (Formazine 
Nephelometric Units) higher than the unmilled lyophilizates.  
  
Figure 3.3.4: Turbidity of A) vaccine lyophilizates and B) cryo-milled lyophilizates stored at 
different storage temperatures and over a time period of 12 months. Three independent 
measurements were performed (n=3). To compare the stored samples, turbidity measurements 
of the buffer solution, the commercial product, and the stressed vaccine (70°C/100min) were 
additionally performed.  
 
 
 
 
62 
 
Table 3.3.1: Detailed turbidity results of the buffer solution, the commercial product, the 
stressed vaccine (70°C/100min), the vaccine lyophilizates, and the cryo-milled lyophilizates 
stored at different storage temperatures and over a time period of 12 months. Three 
independent measurements were performed (n=3).  
Sample Storage  
temperature [°C] 
Turbidity  
[FNU] 
Deviation  
[FNU] 
Time point 
Trehalose-mannitol buffer 2-8 0.50 ±0.01 All time points 
Commercial product 2-8 3.11 ±0.02 All time points 
Vaccine stressed (70°C/100min) 2-8 5.27 ±0.08  
Lyophilizate  11.56 ±0.14 t0  
Lyophilizate  2-8 11.43 ±0.33 2 weeks 
Lyophilizate  2-8 12.07 ±0.04 4 weeks 
Lyophilizate  2-8 14.01 ±0.16 12 weeks 
Lyophilizate  2-8 11.84 ±0.15 6 months 
Lyophilizate  2-8 11.55 ±0,96 12 months 
Lyophilizate  25 11.27 ±0.15 2 weeks 
Lyophilizate  25 11.66 ±0.18 4 weeks 
Lyophilizate  25 11.85 ±0.45 12 weeks 
Lyophilizate  25 11.66 ±0.10 6 months 
Lyophilizate  25 11.93 ±0.22 12 months 
Lyophilizate  40 11.64 ±0.56 2 weeks 
Lyophilizate  40 12.32 ±0.06 4 weeks 
Lyophilizate  40 11.63 ±1.04 12 weeks 
Lyophilizate  40 12.92 ±0.06 6 months 
Lyophilizate  40 13.86 ±0.15 12 months 
Cryo-milled  2-8 11.89 ±0.45 2 weeks 
Cryo-milled  2-8 11.67 ±0.02 4 weeks 
Cryo-milled  2-8 12.07 ±0.42 12 weeks 
Cryo-milled  2-8 12.21 ±0.55 6 months 
Cryo-milled  2-8 13.48 ±0.35 12 months 
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Table 3.3.3.1 continued  
Sample Storage  
temperature [°C] 
Turbidity  
[FNU] 
Deviation  
[FNU] 
Time point 
Cryo-milled  25 11.01 ±0.74 2 weeks 
Cryo-milled  25 11.99 ±0.17 4 weeks 
Cryo-milled  25 13.18 ±0.06 12 weeks 
Cryo-milled  25 12.78 ±0.67 6 months 
Cryo-milled  25 13.87 ±0.66 12 months 
Cryo-milled  40 11.54 ±0.47 2 weeks 
Cryo-milled  40 12.53 ±0.14 4 weeks 
Cryo-milled  40 16.24 ±0.23 12 weeks 
Cryo-milled  40 17.32 ±0.35 6 months 
Cryo-milled  40 28.50 ±1.51 12 months 
 
3.3.4 Sodium dodecyl sulfate-Polyacrylamide gel 
electrophoresis (SDS-Page) 
While hemagglutinin (HA) is composed of two subunits (HA1 Mw of approximately 
55 kDa and HA2 Mw of approximately 25 kDa), the monomer HA (Mw of 75 - 80 
kDa) can aggregate to a dimer (Mw of 150 - 160 kDa) or a trimer (Mw of 
approximately 210 kDa). In order to characterize the integrity of hemagglutinin during 
the storage period of up to 12 months, an electrophoretic separation (SDS-Page) was 
also performed. Changes of intensity and the shares of the different states of HA 
(monomer, dimer, and trimer) can be observed within 12 months of storage compared 
to the starting point at t0 (Figure 3.3.5C). While the results of the lyophilizates showed 
slight changes independent of the storage temperature, a trend of agglomerate 
formations was observed for the cryo-milled samples. The cryo-milled lyophilizates 
stored at 40°C/12 months formed large visible agglomerates in the well which limited 
the migration through the gel (Figure 3.3.5B). Moreover, only pale bands in the dyed 
gel could be detected in these samples (40°C/12 months) for the different states of HA. 
Thus, minor alteration of band intensities and distribution were observed in the SDS-
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Page gels for the cryo-milled lyophilizates stored at lower temperatures (2-8°C and 
25°C) compared to t0 or the lyophilizates (2-8°C, 25°C, and 40°C).  
 
 
  
Figure 3.3.5: SDS-Page results after 12 months of storage A) lyophilizate and B) cryo-milled 
samples at different storage temperatures. Column A1, B1 and C1) commercial product; 
column A2 and B2) liquid pre-lyophilizate-carbohydrate formulation; A3) lyophilizate stored 
at 2-8°C; A4) lyophilizate stored at 25°C; A5) lyophilizate stored at 40°C; B3) cryo-milled 
lyophilizate stored at 2-8°C; B4) cryo-milled lyophilizate stored at 25°C; B5) cryo-milled 
lyophilizate stored at 40°C; C2) lyophilizate; C3) cryo-milled lyophilizate; and C4) liquid pre-
lyophilizate formulation. 
 
3.3.5 Westernblot analysis 
While performing westernblot analysis, changes of structural integrity and antigenicity 
of hemagglutinin in the H1N1 vaccine could be determined more precisely due to a 
magnification of band intensities induced by the formation of antigen-antibody-
complexes. In contrast to the westernblot results of the lyophilizates after six months 
of storage (demonstrated in Chapter 2) the lyophilizates stored at 40°C and the cryo-
milled samples stored at 2-8°C and 25°C resulted in blurred band boundaries. 
Moreover, a tendency to larger agglomerates from monomer to dimer or trimer were 
detected in both groups (lyophilizates and cryo-milled samples) compared to the band 
intensities at the starting point t0 (Figure 3.3.6C). In addition, a complete lack of bands 
was observed for cryo-milled lyophilizates stored at 40°C/12 months (Figure 3.3.6B). 
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Nonetheless, the detected bands of HA independent of the state (monomer, dimer, and 
trimer) were at the predicted Mw on the scans (Figure 3.3.6). 
   
Figure 3.3.6: A) Westernblot results after 12 months of storage A) lyophilizate, B) cryo-milled 
samples at different storage temperatures and C) samples at t0. Column A1, B1 and C1) 
commercial product; column A2 and B2) liquid pre-lyophilizate- carbohydrate formulation; 
A3) lyophilizate stored at 2-8°C; A4) lyophilizate stored at 25°C; A5) lyophilizate stored at 
40°C;; B3) cryo-milled lyophilizate stored at 2-8°C; B4) cryo-milled lyophilizate stored at 
25°C; B5) cryo-milled lyophilizate stored at 40°C;.C2) lyophilizate; C3) cryo-milled 
lyophilizate; and C4) liquid pre-lyophilizate formulation. 
 
3.3.6 Hemagglutination inhibition assay (HAI) 
Consistent results were observed for the reconstituted lyophilizates and cryo-milled 
lyophilizates independent of storage temperatures or time period (Figure 3.3.7). The 
sedimentation of the erythrocytes took place at the 64 fold serial dilution. Yet, the 
sedimentation at a 64 fold dilution corresponded to 0.23 µg/ml of hemagglutinin. 
While the heat stressed hemagglutinin (70°C/100 min) was no longer able to cross-link 
the erythrocytes due to heat-induced degradation, the sedimentation occurred in the 
first well of the 2 fold serial dilution row. However, an increased incidence of 
deviation could be observed for the cryo-milled samples, particularly at higher storage 
temperature during the time period of 12 months (Figure 3.3.7B versus A). The end 
points could visually be determined as red dots consisting of the sedimented 
erythrocytes and could be distinguished to the diffuse patch of erythrocyte in non-
hemagglutinated wells.  
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Figure 3.3.7: Results of the hemagglutination inhibition assay of A) lyophilizates and B) cryo-
milled lyophilizates at different storage temperatures and different time points. Three 
independent measurements were performed (n=3). 
 
3.3.7 Determination of the residual moisture 
content 
As previously described in Chapter 2, results of the residual moisture content of 
lyophilizates stabilized at a value < 1.5% while the cryo-milled samples exhibited with 
a 2-3 fold higher value after a time period of 12 months. Nevertheless, the residual 
moisture content of the cryo-milled lyophilizates plateaued < 3.5% after at the last 
time point (t5, 12 months) of storage (Figure 3.3.8). 
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Figure 3.3.8: Residual moisture content of A) vaccine lyophilizates and B) cryo-milled 
vaccine lyophilizates stored at different storage temperatures and over a time period of 12 
months. Three independent measurements were performed (n=3)  
 
3.3.8 Determination of vaccine stability in 
presence of oily components (AS03, oily 
components of AS03, and paraffin) using 
HAI 
Vaccine stability determinations in presence of oily components using the 
hemagglutination inhibition assay were unexpectedly of poor quality and had 
conflicting results. Samples mixed with oily components deviated between three 
dilution steps while samples with non-extracted AS03 (or oily components) without 
using centrifugation and separation of the oily components reached the limitation of 
the assay at > 4096 fold dilution (Figure 3.3.9). Moreover, after an extraction of AS03 
(oily components) using centrifugation and separation of the oily components from the 
aqueous solution plateaued at 128 fold dilution independent of a presence of 
hemagglutinin (PBS buffer+AS03+extraction versus CP+AS03+extraction). The 
sedimentation of the erythrocytes should occur directly at the first well in a mixture 
without hemagglutinin, while the hemagglutination should be delayed to a higher 
dilution step in presence of hemagglutinin (64 fold serial dilutions). Unexpectedly, 
some oily components added to the commercial product (squalene and paraffin), 
induced a prior erythrocyte sedimentation than the anticipated hemagglutination at 
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64 fold serial dilution where the hemagglutination of the commercial product 
occurred. Furthermore, separately tested oily components revealed Polysorbate 80 as 
the main element which caused the delayed or rather inhibited erythrocyte 
sedimentation.  
 
 
Figure 3.3.9: Results of the hemagglutination inhibition assay of samples (commercial 
product, reconstituted lyophilizates, and 10 mM PBS buffer) mixed with oily components 
(AS03, squalene, DL-α-tocopherol, Polysorbate 80, and paraffin). Three independent 
measurements were performed (n=3). 
 
3.3.9 Determination of vaccine stability in 
presence of oily components (AS03, oily 
components of AS03, and paraffin) using 
RP-HPLC 
Samples with hemagglutinin but without oily components were characterized using 
RP-HPLC using fluorescence detection as a benchmark. For these samples, 
comparable peak values and retention time (17.40 min ± 0.15 min) were observed 
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(Figure 3.3.10). The chromatogram of AS03 exhibited a very broad peak, which was a 
composition of the squalene and DL-α-tocopherol peak. Polysorbate 80 and/or paraffin 
resulted in baselines without any detectable peaks due to a lack of excitable 
compounds (λex 280 nm and λem 335 n) (Figure 3.3.11). Moreover, results showed a 
partially overlay of the broad AS03 peak over the distinct hemagglutinin peak in 
mixed samples (commercial product (CP) or reconstituted lyophilizates (rL) + AS03) 
(Figure 3.3.12). Furthermore, the process of extraction (centrifugation and separation 
of the oily component from the aqueous part) resulted in a partial loss of 
hemagglutinin which was indicated by a lower peak value while peaks of the residual 
oily components were still detectable. The observable peaks of the oily components 
indicated a limitation of the extraction using centrifugation (Figure 3.3.12 and Figure 
3.3.13). DL-α-tocopherol (high but thin peak shape) was still detectable in the samples 
while squalene (flat but broad peak shape) was almost completely extracted from the 
mixture after 10 centrifugation cycles (Figure 3.3.13). Polysorbate 80, which 
demonstrated a high impact on vaccine activity (HAI) (Figure 3.3.7) could not be 
detected using RP-HPLC and fluorescence detection. 
 
Figure 3.3.10: Fluorescence units of the commercially available product (15 µg/ml), stressed 
vaccine (15 µg/ml), collapse lyophilized vaccine (15 µg/ml), AS03, Three independent 
measurements were performed (n=3) 
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Figure 3.3.11: Fluorescence units of the commercially available product (15 µg/ml), AS03, 
oily components of AS03 (squalene, DL-α-tocopherol, Polysorbate 80), paraffin. Three 
independent measurements were performed (n=3) 
 
Figure 3.3.12: Fluorescence units of the commercially available product (15 µg/ml), AS03, 
mixtures of the commercial product with AS03 (CP+AS03) and additional separation of the 
oily components (CP+AS03+extraction). Three independent measurements were performed 
(n=3) 
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Figure 3.3.13: Fluorescence units of the AS03, mixture of the reconstituted lyophilizate with 
AS03 (rL+AS03) and an additional separation of the oily components (rL+AS03+extraction). 
Three independent measurements were performed (n=3) 
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3.4 Discussion 
In this chapter, the storage stability of collapse freeze-dried (and cryo-milled) 
influenza vaccine was characterized. The samples were stored under different storage 
conditions (2-8°C, 25°C, and 40°C) over a time period of 12 months. Hemagglutinin 
as the main antigenic protein in the vaccine was used as a temperature sensitive 
indicator molecule to identify the stress impact during processing and/or storage. 
While the results in Chapter 2 demonstrated a successful stabilization of the vaccine 
using an cost efficient collapse freeze-dry cycle over 6 months of storage, this chapter 
focused on the long-time storage stability (12 months) of the vaccine lyophilizates and 
the characterization of hemagglutinin in presence of oily components such as AS03 
(adjuvant), squalene, DL-α-tocopherol, polysorbate 80, and paraffin. The storage 
stability was analysed using the assays already established in Chapter 2.  
Stabilized vaccine lyophilizates resulted in consisted fluorescence values (RP-HPLC) 
under all storage conditions (2-8°C, 25°C, and 40°C) over the observed time period. In 
contrast, the cryo-milled samples demonstrated a compromised result at high storage 
temperature. The storage stability of cryo-milled vaccine lyophilizates at ambient 
temperatures (25°C) opened the possibility to handle the stabilized vaccine without a 
cold-chain-system. While the long-term heat stress (40°C/12 months) resulted in major 
vaccine alteration indicated by a second peak (Figure 3.3.1) in the cryo-milled samples 
the shortly heated vaccine (70°C/100 minutes) demonstrated still an unchanged peak 
value and retention time. Notable was the chromatographically observable change of 
the cryo-milled lyophilizates (40°C/12 months) but the biological activity of 
hemagglutinin was not affected by the degradation as detected in the consistent HAI 
results. The diverging results of both assays could occur due to a less sensitive 
hemagglutinin activity determination using the HAI assay compared to the high 
sensitive intrinsic fluorescence characterization of minor structural changes during 
RP analysis. The progressed degradation was also detected in the electrophoretic 
assays (SDS-Page and western blot analysis) (Figure 3.3.5 and Figure 3.3.6). The 
alteration of cryo-milled samples led to formation of aggregates, which resulted in a 
reduced ability of protein migration through the gel. Moreover, a changed protein 
structure could be assumed due to a modified binding affinity of the specific anti-HA-
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antibody, which resulted in diminished or rather lack of detectable antigen-antibody-
complexes (Figure 3.3.6).  
The formation of small agglomerates, resulting from progressed protein degradation at 
higher storage temperature, was also observed in light obscuration measurements and 
turbidity analysis. While the turbidity at time-point t0 was comparable between 
lyophilizates and cryo-milled samples, the steady turbidity increase of cryo-milled 
samples might be indicating a self-reinforcing process of degradation. The drastic 
alterations of the particle sizes between the last two time points (6 months and 
12 months) could be a result of the progressing degradation. The higher residual 
moisture of the cryo-milled samples might catalyze the alteration. In contrast to the 
compromised stability of the cryo-milled samples at high storage temperatures, 
consistent results of stable products were observed for the cryo-milled samples stored 
at 2-8°C and ambient temperature (25°C). Unprocessed lyophilizates demonstrated a 
high resistance against induced heat stress over 12 months.  
The second focus of this work was to characterize the vaccine stability in presence of 
oily components. Light obscuration measurements, turbidity analysis and 
electrophoretic characterization could not be used to determine the stability of 
hemagglutinin due to a huge impact of the oily components to the principles of the 
assays. Using the hemagglutination inhibition assay and RP-HPLC seemed expedient 
to determine the vaccine modifications. Nonetheless, oily components, added to the 
commercial product, reconstituted lyophilizates, or buffer resulted in unreproducible 
results performing the HAI assay. In order to accomplish the activity assay, an 
extraction of the oily components using centrifugation was tried out but the effect was 
limited (Figure 3.3.9). The chromatograms using RP-HPLC revealed remaining DL-α-
tocopherol in the solutions after the extraction (Figure 3.3.13) which significantly 
effected the assay. Moreover, the HAI assay revealed that Polysorbate 80, as an 
ingredient of AS03 or as an individual component, disturbed mainly the activity assay 
and led to false results. It is likely that Polysorbate 80 as a surfactant had an impact on 
the erythrocyte membranes. The changed or even destroyed membranes prevent the 
hemagglutination and could result in inconclusive results. Even though the 
characterization of the vaccine in presence of oily components could be performed 
using RP-HPLC the validity was limited. Using only this chromotographical assay, 
structural changes could be characterized but neither the activity of hemagglutinin nor 
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protein degradations without any separations as shown for the commercial product 
versus the heat stressed vaccine could be detected (Figure 3.3.13 and Figure 3.3.13). In 
order to characterize the stability of hemagglutinin in presence of the oily components, 
new analytical assays should be conducted. Moreover, the activity of the antigen could 
be determined in animal experiments during a vaccination study. However, a minor 
activity loss cannot be determined using this concept of animal experiments because 
vaccinations are not subjected to dosage-response relationships [104, 105].    
This work showed a stabilization of collapse-freeze-dried lyophilizates at different 
storage temperatures (2-8°C, 25°C, and 40°C) over a time period of 12 months while 
storage cryo-milled samples were limited to 2-8°C and 25°C. The characterization of 
the vaccine in presence of oily components was not achieved due to the high impact of 
the ingredients to the assays.  
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3.5 Conclusion 
The stabilization of the thermo-sensitive hemagglutinin can be established using a 
collapse-freeze dry-cycle. The lyophilizates showed a consistent stability at different 
storage temperatures over the observed time period of 12 months while the storage 
conditions should be more restricted for cryo-milled samples. However, storage 
stability of all samples at ambient temperatures is a huge improvement compared to 
the strict refrigerator storage of the liquid influenza vaccines.  
Yet, the characterizations of the vaccine in presence of oily components (adjuvants) 
need further investigation because of the limitations of the established analytical 
methods.  
In this work, the long-term storage stability of lyophilized influenza vaccine was 
demonstrated. While the stability of unprocessed lyophilizates was confirmed under 
all storage conditions the cryo-milled samples could be stored at ambient temperatures 
over a time period of 12 months. This storage stability of the vaccine particles opens 
the possibility to distribute vaccines for intradermal vaccination without any cold-
chain-system.  
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4. Chapter – Intradermal 
administration of particles 
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4.1 Introduction 
In the search of new ways of needle-free vaccination the skin can be one of the 
vaccination targets. Intradermally applied vaccines have to be administered through 
the stratum corneum, which is formed by cornified keratinocytes and serves as the 
main physical barrier. The vaccination needs to be displayed directly to the 
immunocompetent cells which migrate and present the antigen fragments to other 
immune cells in the draining lymph nodes [1-6].  
Skin thickness has a major impact on the efficacy of intradermal immunization, as it 
can vary significantly between different body parts [2, 7]. Investigated skin areas of 
subjects of different body mass index (BMI), age, gender, and ethnic origin 
demonstrated an average thickness between 1.5 mm to 2.7 mm: e.g. 1.5 mm at the 
thigh; 1.8 mm at the deltoid and suprascapular; 2.7 mm at the upper abdomen [2, 8, 9]. 
Consistent skin thickness promises an easier handling for intradermal vaccination 
compared to a needle lengths adjustment for i.m. vaccine injections due to varying 
thickness of subcutaneous fat and muscle thickness [2, 10].  
So far results of clinical trials were inconsistent when examining the benefit of 
intradermal vaccination. However, the predominant view in literature reported mostly 
an equivalent or superior immune response for intradermal vaccination [4-6, 11]. 
Generally vaccines for intradermal application can be categorized in: (I) induction of 
superior immune response compared to i.m. or s.c. administration, (II) inconsistent 
results of observed immune response in different clinical trials, and (III) vaccines 
remaining to be investigated for intradermal administration [2]. A superior immune 
response can be a result of wider vaccine distribution and addressing 
immunocompetent cells within the tissue after intradermal vaccination while the 
vaccine deposition of i.m. administration is locally limited and immune cells have to 
migrate to the vaccination area [2, 3, 12]. Moreover, the epidermis promises a painless 
vaccine application due to a lack of sensory nerve endings in the upper skin layers [12, 
13].  
Epidermal powder immunization could deliver powdered vaccines to the skin as an 
immunologically active site and would combine the advantages of needle-free and skin 
vaccination. Moreover, pain and adverse side effects could be minimized or even 
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eliminated due to the small volume and low penetration depth of vaccine particles. In 
addition to that, the high thermo-stability of dried vaccines could make cold chain 
maintenance superfluous [3, 9, 12, 14-16]. In preliminary test, the administration of 
model and vaccine particles into a skin model was tested by our group using an 
experimental ballistic device (BK01) [17].  
This chapter will present a new ballistic device for epidermal powder immunization 
which is based on the patents of P. Lell and will show the successful deposition of 
model particles into the epidermis to target the Langerhans cells [18]. Labelled 
polystyrene particles were mainly used to characterize the properties of particle 
acceleration using the ballistic device and the penetration into the skin. Additionally, 
labelled carbohydrate particles were applied which could easily be detected in the skin 
to bridge the results from the polystyrene model particles to vaccine carbohydrate 
particles. The mechanical properties of human skin during the impact of particles were 
simulated using pig skin while gelatine skin models were used to trace the distribution 
of the particles [17].   
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4.2 Material and Methods 
4.2.1 Materials 
Fluorescence labelled and collapse lyophilized particles were used to determine the 
depth of particle penetration. Fluorescein isothiocyanate (FITC) was purchased from 
Sigma-Aldrich (Sigma-Aldrich, Taufkirchen, Germany). Sodium hydrogen phosphate 
monohydrate was purchased from Gruessing (Gruessing, Filsum, Germany). Sodium 
dihdydrogen phosphate dihydrate, sodium phosphate monobasic and dibasic, sodium 
hydroxide and sodium chloride were obtained from Applichem (Applichem, 
Darmstadt, Germany). Trehalose used as a lyoprotectant was purchased from BDH 
Prolabo (VWR, Ismaning, Germany) and mannitol as a bulking agent was obtained 
from Boehringer Ingelheim (Ingelheim, Germany).  
Fluorescence (FITC) labelled polystyrene (PS) particles (19.78 µm, 41.14 µm, 
60.28 µm) were purchased from microparticles GmbH (Berlin, Germany) as model 
particles. Paraffin (100 cSt) was obtained from Merck KGaA (Darmstadt, Germany) 
and the components of the adjuvant system AS03, DL-α-tocopherol, polysorbat 80, 
and squalene were purchased from Sigma-Aldrich (Taufkirchen, Germany). 
Customized 500 µm glass spheres were purchased from Carl Roth (Karlsruhe, 
Germany). Hematoxylin and eosin stain, 25% hydrochloric acid, 96% ethanol, and 
carbol-xylol were obtained from Merck (Darmstadt, Germany). Xylol was purchased 
from W.Gaeen GmbH&Co. (Munich, Germany). Eukitt solution was purchased from 
Vitro-Clud (Langenbrunck GmbH, Emmendingen, Germany). Hydrochloric acid 
(36%) and sodium hydroxide (32%) were purchased from Applichem (Darmstadt, 
Germany) to dissolve skin samples and cell strainers (70 µm) were obtained from BD 
Biosciences (Erembodegem, Belgium) to prepare the skin suspension. For gelatin skin 
models GELITA Pharmaceutical Gelatin made from pig skin with strength of 180 
Bloom was purchased from DGF STOESS AG (Eberbach, Germany). 1,2,3-
Propantriol (Glycerol) (purity, 99%) and polyethylene glycol 400 (PEG 400) were 
obtained from AppliChem (Darmstadt, Germany). Potassium carbonate was obtained 
from Sigma-Aldrich (Taufkirchen, Germany).   
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4.2.2 Methods 
4.2.2.1 Preparation of collapse lyophilized particles  
The fluorescence labelled and collapse lyophilized particles were prepared using 
300 ml of a 10 mM phosphate buffer at pH 7.0 saturated with FITC. The solution was 
additionally filtered using a 0.22 µm cellulose acetate syringe filter (VWR Ismaning, 
Germany). The saturated FITC solution was mixed with trehalose and mannitol (1:1) 
(w/w) to obtain a final concentration of 15% solid content. The FITC-carbohydrate 
solution was gently stirred at approximately 50 rpm using a magnetic stirrer 
(IGAMAG RCT, IKA®-Werke GmbH & Co. KG, Staufen, Germany) to dissolve the 
additives. The mixed solution was filtered again with a 0.22 µm cellulose acetate 
syringe filter to remove any undissolved residues.  
 
4.2.2.2 Lyophilization processes (as described previously 
in Chapter 2)  
A Martin Christ Epsilon 2-6D freeze-dryer (Martin Christ, Osterode, Germany) 
equipped with a pirani pressure sensor was used to perform the collapse lyophilization. 
A volume of 2.625 ml of the FITC carbohydrate formulation was transferred into each 
of 100 vials DIN 10R (Mglas AG, Muennerstadt, Germany) and were placed in the 
center of a lyophilization shelf. Vials containing FITC-carbohydrate solution were 
surrounded by edge-vials filled with a 15% (w/w) trehalose-mannitol (1:1) (w/w) 
solution. All vials were finally semi-stoppered using Westar
®
RS.stoppers 
(Westpharma, Exton, USA) and transferred to the freeze-dryer.  
The collapse lyophilization cycle started with an equilibration period at 4°C for 1 hour 
and subsequent freezing to -50°C using a ramp within 1.5 hours. The temperature of -
50°C was (isothermally) held for one hour. Afterwards, the temperature was increased 
to -40°C using a ramp of 0.33°C/min. At -40°C, the chamber pressure was reduced to 
1.98 mbar. 
After an equilibration time of 10 minutes the shelf temperature was increased to 45°C 
within 2 hours. Primary drying was carried out for 24 hours and unchanged shelf-
temperature. The chamber pressure was further decreased to 0.03 mbar, after the 
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primary drying. The secondary drying was continued for further 20 hours at 45°C. The 
temperature was reduced to the storage temperature of 4°C, at the end of the collapse 
lyophilization cycle. Finally, the samples were stoppered at approximately 800 mbar 
in dry nitrogen gas atmosphere and crimped after unloading. 
 
4.2.2.3 Cryo-milling and sieving  
The FITC lyophilizates were cryo-milled using a Retsch CryoMill (Retsch Technology 
GmbH, Haan, Germany). Samples in a stainless steel milling jar (Retsch Technology 
GmbH, Haan, Germany) were cooled to -196°C using liquid nitrogen during the cryo-
milling cycle. Approximately 1.5 g of the lyophilizates was filled into the milling jar 
and two steel balls were additionally included. A pre-cooling for 10 min. with a 
milling frequency of 5 Hz was carried out before grinding was performed at 25 Hz for 
15 sec. After the cryo-milling cycle, water condensation was avoided by placing the 
milling jar into a Glove box (customized from a university associated workshop) under 
dry nitrogen gas atmosphere (< 10%) measured with a thermo-hygrometer (TFA 
Dostmann, Wertheim, Germany). The equilibration of the milling jar to room-
temperature was realized within two hours. The powder was sieved with a Retsch 
sieve (Retsch Technology GmbH, Haan, Germany) with mesh sizes of 20 µm, 40 µm, 
80 µm and 125 µm. Classifying by sieving was carried out for 10 minutes and 
weighed afterwards. Classifying steps were repeated until the mass of powder on each 
sieve did not differ more than 1% to the previous weighing. Aliquots of ground and 
classified samples were filled in DIN 10R vials under dry nitrogen atmosphere and 
stoppered with Westar
®
RS.stoppers.   
 
4.2.2.4 Preparation of oily part of AS03 
The oily part of AS03 contains 10.69 g of squalene, 11.86 g DL-α-tocopherol, and 
4.86 g polysorbat 80. All components were mixed using a magnetic stirrer at 
approximately 50 rpm. The oily mixture was stored at 2-8°C until usage.  
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4.2.2.5 Experimental particle applicator device  
The experimental particle applicator was based on pyrotechnical acceleration to 
administer particles into the skin (Figure 4.2.1). The device was divided in two 
functional parts. The pharmaceutical part was designed to provide a sterile 
environment for particles and was composed of support plate, membrane holder, 
customized bilayer of arched membranes, combustor chamber and an oleogel. The 
pyrotechnical part provided the acceleration energy and composed of a gas-generator 
(Chapter 6), and the igniter. After the electrically ignition of the gas-generator the 
pressure was directed by the combustor design and transmitted through the oleogel 
filling of the combustion chamber to the modified bilayer membranes. Membranes and 
oily fixed particles accelerated together, induced by the pulse energy. While the 
acceleration of the membranes slowed down, the fixed particle membranes detached 
from the surface. Further details of the device development are described in 
Chapter 5. 
  
 
Figure 4.2.1: Experimental particle applicator, separated into the two functional parts A) the 
pharmaceutical part, B) the pyrotechnical part. C) The prototype of the powder applicator. 
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4.2.2.6 Particle loading 
The experimental device provided a circular surface area of approximately 0.78 cm² 
for particles. Particle loading on the membrane of the experimental device was 
performed on a clean bench (Herasafe, Thermo Fischer scientific, Rockford, USA). To 
fix particles, the upper membrane was previously coated with an oily component, such 
as paraffin (Merck KGaA, Darmstadt, Germany) or the oily part of AS03 (DL-α-
tocopherol, polysorbat 80, and squalene) using a sterile swab (Copan, Brescia, Italia). 
The sterile swab was led through the nozzle of the experimental device and the oily 
coating was homogenously spread on the membrane (Figure 4.2.2). Afterwards, a 
customized funnel was gently put through the nozzle. The particles (FITC labelled TM 
(trehalose-mannitol) particles or FITC labelled PS particles) were scattered through 
the funnel on the coated membrane until the membrane surface was overfilled (Figure 
4.2.2). The device was inverted and the funnel was carefully taken out to avoid a 
swirling of the particles in the pharmaceutical part of the device. Subsequently the 
inverted particle applicator was tapped on the bench to detach loose particles and 
approximately an amount of 1.7-2.0 mg kept attached on the membrane (Figure 4.2.2). 
Finally, the pharmaceutical part was sealed with a customized foil (IIS, Andernach, 
Germany) to inhibit a permeation of dust and moisture.   
  
 
Figure 4.2.2: Schematic representation of particle loading on membrane of pharmaceutical 
part. 
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4.2.2.7 Animal keeping and skin preparation and particle 
administration ex vivo and in vivo 
Skin parts of commercial cross-breed pigs (LWxPI) were used for ex vivo and in vivo 
experiments to determine the penetration depth of the administered particles. In a first 
step, an examination of the intradermal particle penetration in ex vivo skin was 
realized. The specimens were analyzed for administered particles to adjust the particle 
penetration depth by optimizing the particle velocity. Subsequently, the experiments 
were conducted in vivo using the modified particle velocity.  
All procedures and the experimental protocol for animal experiments were officially 
approved by the Government Office of Upper Bavaria, Munich, Germany 
(authorization reference number 55.2.1.54-2532-87-12; 30.08.2012). 
In order to adjust the velocity of the particles ex vivo experiments were performed 
using frozen skin parts (ventral side) from five to six week old piglets. The frozen 
samples were gently thawed and equilibrated to ambient temperature (25°C) within 2 
hours. Previous to application, the bristles were gently trimmed. Particle loaded device 
was placed on the marked administration site. Directly after particle administration, 
the skin samples with administered particles were frozen again on dry ice. Afterwards, 
the samples were embedded in a tissue freezing media (Leica, Nussloch, Germany) 
and frozen at -80°C until the specimens were prepared for histological examinations. 
Depending on the histological results of the ex vivo preparations the device was 
modified to optimize the safety and penetration depths.  
Six five-week old piglets from farm were transported to the Clinic for Swine 
(Oberschleissheim, Germany). Water and food was available ad libitum. After a 
2 week adaptation phase, the piglets were weighed and clinically examined and 
monitored by veterinarians.  
The in vivo particle administrations to anaesthetized animals with 5 Vol% Isoflurane 
((Isoba® MAC 1,5 Vol% Essex Tierarznei) and O2 were performed with the modified 
device. These animals were also euthanized (as described above) to excise the 
respective skin patches after 90 minutes of particle application. 
In both experiments particles were administered to skin areas ambilateral to the 
mammilla complex. These were carefully cleaned with tissues and the bristles were 
trimmed cautiously to avoid any skin irritation. The concerned areas were marked 
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using a permanent marker. Each lappet was subdivided in five applications sites each a 
size of 6 cm x 6 cm. In contrast to the ex vivo experiments, the skin parts of the in vivo 
experiments were directly frozen on dry ice after the particle administration to the 
marked sites and were subsequently embedded in a tissue freezing medium for 
histological examination. Number of animals could be minimized by using larger skin 
lappets to optimize the device during the ex vivo experiments.  
 
4.2.2.8 Microscopic examination of skin slices  
Skin specimens embedded in the tissue freezing medium were sliced with 10 µm 
thickness using a cryotom Research Cryostat Leica CM35050S (Techno-Med GmbH, 
Bielefeld, Germany). Subsequently, the slices were placed on SuperFrost microscope 
slides (VWR, Ismaning, Germany). Afterwards, the specimens were microscopically 
examined using a BZ8100 Biozero Micrsocope (Keyence, Neu-Isenburg, Germany), 
equipped with objectives Nikon S Plan Fluor (20x/0.45) and Plan Apo (10x/0.45) 
(Nikon GmbH, Duesseldorf, Germany).  
 
4.2.2.9 Microscopic examination of Hematoxylin and 
eosin stained (HE stain) skin slices 
In addition to a microscopical examination of samples, specimens of the intradermal 
particle administration were dyed using a hematoxylin and eosin stain (HE stain). 
Previously prepared skin slices were embedded in HE stain for 5 min. and 
subsequently washed with tap water for further 5 min. Samples were shortly moved 
through a 0.5% hydrochloric acid-ethanol solution with an additional washing step 
afterwards. Thereafter, the samples were briefly put into a 1% eosin solution and then 
washed again with water. The prepared slices were dried in ascending/increasing 
ethanol concentrations (50%, 70%, 80%, 96%, and 100%) for 1 min for each 
concentration. Finally, specimens were shortly covered with carbol-xylol and xylol. 
The slices were fixed with the Eukitt solution on microscope slides. Specimens were 
microscopically examined using a BZ8100 Biozero Micrsocope (Keyence, Neu-
Isenburg, Germany).  
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4.2.2.10 Particle size determination using Scanning 
electron microscopy (SEM)  
Particle samples (polystyrene model particles and cryo-milled carbohydrate particles) 
were carefully transferred onto an adhesive carbon tape (Bal-tec GmbH, Germany) 
and subsequently sputtered with carbon under high vacuum (MED 020, Bal-tec 
GmbH, Germany). Specimens were viewed using a scanning-electron microscope 
(Supra 55VP, Zeiss SMT, Germany) under high vacuum. Scanning electron 
micrographs were recorded at magnifications of 100 fold and 300 fold. 
 
4.2.2.11 Preparation of gelatin skin models for 
determination of penetrated particle counts  
As described in Deng et al. highly purified water was mixed with glycerol in a 200 ml 
Erlenmeyer flask and heated to 55°C using the magnetic hot-plate stirrer (Stable Micro 
Systems Ltd., Surrey, UK). Gelatin was added in a ratio to glycerol of 2:9 (w/w) and 
dissolved by stirring at 700 rpm for 30 minutes. Afterwards, the mixture was filled 
into petri-dishes, which were pre-treated with 70% isopropanol to prevent bubble 
formation on the surface. Petri-dishes were placed in a fume exhaust hood to dry for 
24 hours. Finally the skin models were stored for at least two weeks in a desiccator 
containing a saturated potassium carbonate aqueous solution with a relative humidity 
of 43% [17].  
 
4.2.2.12 Dissolving pig skin and skin model to determine 
penetrated particle count  
Polystyrene spheres were administered to the gelatin skin model and pig skin to 
determine the particle count ejected by the device. Excess particles, which did not 
penetrate into the material properly, were removed with an air pressure gun (2 bar / 
nozzle diameter 3 mm / distance 7 cm) in an angle of 90° for 5 sec. These particles 
were visualized using a Keyence light microscope VHX-500F equipped with an 
objective VH-Z20R (Keyence GmbH, Neu-Isenburg, Germany).   
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Gelatin skin models with administered polystyrene particles (41 µm) were given into a 
falcon tube (50 ml), filled with highly purified water and dissolved at 95°C using a 
magnetic hot-plate stirrer. Solutions were centrifuged at 10000 rpm (Sigma 4K15, 
Sigma Zentrifugen, Osterode am Harz, Germany) for 15 min. The clear supernatants 
were exchanged three times and finally the particles were collected in 1.5 ml of highly 
purified water in an Eppendorf-cup (Eppendorf, Hamburg, Germany). A complete 
transfer from the gelatin solution to the highly purified water was verified using a UV 
lamp to detect residual particles in the gelatin solution. 
The native skin samples were treated with 25 ml of hydrochloric acid (36%) for 
2 hours at ambient temperature in order to retrieve the polystyrene particles. The 
suspension was neutralized with sodium hydroxide (32%), filtered through a cell 
strainer (70 µm), mixed with Isopropanol (100%) (25 ml), and centrifuged at 
10000 rpm for 30 min. The addition of isopropanol led to a separation of bigger cell 
fragments and lipids from the smaller cell fragments and polystyrene particles. Bigger 
fragments and lipids were skimmed using a pipette while cell fragments and particles 
were collected in 1.5 ml suspension. 
 
4.2.2.13 Micro-flow-Imaging (MFI) 
Polystyrene particles in samples were detected using a micro-flow imaging system 
(Brigthwell Technologies Inc., Ottawa, Canada). The system was pre-equalized with 
250 µl of the sample solution / suspension with a flow rate of 0.1 ml/min. Afterwards 
750 µl with a flow rate of 0.1 ml/min of gelatin-glycerol solutions and / or dissolved 
skin suspensions were analyzed to detect the spherical particles. Results were 
evaluated using DPA4100 software (Brigthwell Technologies Inc., Ottawa, Canada). 
 
4.2.2.14 Determination of particle velocity  
In order to determine the velocity of the accelerated particles, a system of flash cams 
was installed at the premises of the cooperation partner (Pyroglobe, Hettenshausen, 
Germany). The flash cams were positioned in an angle of 90° to each other to include 
the flight direction into the velocity calculations (Figure 4.2.3). Accelerated particles 
were repeatedly photographed by each flash cam and an overlay of images was finally 
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generated. Flash cam 1 took a picture every 10 µs, while flash cam 2 took a picture 
every 15 µs. The overlays of the flash cams were used to determine the velocity of the 
particles using the velocity-time theorem.  
Previous to the velocity determination, a straight edge was photographed to determine 
the magnification of the flash cams. The visual correction of the magnification was 
implemented into the velocity calculations.  
The experimental particle applicator was positioned in the focus of both flash cams. 
The ignition of the particle applicator and the flash cams were triggered by a photo 
flash (Metz, Zirndorf, Germany).  
 
 
Figure 4.2.3: Experimental set-up of Flash cams to determine particle velocity. The powder 
applicator was positioned in the focus of the Flash cams. Emission of the particles and velocity 
measurement was triggered by the photo flash. 
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4.3 Results 
4.3.1 Determination of particle velocity (in 
cooperation with Dr. P. Lell, C. Fellner, 
Pyroglobe, Hettenshausen, Germany) 
Previous to the animal experiments, particle velocity was optimized using only one 
single 500 µm glass sphere as a standard model, while the smaller polystyrene 
particles were used as a model for velocity determination of the ejected powder cloud. 
Due to the limitations of process observation, we assumed that acceleration took place 
within the first 3-6 mm. The sudden pressure of the gas-generator hit the membrane 
and led to acceleration of the attached particles. After the acceleration path (3-6 mm), 
the particles could keep the momentum while the membranes slowed down. The glass 
sphere (ƍ= 2.3 g/cm
3
) was accelerated to approximately 620 m/s (Figure 4.3.1A 
and B). We tested different sizes of polystyrene particles (ƍ= 1.1 g/cm
3
) (19.78 µm, 
41.14 µm, and 60.28 µm) to cover the range between 20 µm to 80 µm. All particle 
sizes showed comparable velocities with 516 m/s for 20 µm, 518 m/s for 40 µm and 
521 m/s for 60 µm, respectively (Figure 4.3.1C to H and Table 1). A similar result of 
526 m/s was obtained for the FITC-labelled lyophilizate particles (ƍ= 1.3 g/cm
3
) 
(Figure 4.3.1and J).  
Regarding the shapes of the powder clouds that are emitted from the device it can be 
stated that the powder clouds that form after emission of polystyrene and lyophilizate 
particles from the device show comparable shapes. Interestingly the monodispersed 
polystyrene particles demonstrated a mainly consistent pattern in cloud shape and a 
distinct cloud front, whereas a more unpredictable/irregular shape was observed for 
the polydispersed FITC labelled lyophilized particles. 
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Figure 4.3.1: Overlay of particles accelerated by the experimental device. Flash cam 1 (delay 
time 10 µs) is positioned in a 90° angle to flash cam 2 (delay time 15 µs). A) overlay of 
500 µm glass sphere taken by flash cam 1; B) overlay of 500 µm glass sphere taken by flash 
cam 2; C) overlay of 20 µm FITC labelled polystyrene particles taken by flash cam 1; D) 
overlay of 20 µm FITC labelled polystyrene particles taken by flash cam 2; E) overlay of 
40 µm FITC labelled polystyrene particles taken by flash cam 1; F) overly of 40 µm FITC 
labelled polystyrene particles taken by flash cam 2; G) overlay of 60 µm FITC labelled 
polystyrene particles taken by flash cam 1; H) overlay of 60 µm FITC labelled polystyrene 
particles taken by flash cam 2; I) overlay of 20 µm-80 µm FITC labelled lyophilized particles 
taken by flash cam 1; J) overlay of 20 µm-80 µm FITC labelled lyophilized particles taken by 
flash cam 2. 
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Table 4.3.1 Calculated velocity of particles accelerated by the experimental device 
Particle  Size (µm) Velocity[m/s] 
±standard deviation 
n=2 
Density 
[g/cm3] 
Glass sphere  500 624 ± 13.7   2.3  
Polystyrene particles  20 516 ± 11.5   1.1 
Polystyrene particles  40 518 ± 15.1   1.1 
Polystyrene particles  60 521 ± 9.1   1.1 
Lyophilizate particles 20 – 80  526 ± 12.2   1.3 
 
4.3.2 Scanning electron microscopy (SEM) 
Particle sizes were confirmed using the scanning electron microscopy. The three 
different polystyrene particle sizes demonstrated a high monodispersity (Figure 
4.3.2A - F) and uniform spherical shapes (Figure 4.3.2B, D, and F). On the contrary, 
the electro micrographs displayed the broad distribution of the lyophilizate particles 
between the expected sizes of 20 µm to 80 µm (Figure 4.3.2G and H). Furthermore, 
heterogeneous shapes and rough surfaces of lyophilizate particles were evident but all 
examined particles were in the same magnitude as the comparator polystyrene 
particles.  
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Figure 4.3.2: Scanning electron micrographs A and B) polystyrene particles 20 µm (A: 
magnification: 100 fold; B: magnification: 200 fold); C and D) polystyrene particles 40 µm 
(C: magnification: 100 fold; D: magnification: 200 fold); E and F) polystyrene particles 60 µm 
(E: magnification: 100 fold; F: magnification: 200 fold); G and H) FITC lyophilizates 20 µm-
80 µm (G: magnification: 100 fold; H: magnification: 200 fold). 
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4.3.3 Microscopic examination of skin slices  
Only 40 µm polystyrene particles as model particles and 20 µm-80 µm FITC labeled 
lyophilizate particles were used to determine the penetration depth into the skin (ex 
vivo and in vivo). Polystyrene particles were clearly detectable in ex vivo skin slices of 
10 µm thickness (Figure 4.3.3). The different sizes of spheres were caused by the 
different positions of the 40 µm polystyrene particles within the cutting level of the 
skin sample. Nevertheless, polystyrene particles penetrated in a depth of 
approximately 50-100 µm (Figure 4.3.1A-C). The administration of the polystyrene 
particles to the layer between epidermis and dermis (stratum basale) could be 
determined due to differently stained cell-types in the ex vivo skin slices (Figure 
4.3.3D). The administration of the polystyrene particles was not just a circumscribed 
phenomenon; a distribution over the complete administration site was successfully 
demonstrated (Figure 4.3.3C and Figure 4.3.4). Lesion-free particle administrations 
could be demonstrated due to a lack of tissue scaring in histological samples. 
While the polystyrene particles can distinctively be discovered, a clear determination 
of lyophilizate particles was not possible due to their instant dissolution and 
distribution to surrounding tissue (Figure 4.3.3E and G). Therefore, the penetration 
depths of the FITC labeled lyophilizate particles could only be estimated in a range 
between 20 µm to 150 µm by the fluorescent area. A lesion-free distribution over the 
complete administration site of the FITC-labelled lyophilizate particles was also 
observed (Figure 4.3.3G). In order to confirm the ex vivo results of lesion-free particle 
penetration into the required depths in a living tissue, in vivo administration 
experiments were subsequently performed. In HE stained skin slices, the PS particles 
could be detected as spherical vesicles without any color which were washed out by 
the organic solvents.   
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Figure 4.3.3: Overlay of particle penetration into the skin of German Landrace pigs during the 
ex vivo experiments. A and B) overlay of 40 µm FITC labeled polystyrene particles in skin; C 
and D) HE stained skin slices with penetrated particles; E) overview of the application site of 
40 µm polystyrene particles; F and G) overlay of 20 µm-80 µm FITC lyophilizate particles in 
skin; H) overview of the application site of 20 µm-80 µm FITC lyophilizate particles. 
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Figure 4.3.4: Distribution of 20 µm PS particles applied on ex vivo pig skin using the ballistic 
particle applicator. 
 
Particle penetration was also observed in in vivo skin specimens (Figure 4.3.5). 
Clearly detectable polystyrene particles in the in vivo skin slices were located in a 
depth of approximately 50-120 µm. (Figure 4.3.5A – D). Particles penetrated the skin 
through the stratum corneum up to the stratum basale, which could be observed in the 
histological skin slices (Figure 4.3.5C and D). On the contrary, the FITC-labeled 
lyophilizate particles were not distinctively detectable (Figure 4.3.6E and F). The 
diffused fluorescent dye of dissolved FITC-lyophilizates was observed in penetration 
depths between 20 to 120 µm.  
Generally, a detection of FITC-labeled lyophilizates in histologically stained in vivo 
skin slices to determine the penetrated tissue layer was not possible (Figure 4.3.6G and 
H) due to elimination of the dye during the staining procedure. Yet, an administration 
of the lyophilizates over the complete administration site could be demonstrated in 
unstained skin slices (Figure 4.3.6I). The application of the particles in in vivo skin 
revealed no tissue lesions and scaring, as demonstrated also in the histologically 
stained skin slices after particle administration (Figure 4.3.6C; D; G and H).   
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Figure 4.3.5: Overlay of particles penetration into the skin of German Landrace pigs during 
the in vivo experiments. A and B) overlay of 40 µm FITC labeled polystyrene particles in skin 
slices prepared using the cryotom; C and D) images of 40 µm FITC labeled polystyrene 
particles in histologically stained skin slices 
  
  
 
Figure 4.3.6: Overlay of particles penetration into the skin of German Landrace pigs during 
the in vivo experiments. E and F) overlay of 20 µm-80 µm FITC lyophilizate particles in skin 
slices prepared using the cryotom; G and H) images of 20 µm-80 µm FITC lyophilizate 
particles in histologically stained skin slices; I) overview of the application site of 20 µm-
80 µm FITC lyophilizate particles. 
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4.3.4 Determination of penetrated particle count 
in pig skin and skin model using MFI 
The total amount of particles loaded on the device was determined using FITC 
labelled polystyrene particle (41 µm), by firstly following the loading procedure as 
described in Figure 4.2.2. Afterwards, the particles were rinsed off the membrane with 
highly purified water and the particle count was determined using MFI. A single dose 
(100%) of polystyrene particles (41 µm) loaded on the device was washed into 1.5 ml 
highly purified water and was amounted to 2400 particles per ml +/- 180 (n=4) (i.e. a 
single dose contained about 3600 particles (41 µm)). An application to the gelatin skin 
model with low mechanical resistance (gelatin-glycerol (2/9)) was performed to 
collect all detached particles and to calculate the loaded dose which was set free by the 
device. The gelatin skin model was dissolved and the particles were transferred to 
highly purified water to avoid any differences in viscosity of the solution. 
Approximately 93% ± 7% (n=4) of the particles penetrated into the gelatin skin model 
(i.e. 3600 particles to 3096 particles were detached from the device per dose).    
Microscopic images and particle counts (MFI) revealed a large number of polystyrene 
spheres, which did not penetrate into the pig skin. The major part only (loosely) 
adhered to the surface and could be removed (easily) by pressurized air (Figure 4.3.7 
and Figure 4.3.8). After removal of polystyrene spheres, particles remained on or in 
the skin. Particle agglomerations on bristles and in skin folds were distinctly removed 
by the process while penetrated particles still stuck in the epidermis (Figure 4.3.7). 
After dissolving the skin and transferring the particles in highly purified water the 
amount of particles which had penetrated the skin was determined as about 25% of the 
emitted dose (i.e. 900 particles to 774 particles could penetrate the skin per dose)  
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Figure 4.3.7: Skin samples with administered polystyrene particles A) overview prior to 
removal, B) close-up prior to removal, C) overview after removal, D) close-up after removal 
 
Figure 4.3.8: Polystyrene Particle (41 µm) count in skin samples and skin model using the 
MFI before and after removal of non-penetrated particles into the ex vivo skin. Particle loaded 
on device was washed in 1 ml highly purified water to use MFI. Ex vivo skin without particle 
application was also used as negative sample (n=4). 
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4.4 Discussion 
4.4.1 Device and particle velocity 
In this work, an experimental, pyrotechnical and intradermal powder applicator was 
tested which was capable to generate particle velocities of over 500 m/s for 
polystyrene (ƍ= 1.1 g/cm3) and lyophilizate (ƍ= 1.3 g/cm3) particle clouds to breach 
successfully the stratum corneum and to deposit the particles in the tissue below. 
Particles in a range between 20 µm to 80 µm showed to be large enough to gain 
enough momentum to penetrate into the skin but were still small enough to avoid 
bleedings and pain due to the low penetration depth (Figure 4.3.3). Blood vessels and 
receptors for pain are located in deeper parts of the skin (dermis) in 500 µm-1500 µm 
(Figure 4.3.3) [123]. For sake of comparison a single glass sphere (ƍ= 2.3 g/cm3, 
size = 500 µm) was used as a standard model particle to precisely calculate velocities 
resulting from the actuation of the device (Figure 4.2.3A and B). The glass sphere was 
accelerated to more than 600 m/s due to its high density and size compared to 
polystyrene and lyophilizate particles (Figure 4.2.3A and B).  
Accurate velocity determinations of particle clouds were limited compared to the 
single glass sphere due to the cloud front composed of a high number of small 
particles 20-80 µm). 
The cloud front, which resulted after accelerating lyophilizate particles was rather 
diffuse and blurred and may mainly be attributed to the polydispersity and the 
irregular shape of the particles (Figure 4.3.1G and H) lyophilized. Size, surface 
structure and particle shape were already studied using electron microscopy 
(Chapter 2), but their impact on acceleration and penetration properties needs further 
elucidation. The sizes of the polystyrene model particles were chosen to cover the 
range of the lyophilizate particles from 20 µm to 80 µm. The only slight increase of 
velocity with increasing particle sizes was found to be negligible due to uncertainty of 
particle velocity measurements.  
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4.4.2 Application of particles to skin 
The examination of particle penetration in ex vivo skin demonstrated a successful 
deposition of the particles around the stratum basale to deliver the particles directly to 
the antigen presenting cells (LC and DC). While the polystyrene particles were clearly 
detectable, FITC-labelled lyophilizates dissolved immediately after penetration as 
desired. As a result, the FITC dye diffused in the tissue. The intended dissolving of 
lyophilizate particles results in a broader deposition of e. g. an administered vaccine in 
the skin and might therefore increase vaccination efficacy after intradermal 
administration. 
Despite the differences in shape, density and dispersity, polystyrene and lyophilizate 
particles demonstrated a comparable penetration pattern over the complete application 
site (Appendix and Figure 4.6.2). We demonstrated in preliminary tests that the shape 
of the particles had no impact to the penetration depths (Figure 4.6.3).  
Skin properties as thickness, tissue composition or moisture vary e. g with age and can 
have a wide influence on penetration properties and penetration depth [20]. 
Penetration depth and distribution of particles (polystyrene and lyophilizate particles) 
in ex vivo skin, with one additional freeze-thaw cycle and lack of vascularization and 
nutrient supply, were comparable to in vivo specimens. In order to determine the tissue 
layer of the deposited particles, a HE staining was performed. While the polystyrene 
particles were still detectable, the lyophilizates were washed out during the process of 
the HE-staining of the skin slices (Figure 4.3.6 G and H). Therefore, skin slices were 
prepared without staining using the cryotom to investigate deposition of the FITC-
labeled lyophilizates in the epidermis Figure 4.3.6E and F and Figure 4.6.2). 
 
Summarizing the results of the penetration experiments it can be stated that the new 
device is capable of accelerating particles to a velocity that suffices to make them 
penetrate the epidermis of pig skin. Quantitative assessment of penetrated particles 
showed, that about 25% of the initial applicator loading were finally traceable in the 
skin tissue. Penetrated particles could create a remaining sinkhole in the stiff stratum 
corneum and pressurized air simply might remove them from there again. Therefore 
this technique of excessed particle removal might be reconsidered by using other 
suitable procedures as e. g. tape striping or rinsing with water. However, the removal 
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method is a “worst-case- scenario” so that slightly more, up to 1/3 of the particles 
could had penetrated the skin. Therefore, dose deposition of 1/4 to 1/3 shall be the 
basis of our calculations.  
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4.5 Conclusion 
In summary, we have tested an experimental pyrotechnical device to deposit particles 
into the epidermis, where immunocompetent cells (LCs and DCs) are located. 
Reproducible velocities and cloud shapes of particles could be shown and results 
confirmed a successful administration of particles into desired penetration depths and 
over the complete administration site of about 3.1 cm
2
.  
Further examinations need to be undertaken to increase the count of penetrating 
particles e.g. higher particle velocity or increasing particle density. 
A successful particle loading on the device using oily components (described in 
Chapter 3) and an almost complete detachment (93%) of the particle from the device 
demonstrated a calculable dose administration. In order to increase the dose deposition 
into the skin, particle velocity, particle size or density should be modified to increase 
the momentum of the particles to breach the mechanical barrier (stratum corneum). 
The particle shape played a tangential role to the penetration depths (Figure 4.6.3). 
The deposition of the particles in the desired depth (stratum basale) may result in an 
improved immune response combined with lack of bleedings and pain.  
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4.6 Appendix 
  
  
  
Figure 4.6.1: Overlay of particle penetration into the skin of German Landrace pigs during the 
ex vivo experiments. A -F B) overlay of 40 µm FITC labeled polystyrene particles in skin 
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Figure 4.6.2: Overlay of 20 µm-80 µm FITC lyophilizate particles in skin; H) overview of the 
application site of 20 µm-80 µm FITC lyophilizate particles. 
  
Figure 4.6.3: A) Administered glass spheres (40 µm) into a gelatin-skin model compared 
against B) ground glass particles administered into a gelatin skin model 
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5. Chapter – Device development 
The device development has been carried out by Dr. P. Lell, Mr. C. Fellner (Pyroglobe 
GmbH, Hettenshausen) and me as an assistant researcher. The project was co-
supervised by Prof. G. Winter and Dr. Engert (Ludwig-Maximilians-University, 
Munich) and Dr. S. Henke (Innovative Injektionssysteme GmbH, Andernach). 
The following Chapter contains a know-how reduced version of the full development 
report on file.  
Major results of the development on the device are laid down in Patent application 
No.: EP 14 189 971.6 and EP 14 173 786.6, which will be published in May 2016.  
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5.1 Guiding principles of device design 
This chapter will describe the development of the ballistic, particle acceleration 
device.  
The guiding principles of the ballistic device were designing a particle accelerator 
with immobile parts, a no failure safety concept, providing a platform for easy 
assembly, and enabling a cost reduction. Of course, the device should provide 
sufficient acceleration to particles in order to penetrate into the upper layers of the skin 
(epidermis) and targeting the located antigen presenting cells (APCs) (Figure 5.1.1). 
After the penetration, the particles should dissolve and distribute to the 
immunocompetent cells. On the one hand, the vaccine matrix was composed of known 
and established ingredients in the pharmaceutical environment, the method of 
stabilization (collapse freeze-drying) demonstrated benefits in stability and the 
particles would dissolve almost instantly at the administration site due to the 
properties of a carbohydrate [1-7]. On the other hand, the matrixes of biodegradable 
carbohydrates led to low densities of approximately 1.0-1.5 g/cm
3
 (after 
lyophilization) and irregular particle shapes induced by the production method of a 
collapse freeze-dry cycle and additional cryo-milling step [8]. These facts represented 
major challenges to put enough kinetic energy into the particles to breach through the 
stratum corneum and deliver the particles into the epidermis. The kinetic energy is 
composed of the acceleration and the accelerated mass. However, particles with a low 
density accumulate less kinetic energy compared to their volume, leading to a higher 
deceleration during the flight route of the particles between the detachments from the 
membrane to penetrating the skin. Due to the limitations of galenical density increase, 
higher accelerations are necessary to generate enough momentum in order to deliver 
the biodegradable carbohydrate particles into the epidermis. In preliminary tests, 
particle velocities of > 500 m/s were determined to breach the mechanical barrier 
(stratum corneum) and to accumulate still enough kinetic energy to target the APCs in 
a depth of 100-200 µm under the skin surface. In order to achieve this goal, the 
ballistic device had to be adapted to provide sufficient particle acceleration combined 
with a safe administration. Moreover, the environment of the vaccine powder should 
be serializable to provide a clean environment for the vaccine.  
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The device was composed of two functional parts (Figure 5.1.1). The pharmaceutical 
part was designed to provide a sterile/aseptic environment for the products (vaccine) 
while the pyrotechnical part supplied the energy source to deliver the particles to the 
targeted depth. 
  
Figure 5.1.1: Particle administration through the stratum corneum into the epidermis to 
address the vaccine to the Langerhans cell using the ballistic particle applicator (BK01) A) 
fixed particles previous to administration; B) applied particles penetrated into the epidermis. 
Skin and device lengths not to scale. 
In order to improve the final particle velocity and safety, different mechanical parts of 
the device were optimized. The development of the parts will be described in the 
following section (Figure 5.1.2).  
  
Figure 5.1.2: Experimental particle applicator, separated into the two functional parts  
A) pharmaceutical part, B) the pyrotechnical part. 
112 
 
5.2 Development of the combustor  
While the combustor contains the blast of the gas-generator, it directs the pressure to 
the membrane in order to accelerate the particles towards the tissue. The amount and 
focus of the energy transmission highly depends on the design and the volume of the 
combustion chamber.  
A limitation of the combustion chamber volume was given by the size of the gas-
generator. A small volume of the combustion chamber would lead to a maximum of 
contained energy but would also increase the mechanical stress of the membrane 
disproportionately strong. This energy load could result in membrane damages and 
device failure. On the other hand, a large combustion chamber volume would decrease 
the particle velocity due to energy losses during the transmission through the chamber 
and would effect in insufficient particle acceleration. Fitting the gas-generator into the 
combustion chamber and thus creating safe but high particle acceleration was 
established with optimal choice of volume. Beside the optimized volume, the design 
of the chamber had a great impact to channelize the pressure to the membrane. A 
cylindrical form of the combustion chamber could not focus the energy adequately and 
resulted in unreproducible deformations of the membranes. A cone shape next to the 
membranes would transmit the pressure uniformly but would also increase the 
chamber volume. While a large cone resulted in decreased particle velocity and 
inchoate membrane deformations, a small cone increased reproducibly the final 
velocity.  
The final design of a combustion chamber matched the requirements of high velocity 
and safe particle application due to better channelizing of the driving force through the 
gap between gas-generator and membranes. 
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5.3 Composition and development of 
combustion chamber filling 
Optimal energy transmission to the membrane is crucial to accelerate the particles fast 
enough for sufficient tissue penetration while during the generation of pressure, large 
energies arise in form of heat, gas and pulse. The filling medium should possess 
certain properties such as lossless transmission of the pressure, prevention of gas 
expansion and scattering of gas-generator parts within the combustor, and sufficient 
viscosity and storage stability to facilitate handling operations. Moreover the filling 
should also be inert to avoid any interactions with the materials or be toxic. 
Furthermore, the combustion chamber filling should not evaporate to avoid an 
additional pressure increase within the combustion chamber. For example, water as a 
filling content would evaporate instantly during the gas-generation and would lead to 
an extreme pressure increase within the combustion chamber. Furthermore, storage 
stable and temperature independent fillings would open a large freedom of 
applicability of the device.  
While air or lipophilic lubricants with high viscosity were poor energy transmitters 
which resulted in low particle velocities, fillings with low viscosities such as silicone 
oils (100 cSt, 500 cSt, and 1000 cSt) led to leakages and an oily layer on the 
membrane (pharmaceutical side) (Figure 5.3.1). Finally, silicone oil (100 cSt) mixed 
with 5% of a hydrophilic Aerosil
®
 (type 200 pharma) resulted in a silicone oleogel 5% 
(w/w) with a sufficient viscosity for handling, being safe containing the explosion 
energy and particle scatter, and excellent transmission of the pressure to the 
membrane. The energy, which was focused by the combustor design and optimally 
transferred by the filling, accelerated the membrane and the particles fixed on the 
membrane.  
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Figure 5.3.1: Photographic images of accelerated 500 µm glass sphere and oil droplets. 
Droplets occurred due to a thin layer of oil on the membrane prior to the ignition of the gas 
generator A) leaked out of the combustion chamber; B) coated with a swab on the membrane. 
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5.4 Choice of material and design of the 
membranes  
Membranes function as the barrier between the pyrotechnical and the pharmaceutical 
part. Moreover, the membrane which is hit by the pressure should be stable enough to 
resist the load but at the same time flexible enough to acceleration movement (Figure 
5.4.2). Apart from that, the material should possess a low friction force and a smooth 
surface to prevent irregular deformations during the membrane flipping or material 
split offs. Membranes consisting of stiff und hard materials are not able to deform fast 
enough. This delayed material response would lead to increased material stress and 
damages. On the other hand, materials which are too soft to contain the pulse melt or 
crack while hit by the pressure. The chosen membrane material demonstrated perfect 
compromises between hardness, flexibility, friction force, and surface properties. The 
membranes contained the energy within the combustor and were at the same time 
flexible enough to accelerate with the pressure and deform without damages. Beside 
the choice of material, the membrane design has strong impact of particle velocity. 
Preformed membranes demonstrated an improved acceleration compared to plane 
membranes (Figure 5.4.1). In order to ensure a maximum of safety in particle 
administration, a double layer of preformed membranes was established. Using this 
strategy, micro cracks of one membrane could be sealed by the other layer without any 
loss of particle velocity. After the particle detachments from the upper membrane 
(towards the tissue), subsequent membrane deformations occurred induced by the gas 
generation (Figure 5.4.2).  
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Figure 5.4.1: Schematic figure of membrane imprinting using a customized device. A) plane 
membrane with sphere to arch the membrane; B) imprinted membrane bilayer. 
  
 
 
Figure 5.4.2: Flipping of membrane after gas generation A) Explosion of the gas-generator 
and direction of the pressure through the combustion chamber to the preformed arch; B) 
flipping of the membrane and C) final deformation of the membrane. 
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5.5 Design of support plate 
The membranes should be fixed between the combustor and the support plate to 
transfer the momentum from pyrotechnical side of the membranes (induced by the 
gas-generator) to the particles fixed on the pharmaceutical site of the membranes. The 
design of the device should channel the deformation and support the membrane 
stability to resist the high driving forces of the gas generation (Figure 5.4.2).  
A small nozzle diameter resulted in membrane damages due to high forces focused on 
small membrane areas which were forced to deform the membrane through a small 
nozzle. Furthermore, a smaller nozzle would be accompanied with a reduced loading 
capacity. On the other hand, a large nozzle diameter led to decrease particle velocity 
and caused membrane damages. Medium sized diameter stabilized the membrane 
while the driving force could accelerate the particles without any damages.  
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5.6 Choice of the gas-generator  
The gas-generator as the energy source could be varied in order to optimize the 
particle acceleration. Variations of gas-generator charges were tested to determine 
resulting particle velocities and safety. Low gas-generator charges, let the particle 
velocity (500 µm glass sphere, ƍ= 2.3 g/cm3) drop drastically, while high charges 
could induce micro cracks in the membranes without any further velocity increase.  
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5.7 Conclusion 
A gas-generator was established as the energy source and provided sufficient pulse in 
form of a sudden pressure which could sufficiently accelerate the membrane and the 
particles. Nonetheless, the pressure was channeled by the customized combustor to 
maximize the force of impact to the imprinted membrane bilayer. Moreover, 
transmission of the pulse through the combustor was improved using combustion 
chambers filling (silicon oleogel 5%) Finally, the pressure hit the membranes which 
flip from the preformed arch into the opposite direction (Figure 5.4.2). While the 
membranes deformed, the fixed particles accelerated and finally detached from the 
membrane with over 600 m/s. 
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6. Chapter – Proof of concept of 
intradermal ballistic vaccination 
in an animal model 
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6.1 Introduction  
Upcoming immunization strategies are considering new vaccination routes such as 
oral, pulmonary or epidermal administration (described in Chapter 1). Especially the 
thin layer beneath the skin surface excels as a high potential target due to a high 
density of potent antigen presenting cells (APC, Langerhans cells and dendritic cells) 
which can generate a sufficiently protective immune response [1, 2] 
Human studies would be the most accurate method to determine the effectiveness of 
intradermal vaccination but accessibility to human skin specimens is limited and 
suitable artificial skin models with mechanical properties comparable to human skin 
are lacking. Moreover immune response cannot be determined with artificial models 
or excised skin. Hence, in vivo experiments are inevitable to demonstrate the 
effectiveness of a new vaccination method. Animal studies are primarily used as a 
model for human vaccination and shall serve to assess the potential of the intradermal 
vaccination strategy proposed in this chapter.  
A number of factors need to be considered for the selection of an animal model, in 
particular anatomical and physiological similarities to human skin structure and 
immune response [3]. Pig skin has been identified as a suitable model for human skin, 
as it shows comparable density of body hair, epidermis and stratum corneum (SC) 
thickness, and composition of the keratinous proteins and lipids [4-6]. Moreover, the 
overall structure of the skin demonstrates large similarities between humans and pigs, 
such as epidermal turnover time, orientation, and distribution of blood vessels in the 
dermis.  
 
Intradermal needle injection of liquid vaccines requires intensive and time consuming 
training for health-care workers in order to pierce the needle through the stratum 
corneum and deliver the vaccine as a bolus to the APCs. This vaccination technique is 
difficult to perform and can cause high failure rates. This can be a problem in times of 
an epidemic, where vaccination programs needs to be performed quickly and 
effectively and particularly poorly developed health-care systems might have 
difficulties to implement and carry out extensive vaccination campaigns. [7, 8]. 
Moreover, antigen production capacities are limited and cannot be increased easily 
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according to demand. Cold chain storage and delivery can also contribute to 
shortcomings in vaccine supply. In our experiments we tried to address the above 
mentioned problems by preparing a powder vaccine product with better stability 
(demonstrated in Chapters 2 and 3) and no need for cold chain storage. The new 
concept of a ballistic intradermal powder applicator shall make vaccine application 
simple and painless and therefore speed up vaccination while increasing patient 
compliance at the same time. 
In Chapter 2 to 5 the preparation of a stable lyophilized influenza vaccine and the 
development of the new device for intradermal vaccination were described. The aims 
of the animal experiments presented in this chapter were finally to show whether 
intradermal application of lyophilized vaccine with the help of the new device was 
feasible and safe. For this purpose skin reactions and clinical parameters of the test 
animals before and after immunization were closely monitored. The second objective 
of the study was to find evidence for the immunogenic potential of intradermally 
applied HA-antigen (Pandemrix®, GlaxoSmithKline, Rixensart, Belgium). This was 
investigated by ELISA-assays of sera samples after intradermal vaccination in 
comparison to i.m. application of the commercial vaccine.  
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6.2 Material and Methods  
6.2.1 Materials 
Pandemrix®, H1N1 influenza vaccine, (GlaxoSmithKline, Rixensart, Belgium) was 
used as a model vaccine and was kindly provided by the Bavarian State Ministry of 
Environment and Public Health. The commercial product contains 15 µg/ml 
hemagglutinin formulated in a phosphate buffer with polysorbate 80, octoxynol 10 and 
thiomersal and an adjuvant (AS03) containing  squalene, DL-α- tocopherol, and 
Polysorbate 80 in a phosphate buffer. The mixture of vaccine and adjuvant was used 
for the intra muscular (i.m.) control group in the experiments. The oily components 
of AS03 only (squalene, DL-α- tocopherol, and Polysorbate 80) were used to fix the 
vaccine lyophilizate particles on the device membrane in the verum group 
(intradermal application with adjuvant). Paraffin (Merck KGaA, Darmstadt, 
Germany) was also used for particle fixation (intradermal application without 
adjuvant) and served as a control to investigate the adjuvant effect. For buffer 
preparation, sodium hydrogen phosphate monohydrate was purchased from Gruessing 
(Gruessing, Filsum, Germany) and sodium dihydrogen phosphate dihydrate, sodium 
phosphate monobasic and dibasic, sodium hydroxide, and sodium chloride were 
obtained from Applichem (Applichem, Darmstadt, Germany).  
Trehalose, used as lyoprotectant, was purchased from BDH Prolabo (VWR, Ismaning, 
Germany) and mannitol, used as bulking agent, was obtained from Boehringer 
Ingelheim (Ingelheim, Germany). For the Enzyme-linked Immunosorbent Assay 
(ELISA), di-sodium carbonate, potassium chloride, sodium hydrogen carbonate, and 
potassium dihydrogen phosphate were received from Merck KGaA (Darmstadt, 
Germany). Hematoxylin and eosin stain, 25% hydrochloric acid, 96% ethanol, and 
carbol-xylol were obtained from Merck (Darmstadt, Germany). Xylol was purchased 
from W.Gaeen GmbH&Co. (Munich, Germany). Eukitt solution was purchased from 
Vitro-Clud (Langenbrunck GmbH, Emmendingen, Germany). Tween 20, Bovine 
Serum Albumin (BSA), 3,3´,5,5´-Tetramethylbenzidine (TMB), stop reagent for TMB, 
Nunc maxisorb 96 well-plates, and anti-swine IgG (H+L)-peroxidase, produced in 
goat as secondary antibody, were obtained from Sigma-Aldrich (Taufkirchen, 
Germany). Endotoxin determinations were performed using an EndoSafe-PTS and 
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cartridges with a sensitivity of 0.5-0.005 EU/ml (Charles River Laboratories, 
L´Arbresle, France).  
6.2.2 Methods 
6.2.2.1 Concentration of vaccine by tangential flow 
filtration (TFF)  
The concentration of influenza vaccine using a tangential flow filtration method was 
carried out under laminar air flow (LAF) (HeraSafe, (Thermo Fischer scientific, 
Rockford, USA) in order to ensure aseptic preparation. The vaccine was concentrated 
using a filtration cassette Minimate™ (PALL, Dreieich, Germany) with a cut-off pore 
size of 5 kDa. Prior to usage, the TFF cassette was sanitized with 0.5 M NaOH at 45°C 
for 45 min as recommended by the manufacturer. Subsequently, the TFF cassette was 
rinsed with highly purified water (Sartorius Arium Pro, Sartorius, Goettingen, 
Germany) until a neutral pH was measured, using a seveneasy® pH-meter (Mettler 
Toledo, Giessen, Germany) and until the endotoxin value was below the detection 
limit as described in section 6.2.2.15. The TFF cassette membrane was saturated with 
60 ml of a circulating vaccine solution for 60 minutes. The concentration of the 
influenza vaccine was performed at a flow rate of 100 ml/min as recommended by the 
manufacturer using a peristaltic pump (Masterflex, Ponndorf, Germany). After a 
volume reduction of 96% (final concentration > 150 µg/ml), the concentrated vaccine 
solution was dialyzed against 10 mM phosphate buffer (0.22 µm filtered) (PALL life 
Sciences, Ann Arbor, USA). Finally, the concentration of the modified solution was 
adjusted to 150 µg/ml using RP-HPLC (as described below).  
 
6.2.2.2 Adjusting of vaccine concentration  
Hemagglutinin concentration was determined using RP-HPLC and was calculated as 
follows: area under the curve (AUC) of HA commercial product compared to AUC of 
modified vaccine solution. The hemagglutinin peak was recorded using a fluorescence 
detector (λex 280 nm and λem 335 nm) and the AUC of the modified solution was 
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compared to the commercial product. Pandemrix has a declared hemagglutinin 
concentration by the manufacturer of 15 µg/ml. 
6.2.2.3 Addition of lyoprotectants and bulking agents 
A final concentration of 15% solid content with 3.75 µg/mg hemagglutinin was 
prepared by adding trehalose and mannitol (1:1) (w/w) to the modified vaccine 
solution. After gentle stirring at approximately 50 rpm (IGAMAG RCT, IKA®-Werke 
GmbH & Co. KG, Staufen, Germany), 0.22 µm filtration, and hemagglutinin 
concentration determination (RP-HPLC), the lyophilization mixture was ready for 
collapse freeze-drying.  
 
6.2.2.4 Lyophilization processes 
DIN 10R vials (Mglas AG, Muennerstadt, Germany) were heat sterilized 
(180°C/3 hours) in a Binder FED 53 (Binder GmbH, Tuttlingen, Germany) and filled 
with 2.625 ml of the final lyophilization mixture with a filling level of approximately 
1 cm. Subsequently, the vials were semi-stoppered (Westar®RS.stoppers, 
Westpharma, Exton, USA) and transferred to the Martin Christ Epsilon 2-12D freeze-
dryer equipped with a pirani pressure sensor (Martin Christ, Osterode, Germany).  
The middle shelf was loaded with 84 vials filled with lyophilization mixture, 42 vials 
filled with 15% trehalose-mannitol (1:1) (w/w) solution in 10 mM phosphate buffer 
and surrounded by two rows of edge vials.  
After the equilibration phase at 4°C for 1 hour, samples were frozen to -50°C within 
1.5 hours and stabilized for a further hour. The temperature was increased to -40°C 
(ramp of 0.33°C/min) while the chamber pressure was reduced to 1.98 mbar. 
Subsequently, the shelf temperature was increased to 45°C (ramp of 0.71°C/min) and 
held at that temperature for further 24 hours. Secondary drying started with an 
additional pressure reduction to 0.3 mbar, and these conditions (0.3 mbar / 45°C) were 
maintained for further 20 hours. Finally, the temperature was reduced to the storage 
temperature of 4°C and the samples were stoppered at approximately 800 mbar with 
dry nitrogen gas atmosphere.  
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6.2.2.5 Cryo-milling and sieving  
Previous to milling, the milling tools were placed in hot-air sterilizer (Binder GmbH, 
Tuttlingen, Germany) for heat sterilization and depyrogenation (180°C/3h) while the 
sieving equipment was sanitized in 80% ethanol for 48 hours. Afterwards, 
lyophilizates were transferred under a LAF into stainless steel milling jars with two 
stainless steel balls (Retsch Technology GmbH, Haan, Germany). After a precooling 
(liquid nitrogen) of ten minutes with a milling frequency of 5 Hz, the grinding was 
performed at 25 Hz for 15 sec. using a Retsch CryoMill (Retsch Technology GmbH, 
Haan, Germany). The equilibration of jars to ambient temperatures for 2 hours and 
classifying (20, 80, and 125 µm) was carried out under a LAF. Aliquots of particles 
(20-80 µm) were filled in DIN 10R vials and stoppered with Westar
®
RS.stoppers. 
 
6.2.2.6 Reversed-Phase chromatography (RP-HPLC) 
The hemagglutinin content in the samples was determined using a Dionex HPLC 
system equipped with a Dionex P680 HPLC Pump, ASI-100 automated sample 
injector, Dionex Column oven, Dionex RF-2000 Fluorescence Detector and a Dionex 
UVD170u UV/VIS-detector (Dionex, Idstein, Germany). Separation was performed 
using a Phenomenex Jupiter 5 µ, C18, 300 A column (250 x 4.6 mm) (Phenomenex, 
Aschaffenburg, Germany) at 60°C with a gradient elution over 30 min at a flow rate of 
1.0 ml/min. Eluent A consisted of highly purified water with 0.1% trifluoric acid and 
eluent B comprised 75% 2-propanol, 25% acetonitrile and 0.1% trifluoric acid. 
Lyophilizated samples were dissolved in 2.625 ml highly purified water. The 
separation of a 25 µl sample solution was accomplished with the gradient starting at 
20% eluent B, increasing to 36% within 10 min, a ramp to 95% (14.75%/min), plateau 
for further 4 min. and an abrupt drop to 20% for 12 min. Intrinsic fluorescence (λex 
280 nm and λem 335 nm) was used to determine hemagglutinin. Data acquisition was 
performed using the Chromeleon 6.80 software (Dionex, Idstein, Germany). 
Preparation of the oily part of AS03 
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The oily part of AS03, containing 10.69 g of squalene, 11.86 g DL-α-tocopherol, and 
4.86 g Polysorbat 80 was mixed using a magnetic stirrer at approximately 50 rpm and 
then stored at 2-8°C until usage.  
 
6.2.2.7 Preparing of 5% silicone oleogel as energy 
transmission medium  
In order to transfer the energy from the gas-generator without any loss to the vaccine 
particles fixed on the membrane, a silicone oleogel was prepared (described in 
Chapter 4 and 5). Silicone oil (100 cSt) (Sigma-Aldrich, Taufkirchen, Germany) and 
5% Aerosil R200 Pharma (Evonik Industries AG, Hanau-Wolfgang, Germany) (w/w) 
were mixed in 24 ml syringes (Norm-Ject, HenkeSassWolf, Tuttlingen, Germany) 
connected with a Luer adapter (Combifix Adapter, B.Braun, Melsungen, Germany) 
and depressurized to 10 mbar in a vacuum oven (Memmert, Schwabach, Germany) for 
4 hours (Figure 6.2.1). Afterwards, silicone oil was pressed into Aerosil
®
, while the 
chamber was pressurized back to the atmospheric pressure (approximately 1 bar). 
After a final homogenization by mixing the oleogel within two connected syringes, the 
product was ready to use (Figure 6.2.1).   
 
129 
 
  
 
 
Figure 6.2.1: Schematic figure of air bubble free silicone oleogel 5% preparation. A) syringe 
with silicone oil and Aerosil 200 Pharma, B) depressurizing of Aerosil and silicone oil, C) 
silicone oil pressed into syringe with Aerosil, while pressurizing chamber, D) homogenization 
of oleogel  
 
6.2.2.8 Device preparation and particle loading for 
animal experiments (Group A-C) 
A more detailed description of the device can be found in Chapter 4 and 5. The 
device components of the pharmaceutical part with product contact (modified 
membranes  and supporter plates) were cleaned with 70% 2-propanol and 
subsequently wrapped into aluminum foil (Carl Roth GmbH&Co KG, Karlsruhe, 
Germany) for heat sterilization and depyrogenation (180°C/3h) in a hot-air sterilizer 
(Binder GmbH, Tuttlingen, Germany). After the assembly of the pharmaceutical part 
on a clean bench, the membrane was coated with an oily component (paraffin or oily 
part of AS03) and loaded with prepared vaccine lyophilizate particles using a 
customized funnel which was gently put through the nozzle (Figure 6.2.2). The 
particles (placebo (trehalose-mannitol) particles or vaccine loaded particles) were 
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scattered through the funnel on the coated membrane until the membrane surface was 
overfilled (Figure 6.2.2). The device was inverted and the funnel was carefully taken 
out to avoid a swirling of the particles in the pharmaceutical part of the device. 
Subsequently the inverted particle applicator was tapped on the bench to detach loose 
particles (Figure 6.2.2). Finally, the pharmaceutical part was sealed with a customized 
foil (IIS, Andernach, Germany) to inhibit permeation of moisture and to keep the 
particle applicator clean and sterile until use.  
Three groups of devices were prepared with particles fixed with an oily component on 
the membranes (Table 6.2.1). For the first group (placebo without adjuvant, Group 
A), only carbohydrate lyophilizate (15% trehalose-mannitol (1:1) (w/w) solution in 
10 mM phosphate buffer) particles were fixed with paraffin on the membrane. Vaccine 
particles were fixed with paraffin in the second group (verum without adjuvant, 
Group B), while vaccine particles attached on the membrane using the oily part of 
AS03 in the third group (verum with adjuvant, Group C) (Table 6.2.1). About 
0.35 mg±0.05 mg (n= 5) of the oily adjuvant mixture was coated onto the membrane 
which resulted in a particle amount of 1.81±0.19 mg (n= 5) (Figure 6.2.2) brought on 
the membranes after preparation. The amount of adjuvant loaded on the device was 
determined by the difference of weight of the membrane (before and after coating). 
The maximal particle loading capacity of the device was limited to 1.81 mg±0.19 mg 
(carbohydrate particles, 1.77 mg±0.07 mg for polystyrene particles 40 µm). The 
limitation was a result of the particle fixation area on the membrane of 3.14 cm
2
 and 
the adhesion forces of the oily components to fix the particles on the membrane. The 
dose of 1 mg of vaccine particles was equivalent to 3.75 µg HA.  
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Figure 6.2.2: Preparation and particle loading on the membrane of the ballistic powder 
applicator A) the pharmaceutical part of the device, B) coating with oily component (paraffin 
or oily part of AS03 using a sterile swab, C) particle loading using customized funnel  
 
6.2.2.9 Liquid vaccine preparation for intra muscular 
group (challenge group) (Group D) 
Shortly before the animal experiments were conducted, the adjuvant (AS03) was 
transferred to the influenza vaccine vial using a syringe and carefully mixed as 
recommended by the manufacturer (GSK, Middlesex, United Kingdom) to prepare the 
injection. Doses of 0.5 ml of the mixture were stored in syringes at 2-8°C until use for 
intramuscular administration.  
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Table 6.2.1: List of administration groups, each group consisted of 7 pigs. The amount of 
adjuvant for intradermal administration was determined using three independent 
measurements (n=3). 
Group Particle Fixation  Amount  
of adjuvant 
Administration 
route 
A Placebo Paraffin No adjuvant Intradermally 
B Vaccine Paraffin No adjuvant Intradermally 
C Vaccine Adjuvant (oily components of AS03) 0.35 mg±0.05 mg Intradermally 
D Vaccine Adjuvant (AS03) 0.25 ml Intramuscularly 
 
6.2.2.10 Animal keeping and immunization  
From a farrowing to fattening farm 28 healthy, five weeks old, commercial cross-bred 
piglets (LWxPI) were transported to the Clinic for Swine (Oberschleissheim, 
Germany). Animals were randomly assigned to one of four groups (A-D) according to 
their weight. Each group was housed in pens of 2.5 m
2
 x 4 m
2
 on solid floor and straw. 
Water and food was available ad libitum. The general health status of each piglet was 
documented daily. After a two week adaptation phase, i.e. on study day d 0, piglets of 
groups A, B and C were fixed by one person, an anesthetic mask for dogs was put on 
the nose and anesthesia was introduced using 5 Vol% Isoflurane (Isoba®  MAC 1,5 
Vol% Essex Tierarznei) mixed with oxygen. After muscle relaxation induced by the 
anesthesia, the pig was placed on the right side. Inhalation anesthesia was maintained 
during particle application using the ballistic powder applicator. The administration 
sites for intradermal applications on day 0 were situated on the left of the mammilla 
complex approximately 15-20 cm cranial from the groin. The area was cleaned using 
tissues and the hog hairs were trimmed carefully to avoid any skin irritations. After the 
particle administration, the area application site was carefully marked with tattoo 
color. The animals of the placebo group (Group A) were vaccinated with carbohydrate 
lyophilizate particles fixed with paraffin, while Group B was vaccinated with vaccine 
particles (verum) fixed with also paraffin on the device. Vaccine particles fixed with 
the oily components of AS03 (squalene, DL-α-tocopherol, and Polysorbate 80) were 
applied to the animals of Group C. Particles which did not penetrate the skin could be 
rubbed of due to a lack of a coverage (e.g. adhesive plaster) on the administration site. 
The animals of Group D (positive control group) were fixed using a snear and received 
an intramuscular injection of 0.5 ml ready-made, commercial Pandemrix vaccine (see 
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section 6.2.2.9) into the left neck muscle (injection cannula 19 G) (B.Braun, 
Melsungen, Germany). After 14 days, all animals were boostered with their allocated 
group-vaccine preparation but on the right body side. Every single administration site 
was documented photographically and then covered using an adhesive plaster 
(Hansaplast, BSN medical GmbH, Hamburg, Germany).  
A detailed clinical observation was performed daily from day 0 to day 28 and recorded 
according to a scoring system. (Results of clinical observations are described in 
section 6.3.2) Blood Samples (serum) were collected from the vena cava superior 
before and 1, 14, 21, and 28 days after the first application and stored at -80°C until 
examination. Additionally, the application sites were photographed on days 0 directly 
before and after application and after 5 minutes, 1, 2, and 14 days. On study day 28, all 
animals were euthanized using Pentobarbital (Release 500mg/ml, 45mg/kg i.v.) 
(WDT, Garbsen, Germany). 
All procedures and the experimental protocol were officially approved by the 
Government Office of Upper Bavaria, Munich, Germany (authorization reference 
number 55.2.1.54-2532-87-12; 30.08.2012). 
6.2.2.11 Skin preparation 
On day 28 after euthanasia, the administration sites of the intradermal powder 
immunization were excised manually using a scalpel and stored on dry ice for 
transportation (detailed description in Chapter 4).  
 
6.2.2.12 Hematoxylin and eosin stain (HE stain) of skin 
slices and microscopic examination 
Specimens were dyed using a haematoxylin and eosin stain (HE stain). Skin slices 
were embedded in HE stain for 5 minutes and subsequently washed with tap water for 
further 5 minutes. Samples were shortly moved through a 0.5% hydrochloric acid-
ethanol solution with an additional washing step afterwards. Thereafter, the samples 
were briefly put into a 1% eosin solution and subsequently washed again with water. 
The prepared slices were dried in ascending ethanol concentrations (50%, 70%, 80%, 
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96%, and 100%) for 1 minute per concentration. Finally, specimens were shortly 
covered with carbol-xylol and xylol. The slices were fixed with the Eukitt solution on 
microscope slides.  
Specimens were microscopically examined using a BZ8100 Biozero Micrsocope 
(Keyence, Neu-Isenburg, Germany) (detailed description in Chapter 4).  
6.2.2.13 Processing of blood samples (serum) 
Blood samples were centrifuged at 15000 rpm/min for 45 minutes to separate sera 
from cellular components. Subsequently, these samples were stored at -80°C until 
further usage for specific anti-HA-antibody-titer determination using ELISA. A 
positive control was collected from H1N1 sera positive pigs and was kindly provided 
from the Friedrich-Loeffler-Institute (Riems, Germany).  
6.2.2.14 Enzyme-linked Immunosorbent Assay (ELISA) 
A carbonate-bicarbonate coating buffer pH 9.6 was prepared mixing di-sodium 
carbonate (0.318 g) and sodium hydrogen carbonate (0.586 g) with highly purified 
water (up to 200 ml). A 10x PBS (1.5 M) stock solution pH 7.4 resulted by mixing 
sodium chloride (80 g), di-sodium hydrogen phosphate (14.4 g), potassium di-
hydrogen phosphate (2.0 g), potassium chloride (2.0 g) and highly purified water 
(1000 ml). A washing buffer (PBS-T) was prepared using 10% of the PBS-stock 
solution diluted with highly purified water (900 ml) and Tween 20 (500 µl). Blocking 
buffer and dilution buffer contained 5% (2.0 g/40 ml) or rather 1% (1 g/100 ml) BSA 
respectively and PBS-T was adjusted to pH 7.4. All solutions were adjusted using a 
seveneasy® pH-meter (Mettler Toledo, Giessen, Germany) and filtered through a 
0.22 µm filter. Finally, a vaccine-coating solution was prepared using 200 µl of the 
commercial vaccine filled up to 20 ml with coating buffer. Sera samples were diluted 
1:25 and the anti-swine IgG (H+L)-peroxidase conjugated secondary antibody 
1:25000 with dilution buffer.  
On the first day of the ELISA analysis, each well of a 96 well-plate was coated with 
100 µl of vaccine-coating solution except row 8 (negative control row). After 12 hours 
incubation time at 2-8°C, the well-plates were washed with 600 µl/well PBS-T using a 
hydroflex plate washer (Tecan, Crailsheim, Germany). Subsequently, blocking buffer 
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(100 µl/well) incubated for 1 hour to minimize unspecific adsorptions. After a further 
washing cycle, 50 µl of dilution buffer was pipetted in each well and additionally 
50 µl of serum sample in each well of the first column (two-fold determinations per 
animal). Subsequently, two-fold dilution steps were performed each with a transfer of 
50 µl and incubated for 2 hours. Well-plates were washed again with PBS-T and 
50 µl/well of secondary antibody was added and incubated for 1 hour. After the final 
washing cycle, 50 µl/well TMB was pipetted and developed for exact 10 min before 
the reactions were stopped using the Stop reagent (Figure 6.2.3). Intensity of the 
reaction was red out using a FLUOstar Omega (BMG-Labtech, Ortenberg, Germany). 
Data were collected with Omega Data Analysis (BMG-Labtech, Ortenberg, Germany). 
Statistical calculations were performed using SigmaPlot 12.5 (Systat Software GmbH, 
Erkrath, Germany).  
 
Figure 6.2.3: Schematic presentation of ELISA. A) coating with vaccine-coating solution on 
day 1, B) blocking to prevent unspecific reaction on day 2, C) 2-fold dilution of sera samples 
on day 2, D) TMB reaction and read out on day 2.  
 
6.2.2.15 Endotoxin determination 
EndoSafe- PTS and cartridges with a sensitivity of 0.5-0.005 EU/ml were inserted into 
the EndoSafe-PTS. After the equilibration, 200 µl of sample were carefully pipetted 
into the cartridge as recommended by the manufacturer. Finally, the endotoxin content 
was displayed by the device.   
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6.3 Results  
6.3.1 RP-HPLC – Comparison of antigen 
concentration  
The areas under the curves (AUC) of the samples were determined to calculate the 
amount of hemagglutinin in each specimen using a fluorescence detector (λex 280 nm 
and λem 335 nm). Therefore, the HA content of the commercial product was 
compared to collapse and cryo-milled lyophilized vaccines. The amount of HA was 
calculated as follows: AUC of commercial product (15 µg/ml) was directly compared 
to the AUC of lyophilized samples (adjusted to 15 µg/ml). All samples demonstrated 
an AUC of approximately 115.63 ± 2.71 mV*min (Figure 6.3.1). Neither the process 
of collapse lyophilization nor the cryo-milling had a detectable impact on 
hemagglutinin content and so a comparable dose of dried vaccine particle to the liquid 
dose could be administered to the animals.  
 
Figure 6.3.1: Fluorescence units of the commercially available product (15 µg/ml), stressed 
vaccine (15 µg/ml), and collapse lyophilized vaccine (15 µg/ml). Three independent 
measurements were performed (n=3).   
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6.3.2 Administration sites after intradermal 
powder immunization  
The particles were administered within a marked administration site (marked with a 
permanent marker and tattoo dye) of 5 cm x 5 cm. A round imprint on the skin was 
observed on all administration sites after intradermal powder immunization. Circular 
particle residues were more distinct for the placebo group (Group A) compared to the 
two i.d. verum groups (Groups B and Group C). Redness up to slight bleedings and a 
discharge of tissue fluids were more pronounced in the verum groups (groups B and 
C) and developed within 5 minutes after immunization. The skin of the piglets felt soft 
which got firm over the time of four weeks. The bruises were consistent up to two 
days and vanished afterwards while the scab peeled from the skin without any traces 
(Figure 6.3.2, Figure 6.3.3, Figure 6.3.4 and Figure 6.3.5).  
 
Day 0, group A, animal 1 
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Figure 6.3.2: Group A (animal 1) i.d. application of placebo powder fixed with paraffin on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14 
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Day 0, group A, animal 2 
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Day 0, group A, animal 3 
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Figure 6.3.3: Group A (animal 2 and 3) i.d. application of placebo powder fixed with paraffin 
on ballistic device A) administration site before application; B) administration site directly 
after application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14 
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Day 0, group A, animal 4 
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Day 0, group A, animal 5 
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Figure 6.3.4: Group A (animal 4 and 5) i.d. application of placebo powder fixed with paraffin 
on ballistic device A) administration site before application; B) administration site directly 
after application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14 
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Day 0, group A, animal 6 
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Day 0, group A, animal 7 
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Figure 6.3.5: Group A (animal 6 and 7) i.d. application of placebo powder fixed with paraffin 
on ballistic device A) administration site before application; B) administration site directly 
after application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14 
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The skin irritations of the intradermal powder immunization did not distinctly extend 
to the surrounding tissues after the application. However, the second immunization 
(day 14) left less distinct marks at the administration sites compared to the first 
particle application (day 0) due to firm skin of maturated piglets. The powder 
immunization of the verum groups (Group B and Group C) resulted in a slightly 
stronger irritation on the skin while the administration sites of Group A were barely 
visible. Nevertheless, bleedings or discharges of tissue fluids were not observed and 
all application marks healed until the next day (Figure 6.3.6, Figure 6.3.7, Figure 6.3.8 
and Figure 6.3.9).  
 
Day 0, group B, animal 8 
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Figure 6.3.6: Group B (animal 8) i.d. application of vaccine powder fixed with paraffin on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14  
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Day 0, group B, animal 9 
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Day 0, group B, animal 10 
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Figure 6.3.7: Group B (animal 9 and 10) i.d. application of vaccine powder fixed with paraffin 
on ballistic device A) administration site before application; B) administration site directly 
after application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2; F) administration site after boost application at day 14 
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Day 0, group B, animal 11 
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Day 0, group B, animal 12 
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Figure 6.3.8: Group B (animal 11 and 12) i.d. application of vaccine powder fixed with 
paraffin on ballistic device A) administration site before application; B) administration site 
directly after application; C) administration site after 5 min latency; D) administration site at 
day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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Day 0, group B, animal 13 
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Day 0, group B, animal 14 
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Figure 6.3.9: Group B (animal 13 and 14) i.d. application of vaccine powder fixed with 
paraffin on ballistic device A) administration site before application; B) administration site 
directly after application; C) administration site after 5 min latency; D) administration site at 
day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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After the immunization, the bruises and bleedings of the verum groups were different 
in each animal despite the comparable skin region of the administration sites 15-20 cm 
cranial from the groin. While the administered vaccine powder fixed with oily 
components of AS03 (Group C) induced stronger discharge of tissue fluids, Group B 
resulted in more distinct bruises and slight bleedings (Figure 6.3.10, Figure 6.3.11, 
Figure 6.3.12 and Figure 6.3.13).   
All animals well tolerated the immunizations; however one animal of Group B showed 
side effects of the influenza vaccination such as fever and fatigue on day 1. This 
animal was treated with analgesic and antipyretic drugs. To prevent a superinfection, 
an additional treatment with antibiotics was performed.  
 
Day 0, group C, animal 15 
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Figure 6.3.10: Group C (animal 15) i.d. application of vaccine powder fixed with oily part of 
AS03 on ballistic device A) administration site before application; B) administration site 
directly after application; C) administration site after 5 min latency; D) administration site at 
day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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Day 0, group C, animal 16 
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Day 0, group C, animal 17 
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Figure 6.3.11: Group C (animal 16 and 17) i.d. application of vaccine powder fixed with oily 
part of AS03 on ballistic device A) administration site before application; B) administration 
site directly after application; C) administration site after 5 min latency; D) administration site 
at day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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Day 0, group C, animal 18 
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Day 0, group C, animal 19 
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Figure 6.3.12: Group C (animal 18 and 19) i.d. application of vaccine powder fixed with oily 
part of AS03 on ballistic device A) administration site before application; B) administration 
site directly after application; C) administration site after 5 min latency; D) administration site 
at day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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Day 0, group C, animal 20 
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Day 0, group C, animal 21 
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Figure 6.3.13: Group C (animal 20 and 21) i.d. application of vaccine powder fixed with oily 
part of AS03 on ballistic device A) administration site before application; B) administration 
site directly after application; C) administration site after 5 min latency; D) administration site 
at day 1; E) administration site at day 2; F) administration site after boost application at day 14  
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6.3.3 Histological characterization of 
administration site  
The excised and stained skin was microscopically characterized to determine any 
tissue changes after intradermal vaccine deposition using the ballistic powder 
applicator. Skin samples from the administration sites were taken after the euthanasia 
of the animals. Therefore, the tissue could heal 28 or 14 days after the administration. 
It should be kept in mind if the particles would damage parts of the viable skin (below 
stratum basale), this could lead to tissue scarring. The results of the skin samples 
demonstrated an unchanged tissue independently of the healing time (28 days or 
14 days after administration) and particle/coating compared to an unprocessed control 
side. No scarring or tissue changes could be detected (Figure 6.3.14).  
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Figure 6.3.14: Images of histological HE stained skin slices taken at day 28 of administration 
sites after ballistic powder deposition. A) placebo particles coated with paraffin administered 
on day 0; B) placebo particles coated with paraffin administered on day 14; C) vaccine 
particles coated with paraffin administered on day 0; D) vaccine particles coated with paraffin 
administered on day 14; E) vaccine particles coated with oily components of AS03 
administered on day 0; F) vaccine particles coated with oily components of AS03 
administered on day 14; G and H) control sites without any particle deposition 
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6.3.4 Determination of endotoxin content in 
samples  
Endotoxins (pyrogens) can influence immune response and therefore interfere with 
immunogenicity of HA. [134, 135]. Low endotoxin content has to be warranted, when 
the genuine specific immune response triggered only by the antigen (hemagglutinin) is 
under investigation. While highly purified water demonstrated endotoxin content 
below the detection limit, the measurement of the commercial product resulted in 
approximately 0.71 Endotoxin Units (EU)/dose (Figure 6.3.15). The placebo 
formulation, composed of the buffer components (10 mM phosphate buffer) and 
carbohydrates (trehalose and mannitol), was measured with approximately 
0.34 EU/dose. The concentration of the vaccine using TFF and dialyzed against 
10 mM phosphate buffer resulted in an endotoxin level of about 1.1 EU/dose, while 
the addition of a bulking agent, cryo-protectant (trehalose and mannitol), collapse 
lyophilization and cryo milling increased the content only up to approximately 
2 EU/dose. Endotoxins levels < 2 EU/dose were sufficiently low to match the 
requirements of the European Pharmacopoeia (< 100 EU/dose) for influenza subunit 
vaccines (Pharm. Eur. 2.6.14). Using the EndoSafe-PTS system with cartridges, the 
recovery of the test may vary between 50% and 200% as described by the 
manufacturer. Keeping this in mind, recoveries from 76% to 109% of additionally 
spiked endotoxins into the samples were perfectly in range of the assay. 
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Figure 6.3.15: Content in EU/ml of commercially available product, collapse lyophilized 
vaccine and cryo-milled lyophilized vaccine.  
 
6.3.5 Blood samples and IgG immune response 
determined using ELISA  
All sera samples from the i.d. and i.m. vaccination were successfully tested using the 
enzyme-linked immunosorbent assay (ELISA) (Figure 6.3.16). The results of the assay 
demonstrated a consistent H1N1-specific antibody titer of Group A (placebo group) 
over the whole period of 28 days. Intradermal application of vaccine powder (verum 
groups B and C) resulted in higher antibody titers compared to the placebo group 
regardless of an adjuvant usage while the immunization (Group D) strongly increased 
the specific antibody titer significantly. The intradermal vaccine administration 
independently of adjuvant usage induced in four of seven animals a significant 
immune response compared to the placebo group. The booster immunization on day 
14 only improved the immune response in the positive control group D leading to 
higher titers while only slight titer increases were observed for Group B and C within 
the period from day 14 to 28.  
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,
Figure 6.3.16: ELISA results of specific anti-hemagglutinin-antibody measurements. A) i.d. 
placebo group; B) i.d. vaccine particles without oily adjuvant (paraffin); C) i.d. vaccine 
particles with oily adjuvant (AS03); D) i.m. commercial vaccine injection with adjuvant 
(AS03). Red line marks the mean value of the titer, * with black bar marks the significance P= 
0.005    
The comparable anti-HA-specific antibody titers of all four groups demonstrated a 
similar starting titer at day 0. A value unequal zero can be induced due to unspecific 
surface/protein adsorptions or randomly matching antibodies against the antigen. Due 
to the lag time of the immune response, the titers were still unchanged at day 1 after 
the immunization. While the i.m. immunization modified the titer significantly at 
day 14, both intradermal verum groups resulted in observable but not significant 
antibody titer increase compared to the placebo group due to the broader deviation. 
These trends continued after the boost administration (day 14) at days 21 and 28. 
However, the development of the intradermal verum powder group titers was not high 
enough for significance compared to Group 1. Additionally no significance could be 
calculated between titers of the intradermal groups and the i.m. group.  
154 
 
 
Figure 6.3.17: Comparison of ELISA results of specific anti-hemagglutinin-antibody 
measurements. IgG levels of A) Day 0; B) Day 1; C) Day 14; D) Day 21; E) Day 28. Red line 
marks the mean value of the titer, * with black bar marks the significance P= 0.005    
 
The broad titer value distribution of the EPI groups resulted in a lack of significance 
between the control and the EPI group (Table 2.4.1). While the titers of the control 
group showed a narrow distribution about 58±23 titer value the titers of the EPI groups 
were distributed in a range of 490±426 titer value (H1N1 + paraffin) or 650±486 titer 
value, respectively. The larger range of the titer values of the i.m. group 
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(21078±7615 titer value) resulted in a lack of significance to the EPI groups while 
demonstrating significance against the control group (Figure 6.3.17 and Table 6.3.1).  
 
Table 6.3.1: Titer values of each animal at day 28 after immunization  
 EPI  
(placebo + 
paraffin) 
EPI  
(H1N1 + 
paraffin) 
EPI  
(H1N1 + 
AS03 
i.m.  
(H1N1 + 
AS03) 
Titer animal 1/group 79.64 380.36 764.82 22269.95 
Titer animal 2/group 59.13 400.31 610.93 18795.83 
Titer animal 3/group 85.90 193.27 202.98 11463.83 
Titer animal 4/group 34.59 219.95 231.82 18270.88 
Titer animal 5/group 62.61 675.03 1430.16 18761.72 
Titer animal 6/group 64.32 1375.70 200.01 21560.94 
Titer animal 7/group 19.24 188.28 1113.95 36420.27 
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6.4 Discussion  
The application of both the intramuscular administration of the commercial liquid 
vaccine and the intradermally deposited lyophilized vaccine led to a detectable 
increase of IgG antibody titer. The latter (for each intradermal application group) 
however was not statistically significant. The HA content for each delivery route (i.d. 
or i.m) was determined and confirmed using RP-HPLC measurements with 
fluorescence detection. While the complete dose of 3.75 µg of HA and the whole 
amount of 27.41 mg of adjuvant (squalene 10.69 mg, DL-α-tocopherol 11.86 mg, and 
Polysorbate 80 4.86 mg) mixed in 0.25 ml emulsion was injected intramuscularly to 
animals of the positive control group, the actual available dose of the intradermal 
application in the verum groups was significantly lower. As described in 
Chapter 4.3.2 ca. 93% of HA and adjuvant could be ejected from the device. Only a 
fraction (about 25%) of the ejected dose actually could penetrate the stratum corneum 
and could reach the immune cells located in the epidermis. The device was loaded 
with 1.81±0.19 mg and each mg of the particles was equivalent to 3.75 µg of the 
vaccine. Thus the amount of vaccine particles that was delivered to the immune cells 
in the epidermis amounted to 0.4-0.5 mg. This led to an intradermally applied vaccine 
dose of 1.5-1.875 µg and would result in 40-50% of the i.m. dose. Regarding the 
adjuvant (oily components) amount 27.41 mg (in 0.25 ml emulsion) were injected with 
a single commercial vaccine dose intramuscularly but only 1.28% ± 0.74% thereof 
were used to fix the particles on the device membrane. The H1N1 specific IgG titer of 
all laboratory animals of Group D (i.m. vaccine injection) was indicative of a strong 
immune response and resulted in titers that elicited more than two orders of magnitude 
after the vaccination while the i.d. verum groups B and C developed an increase of 
approximately one order of magnitude. A more differentiated view revealed that 
within each intradermally vaccinated group (groups B and C) four of seven animals 
showed a significant increase while the other three animals responded with a poor 
immune reaction. This titer deviation of both sub groups limited the intradermal 
vaccination success. The immune-stimulating effect of the oily components of AS03 
(group C) was comparable to paraffin. The immune-stimulating effect of oily 
components could be increased, if an emulsification within the administration site 
could occur as described in the literature [136]. Additionally, it can be excluded that 
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the minimal increase of endotoxins (from 0.71 EU/dose for the commercial i.m. 
vaccine to 2 E markedly below the requirements of the Ph. Eur. (< 100 EU/dose; 
Pharm. Eur. 2.6.14) and thus unlikely to contribute to the specific immune response 
[12, 13].  
After boost administration at day 14 IgG titers increased further in the i.m. group 
whereas both i.d. groups barely changed. The lack of a boost effect could be caused by 
a poorer particle penetration into the epidermis. After the first intradermal powder 
administration (day 0), the skin of all laboratory animals showed reactions to the 
procedure (bruising or discharge of fluids) but poorer skin responses were observed 
after the boost powder application (day 14). This effect may be attributed to changed 
mechanical skin properties as a result of weight gain and aging of the laboratory 
animals which demonstrate the requirement of human studies.  
Further phenomena were observed considering the skin reactions, which could be 
summarized as particle and/or fixation type induced effects. The first observation was 
that the skin responded differently to placebo and verum powder. Intradermal powder 
application with verum particles induced distinct bruises, minimal bleedings and a 
discharge of tissue fluids, while placebo particles induced primarily erythema. More 
intense redness could be a result of higher proportion of larger particles within the 
range of 20-80 µm of the verum particles compared to the placebo particles which may 
be induced by different milling properties (incorporated protein). Larger particles 
would result in higher momentum and higher impact forces into the skin. The second 
observation was that applied verum particles attached with paraffin resulted in bruises 
and bleedings while verum particle fixed with the oily components of AS03 
demonstrated a trend to stronger tissue fluid outflow. However, the observed effect 
could be caused by the different wetting characteristics of the oils used for particle 
fixation. Nonetheless, all i.d. administration sites healed within 2-3 days after the 
epidermal powder immunization (day 0 and day 14) without any visible tissue lesions 
or scaring (see Attachments Figure 6.6.1 to Figure 6.6.5).  
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6.5 Conclusion 
We were able to demonstrate a successful and safe intradermal powder immunization 
using a new ballistic device. Vaccine preparation and device loading could be 
performed under aseptic conditions. After i.d. immunization, the H1N1 specific IgG 
titer was lower compared to the benchmark i.m. vaccination. However, the 
administered dose using the EPI was only 50% compared to the i.m dose due to 
incomplete administration or penetration of the vaccine particles into the skin, 
respectively. The particle penetration hardly depends on particle momentum and 
mechanical properties of the skin. While the particle momentum should be comparable 
between the two application time points, the skin of the laboratory animals could be 
changed drastically due to ageing and weight gain.  
Moreover, the amount of adjuvant in the EPI group was limited by the coated 
membrane area and the coating thickness and resulted in only 1.28% ± 0.74% of the 
recommended amount for the i.m. application. Therefore, the contribution to an 
immune-stimulating effect in order to induce a sufficient immune response was 
limited due to the low delivered quantity. Despite all these facts, the intradermal 
powder immunization induced an observable H1N1 specific IgG titer increase.  
Intradermal powder immunization using the new ballistic device is a safe and fast 
technique. The stable, lyophilized vaccines and easy handling promise advantages 
such as a cost reduction for health-care staff training and a minimization of cold chain 
maintenance. The potential of dose-reduction as described by Romani et al. could be 
achieved if a sufficient vaccine dose and adjuvant could be delivered into the skin   
Furthermore, the minimal invasive route of the vaccine application may prevent pain 
during the vaccination and demonstrated healed administration sites within 2-3 days 
without any tissue lesions and scars. In times of vaccine shortage and distribution 
problems, this new epidermal powder immunization technique could provide a method 
to face the vaccination challenges. In addition, the alleviating fear of needles and the 
reduction of needle-stick injuries (more than 500 000 deaths per year) could increase 
the patient compliance and improve worldwide accessibility to vaccination, especially 
in times of a pandemic outbreak [14]. The ballistics powder applicator could provide a 
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technology for epidermal powder immunization for a minimal invasive, painless, and 
simple vaccination.  
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6.6 Attachments  
Verum particles fixed with paraffin 
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Verum particles fixed with paraffin 
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Figure 6.6.1: Administration site of i.d. application of verum powder fixed with paraffin on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2 
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Figure 6.6.2: Administration site of i.d. application of verum powder fixed with paraffin on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2 
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Verum particles fixed with AS03 
A 
 
B 
 
C 
 
D 
 
E 
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Figure 6.6.3: Administration site of i.d. application of verum powder fixed with AS03 on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2 
 
 
 
163 
 
Verum particles fixed with AS03 
A 
 
B 
 
C 
 
D 
 
E 
 
 
Verum particles fixed with AS03 
A 
 
B 
 
C 
 
D 
 
E 
 
 
Figure 6.6.4: Administration site of i.d. application of verum powder fixed with AS03 on 
ballistic device A) administration site before application; B) administration site directly after 
application; C) administration site after 5 min latency; D) administration site at day 1; E) 
administration site at day 2 
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Placebo versus verum particles fixed with paraffin 
A 
 
B 
 
C 
 
D 
 
E 
 
F 
 
Placebo versus verum particles fixed with paraffin 
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Figure 6.6.5: Administration site of i.d. application of placebo and verum powder fixed with 
paraffin on ballistic device A) administration site directly after application of placebo; B) 
administration site after 5 min latency of placebo administration; C) administration site 2 days 
after placebo administration; D) administration site directly after application of verum; E) 
administration site after 5 min latency of verum administration; F) administration site 2 days 
after verum administration 
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7. Chapter - Final summary of the 
thesis  
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7.1 Basis of the thesis 
Vaccination is one of the most effective medical interventions to prevent infections 
[1]. Generally, vaccines are administered intramuscularly (i.m.) via syringe and needle 
while few can also be delivered orally or intradermally [2, 3]. Though intramuscularly 
application is the mainly used administration, several major drawbacks have to be 
taken into consideration. First of all, for a successful liquid vaccine administration into 
the muscle intensive training of health care staff is mandatory [4-6]. Moreover, the 
deposition into a tissue (muscle) in which the circulation of immune cells is low can 
result in delayed and reduced immune response [7, 8]. In addition, the humoral 
immune response is limited to systemic antibodies (e.g. to IgM, IgG, IgD) due to the 
application site deep in the tissue and may result in a lack of IgA secreted into the 
mucosa. The invasive application can induce pain, tissue damage, and bleedings which 
open possibilities to transmit blood-borne diseases after needle-stick injuries or needle 
reuses [9]. Beside the administration drawbacks, the storage stability of the liquid 
vaccine calls for special handling in a small temperature range (2-8°C) to prevent a 
temperature induced degradation [10, 11]. 
Keeping this in mind, a project on epidermal powder immunization (EPI) was 
conducted to provide a minimally invasive administration route which could improve 
immunogenicity and patient compliance and additionally to design a vaccine vehicle 
which can improve the product storage stability.  
The skin excels as a multifunctional tissue. Beside the physiological support to control 
body temperature and moisture, the skin also forms a physical barrier to the 
environment and has built in the first line of immunogenic defense against pathogens 
[12]. Furthermore, the skin stands out as an easily accessible application site. The 
target area in 100-200 µm depths in the epidermis, where the immunocompetent cells 
(APCs) are located, can induce an improved immune response while a lack of blood 
vessels and free nerve endings would bypass pain induction and bleedings. Moreover, 
a dose reduction can be envisaged due to the effective antigen presentation and 
escalation of immune response [13]. After an antigen contact or immunization, APCs 
from the epidermis migrate to the draining lymph nodes to present the fragments of 
scavenged pathogens and provoke an intensified immune response. This mechanism 
results in a sufficient systemic immunogenicity and additional mucosal protection by 
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secreted IgA from specific immune cells (B-plasma cells) which can prevent the entry 
of pathogens into the host [5].  
In order to take full advantage of the benefits of intradermal immunization (i.d.) it is 
vital to design an appropriate administration technology. The most known i.d. 
vaccination technologies are i.d. injections, liquid jets, micro-needle systems, and the 
PowderJect
®
-technology [6]. Up to date, the introduced platform technologies could 
not fully convince their suitability as a cost-effective and competent vaccination 
system. The i.d. injection (known as the Mantoux technique), needs intensive and 
specialized training of health-care staff and, thus, result in comparatively high error 
rates [14]. The liquid jet technology deposits the vaccine into the whole skin, from the 
epidermis down to the subcutaneous tissue. Consequently higher vaccine doses are 
applied and pain and bleedings can result from this technique because of the higher 
administered volume. Both platforms (i.d. injection and liquid jets) can utilize the 
existing liquid vaccines without intensive galenical developments but the handling is 
limited to the strict storage temperature range of 2-8°C. The PowderJect
®
 
administration aimed specifically in this direction by stabilizing the temperature 
sensitive vaccine in a dry vehicle to improve the storage stability [15, 16]. The spray 
(freeze) dried powder particles were accelerated using pressurized helium gas to 
penetrate the skin. The cost-intensive technology limited the field of application, 
particularly in developing countries. However, vaccine stabilization using a dry 
carbohydrate matrix was a step in the right direction due to improved storage stability, 
low ingredient costs, known material properties, and biocompatibility. Moreover, a 
carbohydrate matrix would dissolve instantly after particle deposition into the skin 
which would result in largely distributed vaccine in the tissue. A large immunized area 
would address a high number of APCs that would induce an exceled immune 
response. 
Consequently, a concept of intradermal powder application was conducted using a 
new platform of vaccine stabilization, particle preparation, and vaccine powder 
application into the skin. Primarily, collapse freeze-drying was performed to stabilize 
the vaccine, a new pyrotechnical ballistic device was designed to transfer the powder 
particles into the skin and finally, the innovative concept were confirmed in provoking 
an immune response in an animal experiment.   
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In Chapters 2 and 3 the stabilization of an influenza vaccine in a carbohydrate matrix 
using collapse freeze-drying, preparation of vaccine particles using cryo-milling, and 
the characterization of the product stored at 2-8°C, 25°C, and 40°C over a time period 
of 12 months was described. The galenical stabilization was necessary because the 
liquid vaccine loses activity after approximately 24 hours when stored outside the 
approved temperature range of 2-8°C. In order to optimize the energy and time 
consuming process of lyophilization, the model vaccine was stabilized in a faster and 
more aggressive collapse freeze-drying cycle above the glass transition temperature of 
the carbohydrate matrix. In addition, the process of collapse freeze-drying was 
selected to reduce the specific surface area (SSA) to obtain harder lyophilizates which 
would prevent a shattering on the skin surface of the particles during the impact. The 
potential of SSA reduction was previously demonstrated in the work by E. Etzl et al 
[17]. The influence of the more aggressive collapse-freeze-drying cycle to the product 
was monitored using the thermo-sensitive influenza vaccine which was incorporated 
into a carbohydrate matrix. A large set of analytical tools was established to 
characterize the stability and activity of the influenza vaccine during preparation, 
collapse-freeze-drying, and storage under different conditions (2-8°C, 25°C, and 
40°C) over a time period of 12 months. Beside a successful freeze-drying cycle a 
particle preparation at the desired size range of 20 µm-80 µm could also be confirmed 
by scanning electron micrographs (SEM). Consistent vaccine content and structural 
integrity of lyophilizates and vaccine particles were determined using RP-HPLC. 
However, results of the chromatographical method did not correlate with an alteration 
in activity of the protein (hemagglutinin). In order to fill this gap, the samples were 
characterized using the hemagglutination inhibition assay (HAI). The membrane 
affinity and cross-linking property of hemagglutinin (HA) was determined in a red 
blood cell suspension and resulted in unchanged biological activity despite certain 
degradation detectable in the electrophoretic assays. Unexpected was the clearly 
visible formation of agglomerates in the electrophoretic assays (SDS-Page and 
westernblot). The distinct alteration, particularly observed in cryo-milled samples 
stored at 40°C/12 months, resulted in modified protein migration through the SDS-
Page gels and ended in faded bands (SDS-Page) and a lack of bands in westernblot 
analytics. The formation of aggregates was further investigated using light obscuration 
(sub-visible particle counts) and turbidity measurements. While the results showed 
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consistently low counts for lyophilizates the particle counts increased 5-8 folds for 
cryo-milled samples stored at high storage temperatures. At the same time, slightly 
higher turbidity results but an additional tendency to increasing turbidity values under 
higher storage temperature conditions of cryo-milled samples demonstrated a less 
unambiguous impact of cryo-milling to the storage samples. Beside the stability of the 
incorporated vaccine, the integrity of the lyophilizate was determined using Karl-
Fisher measurement. While the values for the unprocessed lyophilizates were 
plateaued at < 1.5% the residual moisture of cryo-milled samples increased after cryo-
milling but leveled out at / or below 3.5%. The successful collapse lyophilization and 
vaccine stabilization in the carbohydrate vehicle at up to 25°C/12 months was the first 
major step for this work.  
Some liquid vaccines, as the model influenza vaccine, are delivered in association with 
an adjuvant (e.g.:AS03) to boost the immune response. The adjuvant can improve the 
immune response, so that e.g. the WHO recommended amount of hemagglutinin of 15 
µg/dose could be reduced to 3.75 µg/dose in an influenza vaccination. In order to 
utilize the benefits offered by adjuvants (e.g. AS03) the powdered vaccine stability in 
presence of adjuvants was investigated. The usage of freeze-dried vaccines limited the 
choice of adjuvants to oily components to prevent a premature dissolution of the 
matrix. In this work, the lyophilized vaccine was not stored in presence of the oily 
components. In order to compare the stability and biological activity of the freeze-
dried vaccine and the liquid vaccine (commercial product), both samples were mixed 
with the adjuvant prior to analytical testing. The characterization of the vaccine 
stability in presence of oily components was limited. Therefore, the tests focused on 
biological activity using HAI while vaccine content and integrity was determined 
using RP-HPLC. The biological activity determination failed due to the unexpected 
strong influence of the oily components. While the vaccine samples dissolved in the 
aqueous phase (HAI), hemolysis of the red-blood cells prevented a successful read-out 
of the assay and meaningful data could not be collected. The vaccine stability could 
only be characterized using the chromatographic assay. In future works, vaccine 
activity could be determined in immunization studies of laboratory animals as an 
alternative to tested assay (HPLC, gel electrophoresis etc.).  
This work could demonstrate a successful particle preparation and sufficient 
stabilization of the thermo-sensitive influenza vaccine as a freeze-dried product over a 
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time period of 12 months and particle preparation of the cryo-milled samples were 
storage stable at 2-8°C and 25°C for up to 12 months.  
In Chapters 4 and 5, the detailed device development, velocity determination, and 
penetration tests into excised pig skin as a model for human skin were described. The 
device design put the accent on two crucial conceptions. The first aspect was to 
accelerate particles using a pyrotechnical energy source and secondly an independent 
preparation of a sterile pharmaceutical part from the pyrotechnical part to load the 
stabilized vaccine particles. Due to the low density of the carbohydrate particle matrix 
(1.3 g/cm
3
) only particles sizes of (20-80 µm) could store enough momentum to 
breach through the mechanical barrier (stratum corneum) of the skin and deposit the 
vaccine into the epidermis [18]. Therefore, gas-generator excelled as the energy source 
to generate enough impulse to accelerate the particles at a sufficient rate. A maximum 
of safety for both caregiver and patient, possible sterilization of the pharmaceutical 
part, reproducible particle velocity and particle distribution were continuously 
considered during the design and optimization of all device components (combustor, 
support plate, customized membranes, silicone oleogel and membrane holder). While 
the combustor concealed the generated high pressure, it also directed the impulse 
towards the particles fixed on a customized membrane. In order to reduce the energy 
losses and prevent impacts of gas-generator fragments the combustor was filled with a 
viscous silicone oleogel which transferred the pressure more efficiently compared to 
other fillings (air, water, hydrogels etc.). When the load hit the customized membrane, 
the surface with the fixed particles was accelerated to velocities larger 550 m/s. During 
the acceleration, the customized membrane flipped instantly and formed a curvature 
which improved the particle velocity due to the stored material tension.  
Velocity, trajectory, the flight characteristics, penetration behavior into skin of model 
particles (glass sphere 500 µm for velocity determination and polystyrene particles 
20 µm, 40 µm, and 60 µm for penetration test) were compared against the lyophilizate 
particles. The particle penetration behavior and depths was investigated in excised pig 
skin to ensure the highest possible degree of comparability with the mechanical 
properties of human skin. The penetration depths of the particles in skin samples were 
histologically examined and an administration into the desired depths of 100-200 µm 
was successfully demonstrated. The device was modified for the animal experiments 
using the data of the particle penetration tests in excised pig skin. Particles applied in 
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in vivo skin of the laboratory animals demonstrated that the skin healed completely 
after two days (macroscopic images) (Chapter 6). In addition, a lack of tissue 
damages and scarring was shown in the histological skin samples after the completion 
of the animal experiment. Moreover, the dissolving and distribution of the 
carbohydrate matrix could also be shown which was requested to address as much 
APCs as possible with one epidermal powder immunization.   
Chapter 6 describes the proof of concept of the new epidermal powder immunization 
technology by depositing the stabilized influenza vaccine particles into the skin in vivo 
with the pyrotechnical powder applicator. The study was performed on pigs as 
laboratory animals due to the close similarity of mechanical properties between human 
and pig skin. During the animal experiment the i.d. powder application was challenged 
against the conventional i.m. liquid vaccine injection. Additionally, the adjuvant effect 
of the oily components of the adjuvant AS03 used in one EPI-group as well as AS03 
in the i.m. group (commercial product) was analyzed. Three groups of i.d. applications 
were tested against one i.m. injection: (A) EPI negative control group (placebo 
particles + paraffin); (B) EPI group (vaccine particles + paraffin); (C) EPI challenge 
group (vaccine particles + oily components of an adjuvant); (D) i.m. positive control 
group (liquid vaccine + AS03). The specific antibody titer of the control group 
remained low while all other groups demonstrated a titer increase during the four 
weeks of the immunization study. On day 14, the ELISA assay revealed comparably 
elevated titer of both i.d. groups (groups B and C) and a one magnitude higher 
immune response of the positive control group (group D). The anti-HA-antibody titer 
of the i.m. positive control group increased further while the i.d. verum groups only 
changed minimally after the observed 28 days. The particle deposition into the skin 
was not complete. Using the micro flow imaging system the deposition of vaccine 
particles into the skin could be determined which revealed an approximately 50% 
lower dose (1.875 µg/dose) in the EPI groups compared to the i.m. positive control 
group (3.75 µg/dose). Beside the lower vaccine dose, the weak titer increase of the 
challenge group (group C) could be explained by the low amount of adjuvant which 
was transferred with the vaccine. The surface area to fix the powdered vaccine with 
the oily components of AS03 was limited to 3.14 cm
2
 which resulted in an amount of 
only 1.5-1.1875 µg compared to 27.41 mg (in 0.25 ml emulsion). The low amount 
only 1.28% ± 0.74% of the oily components of the adjuvants and the lower deposited 
 
173 
 
vaccine dose was not enough to provoke a comparably strong immune response to 
i.m. vaccination. 
It should be kept in mind that the WHO recommends 15 µg/dose if no adjuvant is 
administered. The intradermal deposited vaccine was only 1/10 of the recommended 
dose. Therefore, it was a remarkable success of the new vaccination strategy that a 
titer increase was still observable in spite of a lack of adjuvant boosting effects and 
low deposited vaccine dose. 
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7.2 Final summary and outlook 
In summary, the present study demonstrated a successful immunization of laboratory 
animals using a newly developed and built pyrotechnical powder applicator which 
deposited stabilized influenza vaccine particles into the skin. The new concept of 
vaccine stabilization using an economic collapse freeze-drying resulted in storable 
vaccine lyophilizates and vaccine particles at up to 25°C over a time period of 
12 months. Moreover, a sufficient acceleration of the vaccine particles using the newly 
designed powder applicator was demonstrated in histological examined skin samples 
in which the particles were deposited into the desired penetration depths to deliver the 
vaccine directly to the APCs. The concept of instantly dissolving vaccine particles in 
the tissue to address as many APCs as possible could also be shown. Future studies 
could further optimize the powder applicator to generate higher particle velocities or 
prepare particles with higher density to store more momentum into the particles to 
deposit higher amounts of particles into the skin. However, it should be kept in mind 
that the impact energy of the particles should be limited to prevent skin lesions, pain 
and bleedings induced by deeply penetrated or shattering particles. Beside the 
modification of particle administration, a higher vaccine load (using a model protein) 
into the vehicle successfully were investigated in preliminary tests to optimize the 
intradermal vaccine deposition. Despite the small amount of deposited vaccine and 
adjuvant into the skin, an observable titer increase could be detected which 
demonstrated potential of this new strategy of epidermal powder immunization. The 
feasibility of ballistic intradermal vaccination has to be tested for each vaccine but the 
concept of stabilized freeze-dried vaccine and pyrotechnical powder administration 
opens a new possibility to safe, ease-of-use and effective vaccination. 
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